Pfizer (PFE) 10-Q 10 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Oct. 02, 2016	Nov. 07, 2016
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Oct. 2, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Trading Symbol	PFE
Entity Registrant Name	PFIZER INC
Entity Central Index Key	78,003
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		6,068,355,132

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions		3 Months Ended		9 Months Ended
		Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016		Sep. 27, 2015
Income Statement [Abstract]
Revenues	[1],[2],[3]	$ 13,045	$ 12,087	$ 39,196		$ 34,804
Costs and expenses:
Cost of sales	[1],[2]	3,085	2,219	9,111		6,238
Selling, informational and administrative expenses	[1],[2]	3,559	3,270	10,414		9,761
Research and development expenses	[1],[2]	1,881	1,722	5,360		5,342
Amortization of intangible assets	[1]	968	937	2,934		2,748
Restructuring charges and certain acquisition-related costs	[1]	531	581	988		727
Other (income)/deductions––net	[1]	1,417	661	2,815		670
Income from continuing operations before provision for taxes on income	[1],[4]	1,604	2,697	7,575		9,319
Provision for taxes on income	[1]	284	567	1,194		2,178
Income from continuing operations	[1]	1,320	2,130	6,380		7,141
Discontinued operations––net of tax	[1]	0	8	0		14
Net income before allocation to noncontrolling interests	[1],[5]	1,319	2,139	6,380	[6]	7,155	[6]
Less: Net income attributable to noncontrolling interests	[1]	0	9	25		23
Net income attributable to Pfizer Inc.	[1]	$ 1,320	$ 2,130	$ 6,355		$ 7,132
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.22	$ 0.34	$ 1.04		$ 1.15
Discontinued operations––net of tax (in dollars per share)	[1]	0	0	0		0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.22	0.35	1.04		1.15
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.22	0.34	1.03		1.14
Discontinued operations––net of tax (in dollars per share)	[1]	0	0	0		0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.21	$ 0.34	$ 1.03		$ 1.14
Weighted-average shares––basic	[1]	6,066	6,168	6,095		6,176
Weighted-average shares––diluted	[1]	6,138	6,243	6,164		6,259
Cash dividends paid per common share (in dollars per share)	[1]	$ 0.3	$ 0.28	$ 0.9		$ 0.84
[1]	Amounts may not add due to rounding.
[2]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
[3]	On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Hospira. As a result, legacy Hospira operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. On June 24, 2016, we acquired Anacor. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Anacor. As a result, legacy Anacor operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic reporting period, our results of operations and IH's operating results for the third quarter and first nine months of 2016 include approximately three months of legacy Anacor operations. Additionally, on September 28, 2016, we acquired Medivation. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Medivation. As a result, legacy Medivation operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and IH's operating results for the third quarter and first nine months of 2016 reflect three business days of legacy Medivation operations, which were immaterial. See Note 2A for additional information.
[4]	Income from continuing operations before provision for taxes on income.
[5]	Amounts may not add due to rounding.
[6]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016		Sep. 27, 2015
Statement of Comprehensive Income [Abstract]
Net income before allocation to noncontrolling interests	[1],[2]	$ 1,319	$ 2,139	$ 6,380	[3]	$ 7,155	[3]
Foreign currency translation adjustments, net	[1]	418	(535)	999		(2,170)
Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax	[1]	418	(535)	999		(2,170)
Unrealized holding losses on derivative financial instruments, net	[1]	(126)	(217)	(970)		(80)
Reclassification adjustments for realized (gains)/losses	[1],[4]	150	(35)	280		(545)
Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total	[1]	24	(251)	(690)		(625)
Unrealized holding gains/(losses) on available-for-sale securities, net	[1]	261	25	740		(502)
Reclassification adjustments for realized (gains)/losses	[1],[4]	(112)	69	(129)		815
Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total	[1]	149	94	611		312
Benefit plans: actuarial losses, net	[1]	(82)	(144)	(101)		(122)
Reclassification adjustments related to amortization	[1],[5]	140	140	418		409
Reclassification adjustments related to settlements, net	[1],[5]	28	36	76		98
Other	[1]	69	(10)	51		120
Defined benefit plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total	[1]	155	23	444		506
Benefit plans: prior service credits and other, net	[1]	95	0	182		506
Reclassification adjustments related to amortization	[1],[5]	(45)	(46)	(127)		(115)
Reclassification adjustments related to curtailments, net	[1],[5]	(8)	(4)	(14)		(21)
Other	[1]	6	(1)	12		(3)
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax	[1]	48	(51)	54		366
Other comprehensive income/(loss), before tax	[1]	794	(721)	1,418		(1,611)
Tax provision/(benefit) on other comprehensive income (loss)	[1],[6]	116	(65)	111		267
Other comprehensive income/(loss) before allocation to noncontrolling interests	[1]	678	(656)	1,307		(1,878)
Comprehensive income before allocation to noncontrolling interests	[1]	1,997	1,483	7,687		5,277
Less: Comprehensive income/(loss) attributable to noncontrolling interests	[1]	0	2	24		(1)
Comprehensive income attributable to Pfizer Inc.	[1]	$ 1,997	$ 1,481	$ 7,664		$ 5,278
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Reclassified into Other (income)/deductions—net in the condensed consolidated statements of income.
[5]	Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.
[6]	See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income/(Loss).

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Oct. 02, 2016	Dec. 31, 2015
Assets
Cash and cash equivalents	[1],[2]	$ 2,094	$ 3,641
Short-term investments	[1]	12,277	19,649
Trade accounts receivable, less allowance for doubtful accounts: 2016—$672; 2015—$384	[1]	9,836	8,176
Inventories	[1],[3]	7,507	7,513
Current tax assets	[1]	2,825	2,662
Other current assets	[1]	2,843	2,154
Assets held for sale	[1]	1,119	9
Total current assets	[1]	38,501	43,804
Long-term investments	[1]	9,507	15,999
Property, plant and equipment, less accumulated depreciation: 2016—$14,838; 2015—$13,502	[1]	13,284	13,766
Identifiable intangible assets, less accumulated amortization	[1],[4]	54,238	40,356
Goodwill	[1]	56,281	48,242
Noncurrent deferred tax assets and other noncurrent tax assets	[1]	1,859	1,794
Other noncurrent assets	[1]	4,759	3,420
Total assets	[1]	178,430	167,381
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt	[1]	13,633	10,159
Trade accounts payable	[1]	3,476	3,620
Dividends payable	[1]	1,821	1,852
Income taxes payable	[1]	1,158	418
Accrued compensation and related items	[1]	2,048	2,359
Other current liabilities	[1]	12,623	10,990
Total current liabilities	[1]	34,759	29,399
Long-term debt	[1]	30,437	28,740
Pension benefit obligations, net	[1]	5,312	6,310
Postretirement benefit obligations, net	[1]	1,808	1,809
Noncurrent deferred tax liabilities	[1]	31,687	26,877
Other taxes payable	[1]	4,767	3,992
Other noncurrent liabilities	[1]	6,059	5,257
Total liabilities	[1]	114,829	102,384
Commitments and Contingencies	[1]
Preferred stock	[1]	25	26
Common stock	[1]	461	459
Additional paid-in capital	[1]	82,534	81,016
Treasury stock	[1]	(84,346)	(79,252)
Retained earnings	[1]	72,846	71,993
Accumulated other comprehensive loss	[1]	(8,214)	(9,522)
Total Pfizer Inc. shareholders’ equity	[1]	63,306	64,720
Equity attributable to noncontrolling interests	[1]	294	278
Total equity	[1]	63,601	64,998
Total liabilities and equity	[1]	$ 178,430	$ 167,381
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	The change from December 31, 2015 reflects, among other things, the reclassification of $369 million to Assets held for sale during the third quarter of 2016 (see Note 2B).
[4]	The increase in Identifiable intangible assets, less accumulated amortization, is primarily related to assets acquired as part of the acquisitions of Medivation, Anacor and Bamboo (see Note 2A), the impact of foreign exchange and the impact of measurement period adjustments related to our acquisition of Hospira (see Note 2A), partially offset by amortization, impairments and the reclassification of $1.3 billion to Assets held for sale during the third quarter of 2016 (see Note 2B). For information about impairments, see Note 4.

CONDENSED CONSOLIDATED BALANCE5

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Millions	Oct. 02, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 672	$ 384
Property, plant and equipment, accumulated depreciation	$ 14,838	$ 13,502

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions		9 Months Ended
		Oct. 02, 2016		Sep. 27, 2015
Operating Activities
Net income before allocation to noncontrolling interests	[1],[2],[3]	$ 6,380		$ 7,155
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization	[2]	4,208		3,733
Asset write-offs and impairments	[2]	1,146		864
Write-down of HIS net assets to fair value less estimated costs to sell	[2],[4]	1,422		0
Deferred taxes from continuing operations	[2]	(1,335)		(165)
Share-based compensation expense	[2]	532		488
Benefit plan contributions in excess of expense	[2]	(775)		(804)
Other adjustments, net	[2]	68		(184)
Other changes in assets and liabilities, net of acquisitions and divestitures	[2]	(1,718)		(1,297)
Net cash provided by operating activities	[2]	9,929		9,790
Investing Activities
Purchases of property, plant and equipment	[2]	(1,134)		(786)
Purchases of short-term investments	[2]	(15,170)		(21,068)
Proceeds from redemptions/sales of short-term investments	[2]	20,685		33,609
Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less	[2]	6,485		5,557
Purchases of long-term investments	[2]	(4,771)		(6,578)
Proceeds from redemptions/sales of long-term investments	[2]	6,915		4,535
Acquisitions of businesses, net of cash acquired	[2]	(17,679)		(16,322)
Acquisitions of intangible assets	[2]	(96)		(48)
Other investing activities, net	[2]	60		346
Net cash used in investing activities	[2]	(4,704)		(756)
Financing Activities
Proceeds from short-term borrowings	[2]	6,397		2,022
Principal payments on short-term borrowings	[2]	(3,321)		(16)
Net proceeds from/(payments on) short-term borrowings with original maturities of three months or less	[2]	(963)		1,907
Proceeds from issuance of long-term debt	[2]	5,031		0
Principal payments on long-term debt	[2]	(4,317)		(2,994)
Purchases of common stock	[2]	(5,000)		(6,160)
Cash dividends paid	[2]	(5,496)		(5,211)
Proceeds from exercise of stock options	[2]	946		1,165
Other financing activities, net	[2]	29		171
Net cash used in financing activities	[2]	(6,693)		(9,115)
Effect of exchange-rate changes on cash and cash equivalents	[2]	(79)		(162)
Net decrease in cash and cash equivalents	[2]	(1,547)		(244)
Cash and cash equivalents, beginning	[2]	3,641	[5]	3,343
Cash and cash equivalents, end	[2]	2,094	[5]	3,099
Cash paid during the period for:
Income taxes	[2]	1,430		1,414
Interest	[2]	$ 1,177		$ 1,162
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	In the third quarter and first nine months of 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. In October 2016, ICU Medical and Pfizer announced that they entered into a definitive agreement under which ICU Medical will acquire all of Pfizer’s global infusion therapy net assets, HIS, for approximately $1 billion in cash and ICU Medical stock. HIS includes IV pumps, solutions and devices. See Note 2B for additional information.
[5]	Amounts may not add due to rounding.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Oct. 02, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies A. Basis of Presentation See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q. We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 28, 2016 and August 23, 2015 . The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and nine months ended October 2, 2016 and September 27, 2015 . Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2015 Form 10-K. Unless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this Quarterly Report on Form 10-Q refer to Pfizer Inc. and its subsidiaries. Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts. Effective in the second quarter of 2016, our segments were reorganized to reflect that we now manage our innovative pharmaceutical and consumer healthcare operations as one business segment, Pfizer Innovative Health (IH) (previously these businesses were managed as two segments: the GIP segment and the VOC segment). Also, in the second quarter of 2016, we changed the name of our Established Products business to Pfizer Essential Health (EH). We have revised prior-period segment information to reflect the reorganization. For additional information, see Note 13 . In the condensed consolidated balance sheet as of December 31, 2015, we performed certain reclassifications to conform to the current period presentation of Other current assets , Other noncurrent assets , Short-term borrowings, including current portion of long-term debt and Long-term debt , and in the condensed consolidated statement of cash flows for the nine months ended September 27, 2015, we performed certain reclassifications to conform to the current presentation of Other changes in assets and liabilities, net of acquisitions and divestitures , Principal payments on short-term borrowings, and Principal payments on long-term debt, for debt issuance costs in accordance with the adoption of a new accounting standard. For additional information, see Note 1B . On October 6, 2016, we announced that we entered into a definitive agreement under which ICU Medical will acquire all of Pfizer’s global infusion therapy net assets, HIS, for approximately $1 billion in cash and ICU Medical stock. HIS includes IV pumps, solutions, and devices. Pfizer has also agreed to certain restrictions on transfer of its ICU Medical shares for at least 18 months. Assets and liabilities associated with HIS were reclassified as held for sale in the condensed consolidated balance sheet as of October 2, 2016. The companies expect to complete the transaction in the first quarter of 2017, subject to customary closing conditions, including required regulatory approvals. For additional information, see Note 2B. On September 28, 2016 (the acquisition date), we acquired Medivation for $81.50 per share. The total fair value of consideration transferred for Medivation was approximately $14.3 billion in cash ( $13.9 billion , net of cash acquired). Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Medivation, and, in accordance with our domestic and international reporting periods, our consolidated financial statements for the three and nine months ended October 2, 2016 reflect three business days of legacy Medivation operations, which were immaterial. See Note 2A for additional information. On June 24, 2016 (the acquisition date), we completed our acquisition of Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor was approximately $4.9 billion in cash ( $4.5 billion , net of cash acquired), plus $698 million debt assumed. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Anacor, and, in accordance with our domestic reporting period, our consolidated financial statements for the three and nine months ended October 2, 2016 reflect approximately three months of legacy Anacor operations, which were immaterial. See Note 2A for additional information. On April 6, 2016, we announced that the merger agreement between Pfizer and Allergan entered into on November 22, 2015 was terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an “Adverse Tax Law Change” under the merger agreement. In connection with the termination of the merger agreement, on April 8, 2016 (which fell into Pfizer’s second fiscal quarter), Pfizer paid Allergan $150 million (pre-tax) for reimbursement of Allergan’s expenses associated with the terminated transaction (see Note 4 ). Pfizer and Allergan also released each other from any and all claims in connection with the merger agreement. On September 3, 2015, we acquired Hospira and, commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Hospira. As a result, legacy Hospira operations are reflected in our results of operations, EH’s operating results, and cash flows for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our consolidated statements of income for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. Legacy Hospira assets and liabilities are reflected in our balance sheets as of October 2, 2016 and December 31, 2015. See Note 2A for additional information. B. Adoption of New Accounting Standards We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. The update does not impact the measurement or recognition of debt issuance costs. As of October 2, 2016 , debt issuance costs were $89 million and are presented as contra-liabilities to Short-term borrowings, including current portion of long-term debt ( $1 million ) and Long-term debt ( $88 million ). In the December 31, 2015 condensed consolidated balance sheet, we have reclassified debt issuance costs of $79 million ( $1 million from Other current assets and $79 million from Other noncurrent assets ) and have presented them as contra-liabilities to Short-term borrowings, including current portion of long-term debt ( $1 million ) and Long-term debt ( $79 million ) to conform to the current period presentation. For additional information, see Note 7A. We adopted a new standard as of January 1, 2016 that requires an acquirer to recognize adjustments made in the measurement period to provisional amounts of assets acquired and liabilities assumed in a business combination in the reporting period in which the adjustment amounts are determined. There was no material impact to our condensed consolidated financial statements in the third quarter and first nine months of 2016 from adopting this standard. For additional information, see Note 2A. We adopted a new standard as of January 1, 2016 related to the accounting for hybrid financial instruments issued or held as investments and there was no material impact to our condensed consolidated financial statements from adopting this standard. C. Fair Value Our fair value methodologies depend on the following types of inputs: • Quoted prices for identical assets or liabilities in active markets (Level 1 inputs). • Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs). • Unobservable inputs that reflect estimates and assumptions (Level 3 inputs). A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.

Acquisitions, Assets and Liabil

Acquisitions, Assets and Liabilities Held for Sale, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment	9 Months Ended
	Oct. 02, 2016
Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]
Acquisitions, Assets and Liabilities Held for Sale, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment	Acquisitions, Assets and Liabilities Held for Sale, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment A. Acquisitions Medivation, Inc. On September 28, 2016 (the acquisition date), we acquired Medivation for $81.50 per share. The total fair value of consideration transferred for Medivation was approximately $14.3 billion in cash ( $13.9 billion , net of cash acquired). Of this consideration, $1.0 billion was not paid as of October 2, 2016, and was recorded in Other current liabilities. Medivation is now a wholly-owned subsidiary of Pfizer. Medivation is a biopharmaceutical company focused on developing and commercializing small molecules for oncology. Medivation’s portfolio includes Xtandi (enzalutamide), an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within the tumor cell. Xtandi is being developed and commercialized through a collaboration between Pfizer and Astellas. Astellas has exclusive commercialization rights for Xtandi outside the U.S. In addition, Medivation has two development-stage oncology assets in its pipeline: talazoparib, which is currently in a Phase 3 study for the treatment of BRCA-mutated breast cancer, and pidilizumab, an immuno-oncology asset being developed for diffuse large B-cell lymphoma and other hematologic malignancies. In connection with this acquisition, we provisionally recorded $13.2 billion in Identifiable intangible assets , primarily consisting of $8.5 billion of Developed technology rights with an average useful life of approximately 12 years and $4.8 billion of In-process research and development, and provisionally recorded $5.5 billion of Goodwill, $4.4 billion of net deferred tax liabilities, and $374 million of assumed contingent consideration. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized. Bamboo Therapeutics, Inc. On August 1, 2016 (the acquisition date), we acquired all the remaining equity in Bamboo, a privately held biotechnology company focused on developing gene therapies for the potential treatment of patients with certain rare diseases relating to neuromuscular conditions and those affecting the central nervous system, for $150 million , plus potential milestone payments of up to $495 million contingent upon the progression of key assets through development, regulatory approval and commercialization. The total fair value of the consideration transferred for Bamboo was approximately $331 million , including cash of $130 million ( $101 million , net of cash acquired), contingent consideration of $157 million , consisting of milestone payments, and the fair value of Pfizer’s previously held equity interest in Bamboo of $44 million . We previously purchased a minority stake in Bamboo in the first quarter of 2016 for a payment of approximately $43 million . Upon acquiring the remaining interest in Bamboo, we recognized a gain of $1 million on our existing investment in Other (income)/deductions––net. This acquisition provides us with several clinical and pre-clinical assets that complement our rare disease portfolio, an advanced recombinant AAV vector design and production technology, and a fully functional Phase I/II gene therapy manufacturing facility. Bamboo is now a wholly-owned subsidiary of Pfizer. In connection with this acquisition, we provisionally recorded $325 million of Identifiable intangible assets, consisting entirely of In-process research and development. We also provisionally recorded $130 million of Goodwill and $94 million of net deferred tax liabilities. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized. Anacor Pharmaceuticals, Inc. On June 24, 2016 (the acquisition date), we acquired Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor was approximately $4.9 billion in cash ( $4.5 billion net of cash acquired), plus $698 million debt assumed. Anacor is now a wholly-owned subsidiary of Pfizer. Anacor is a biopharmaceutical company focused on novel small-molecule therapeutics derived from its boron chemistry platform. Included within Anacor’s pipeline is crisaborole, a non-steroidal topical PDE-4 inhibitor with anti-inflammatory properties. In connection with this acquisition, we recorded $698 million as the fair value of notes payable in cash, and provisionally recorded $5.0 billion in Identifiable intangible assets , primarily consisting of $4.8 billion of In-process research and development , and provisionally recorded $1.8 billion of Goodwill and $1.6 billion of net deferred tax liabilities. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized. Hospira, Inc. On September 3, 2015 (the acquisition date), we acquired Hospira, a leading provider of sterile injectable drugs and infusion technologies as well as a provider of biosimilars, for $90 per share in cash. The total fair value of consideration transferred for Hospira was approximately $16.1 billion in cash ( $15.7 billion , net of cash acquired). Hospira is now a subsidiary of Pfizer. The combination of local Pfizer and Hospira entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory steps. The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as adjustments made in the first nine months of 2016 to the amounts initially recorded in 2015 (measurement period adjustments) with a corresponding change to goodwill. The measurement period adjustments did not have a material impact on our earnings in any period. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed. (MILLIONS OF DOLLARS) Amounts Recognized as of Acquisition Date (as previously reported as of December 31, 2015) Measurement Period Adjustments (a) Amounts Recognized as of Acquisition Date (as adjusted) Final Working capital, excluding inventories $ 274 $ 68 $ 342 Inventories 1,924 (23 ) 1,901 PP&E 2,410 (57 ) 2,352 Identifiable intangible assets, excluding IPR&D 8,270 20 8,290 IPR&D 995 35 1,030 Other noncurrent assets 408 (46 ) 362 Long-term debt (1,928 ) — (1,928 ) Benefit obligations (117 ) — (117 ) Net income tax accounts (3,394 ) 14 (3,380 ) Other noncurrent liabilities (39 ) (23 ) (61 ) Total identifiable net assets 8,803 (12 ) 8,791 Goodwill 7,284 12 7,295 Net assets acquired/total consideration transferred $ 16,087 $ — $ 16,087 (a) The changes in the estimated fair values are primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date. • Environmental Matters —In the ordinary course of business, Hospira incurs liabilities for environmental matters such as remediation work, asset retirement obligations and environmental guarantees and indemnifications. The contingencies for environmental matters are not significant to Pfizer’s financial statements. • Legal Matters —Hospira is involved in various legal proceedings, including product liability, patent, commercial, antitrust and environmental matters and government investigations, of a nature considered normal to its business. The contingencies arising from legal matters are not significant to Pfizer’s financial statements. • Tax Matters —In the ordinary course of business, Hospira incurs liabilities for income taxes . Income taxes are exceptions to both the recognition and fair value measurement principles associated with the accounting for business combinations. Reserves for income tax contingencies continue to be measured under the benefit recognition model as previously used by Hospira. Net liabilities for income taxes approximate $3.4 billion as of the acquisition date, which includes $109 million for uncertain tax positions. The net tax liability includes the recording of additional adjustments of approximately $3.2 billion for the tax impact of fair value adjustments and approximately $719 million for income tax matters that we intend to resolve in a manner different from what Hospira had planned or intended. For example, because we plan to repatriate certain overseas funds, we provided deferred taxes on Hospira’s unremitted earnings for which no taxes have been previously provided by Hospira as it was Hospira’s intention to indefinitely reinvest those earnings. The following table provides supplemental pro forma information as if the acquisition of Hospira had occurred on January 1, 2014: Unaudited Supplemental Pro Forma Consolidated Results Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS, EXCEPT PER SHARE DATA) September 27, September 27, Revenues $ 12,957 $ 38,034 Net income attributable to Pfizer Inc. common shareholders 2,513 7,577 Diluted EPS attributable to Pfizer Inc. common shareholders 0.40 1.21 The unaudited supplemental pro forma consolidated results were prepared using the acquisition method of accounting and do not purport to reflect what the combined company’s results of operations would have been had the acquisition occurred on January 1, 2014, nor do they project the future results of operations of the combined company or reflect the expected realization of any cost savings associated with the acquisition. The actual results of operations of the combined company may differ significantly from the pro forma adjustments reflected here due to many factors. The unaudited supplemental pro forma consolidated results reflect the historical financial information of Pfizer and Hospira, adjusted to give effect to the acquisition of Hospira as if it had occurred on January 1, 2014, primarily for the following pre-tax adjustments: • Elimination of Hospira’s historical intangible asset amortization expense (approximately $9 million in the third quarter of 2015 and $33 million in the first nine months of 2015 ). • Additional amortization expense (approximately $70 million in the third quarter of 2015 and $321 million in the first nine months of 2015 ) related to the fair value of identifiable intangible assets acquired. • Additional depreciation expense (approximately $14 million in the third quarter of 2015 and $57 million in the first nine months of 2015 ) related to the fair value adjustment to PP&E acquired. • Adjustment related to the non-recurring fair value adjustment to acquisition-date inventory estimated to have been sold (the elimination of $75 million of charges in the third quarter of 2015 and $66 million of charges in the first nine months of 2015 ). • Adjustment to decrease interest expense (approximately $3 million in the third quarter of 2015 and $23 million in the first nine months of 2015 ) related to the fair value adjustment of Hospira debt. • Adjustment for non-recurring acquisition-related costs directly attributable to the acquisition (the elimination of $680 million of charges in the third quarter of 2015 and $724 million of charges in the first nine months of 2015 ), reflecting non-recurring charges incurred by both Hospira and Pfizer, which would have been recorded in 2014 under the pro forma assumption that the Hospira acquisition was completed on January 1, 2014. The above adjustments were adjusted for the applicable tax impact. The taxes associated with the adjustments related to the fair value adjustment for acquired intangible assets, PP&E, inventory and debt reflect the statutory tax rates in the various jurisdictions where the adjustments are expected to be incurred. The taxes associated with the elimination of Hospira’s historical intangible asset amortization expense and the adjustment for the acquisition-related costs directly attributable to the acquisition were based on the tax rate in the jurisdiction in which the related deductible costs were incurred. Marketed Vaccines Business of Baxter International Inc. On December 1, 2014 (which fell in the first fiscal quarter of 2015 for our international operations), we acquired Baxter ’ s portfolio of marketed vaccines for a final purchase price of $648 million . The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. NeisVac-C is a vaccine that helps protect against meningitis caused by group C meningococcal meningitis and FSME-IMMUN/TicoVac is a vaccine that helps protect against tick-borne encephalitis. In connection with this acquisition, we recorded $376 million in Identifiable intangible assets, primarily consisting of $371 million in Developed technology rights. We also recorded $194 million of Inventories and $12 million in Goodwill . The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed. B. Assets and Liabilities Held for Sale On October 6, 2016, we announced that we entered into a definitive agreement under which ICU Medical will acquire all of Pfizer’s global infusion therapy net assets, HIS, for approximately $1 billion in cash and ICU Medical stock. HIS includes IV pumps, solutions, and devices. Under the terms of the agreement, Pfizer will receive approximately $400 million in newly issued shares of ICU Medical common stock and $600 million in cash from ICU Medical, subject to customary adjustment for net working capital. Upon completion of the transaction, which the companies expect to occur in the first quarter of 2017, subject to customary closing conditions, including required regulatory approvals, Pfizer will own approximately 16.6% of ICU Medical. Pfizer has also agreed to certain restrictions on transfer of its ICU Medical shares for at least 18 months. At October 2, 2016 , we determined that the carrying value of the HIS net assets held for sale exceeded their fair value less estimated costs to sell, resulting in a pre-tax impairment charge of $1.4 billion , which is included in Other (income)/deductions––net (see Note 4 ). Assets and liabilities associated with HIS were reclassified as held for sale in the condensed consolidated balance sheet as of October 2, 2016 . The HIS assets held for sale are reported in Assets held for sale and HIS liabilities held for sale are reported in Other current liabilities . The amounts associated with HIS, as well as other assets classified as held for sale as of October 2, 2016 and December 31, 2015 , consisted of the following: (MILLIONS OF DOLLARS) October 2, December 31, Assets Held for Sale Inventories $ 369 $ — Property, plant and equipment 441 — Identifiable intangible assets 1,322 — Goodwill 243 — Other assets 60 — Less: adjustment to HIS assets for net realizable value (a) (1,394 ) — Total HIS assets held for sale 1,042 — Other assets held for sale (b) 77 9 Assets held for sale $ 1,119 $ 9 Liabilities Held for Sale Accrued compensation and related items $ 42 $ — Other liabilities 68 — Total HIS liabilities held for sale $ 110 $ — (a) For the quarter ending October 2, 2016 , we recorded an adjustment to HIS assets for net realizable value of $1,394 million plus estimated costs to sell of $28 million for a total impairment on HIS net assets of $1,422 million . (b) Other assets held for sale consist primarily of property, plant and equipment and other assets. C. Research and Development and Collaborative Arrangements Research and Development Arrangement with NovaQuest Co-Investment Fund II, L.P. On November 1, 2016, we announced the discontinuation of the global clinical development program for bococizumab. Except for a refund to NovaQuest of development cost amounts prepaid by NovaQuest to the extent such amounts were not used for program expenses, no additional payments are expected to be received from or paid to NovaQuest under this agreement. In May 2016, our agreement with NovaQuest became effective, under which NovaQuest agreed to fund up to $250 million in development costs related to certain Phase III clinical trials of Pfizer’s bococizumab compound and Pfizer agreed to use commercially reasonable efforts to develop and obtain regulatory approvals for such compound. NovaQuest’s development funding was expected to cover up to 40% of the development costs and was to be received over five quarters during 2016 and 2017. As there was a substantive and genuine transfer of risk to NovaQuest, the development funding applicable to program expenses through the third quarter of 2016 has been recognized by us as an obligation to perform contractual services and therefore has been recognized as a reduction of Research and development expenses as incurred. The reduction to Research and development expenses for the third quarter of 2016 totaled $67.6 million and for the first nine months of 2016 totaled $136.9 million . Research and Development Arrangement with NovaQuest Co-Investment Fund V, L.P. In April 2016, Pfizer entered into an agreement with NovaQuest under which NovaQuest will fund up to $200 million in development costs related to certain Phase III clinical trials of Pfizer’s rivipansel compound and Pfizer will use commercially reasonable efforts to develop and obtain regulatory approvals for such compound. Following potential regulatory approval, NovaQuest will be eligible to receive a combination of fixed milestone payments of up to approximately $267 million in total based on achievement of first commercial sale and certain levels of cumulative net sales as well as royalties on rivipansel net sales over approximately eight years. NovaQuest’s development funding is expected to cover up to 100% of the development costs and will be received over approximately twelve quarters from 2016 to 2019. As there is a substantive and genuine transfer of risk to NovaQuest, the development funding is recognized by us as an obligation to perform contractual services and therefore is a reduction of Research and development expenses as incurred. The reduction to Research and development expenses for the third quarter of 2016 totaled $14.5 million and for the first nine months of 2016 totaled $29.5 million . Fixed sales-based milestone payments will be recorded as intangible assets and amortized to Amortization of intangible assets over the estimated commercial life of the rivipansel product and royalties on net sales will be recorded as Cost of sales when incurred. Research and Development Arrangement with RPI Finance Trust In January 2016, Pfizer entered into an agreement with RPI, a subsidiary of Royalty Pharma, under which RPI will fund up to $300 million in development costs related to certain Phase III clinical trials of Pfizer’s Ibrance (palbociclib) product primarily for adjuvant treatment of hormone receptor positive early breast cancer (the Indication). If successful and upon approval of Ibrance in the U.S. or certain major markets in the EU for the Indication based on the applicable clinical trials, RPI will be eligible to receive a combination of approval-based fixed milestone payments of up to $250 million dependent upon results of the clinical trials and royalties on certain Ibrance sales over approximately seven years. RPI’s development funding is expected to cover up to 100% of the costs primarily for the applicable clinical trials through 2021. As there is a substantive and genuine transfer of risk to RPI, the development funding is recognized by us as an obligation to perform contractual services and therefore is a reduction of Research and development expenses as incurred. The reduction to Research and development expenses for the third quarter of 2016 totaled $11.0 million and for the first nine months of 2016 totaled $32.7 million . Fixed milestone payments due upon approval will be recorded as intangible assets and amortized to Amortization of intangible assets over the estimated commercial life of the Ibrance product and sales-based royalties will be recorded as Cost of sales when incurred. Collaboration with Eli Lilly & Company In October 2013, we entered into a collaboration agreement with Lilly to jointly develop and globally commercialize Pfizer’s tanezumab, which provides that Pfizer and Lilly will equally share product-development expenses as well as potential revenues and certain product-related costs. Following the decision by the FDA in March 2015 to lift the partial clinical hold on the tanezumab development program, we received a $200 million upfront payment from Lilly in accordance with the collaboration agreement between Pfizer and Lilly, which is recorded as deferred income in our condensed consolidated balance sheet and is being recognized into Other (income)/deductions––net over a multi-year period beginning in the second quarter of 2015. Pfizer and Lilly resumed the Phase 3 chronic pain program for tanezumab in July 2015, which will consist of six studies in approximately 7,000 patients across osteoarthritis, chronic low back pain and cancer pain. Under the collaboration agreement with Lilly, we are eligible to receive additional payments from Lilly upon the achievement of specified regulatory and commercial milestones. Collaboration with OPKO Health, Inc. We entered into a collaborative agreement with OPKO, which closed in January 2015, to develop and commercialize OPKO’s long-acting hGH-CTP for the treatment of GHD in adults and children, as well as for the treatment of growth failure in children born SGA who fail to show catch-up growth by two years of age. hGH-CTP has the potential to reduce the required dosing frequency of human growth hormone to a single weekly injection from the current standard of one injection per day. We have received the exclusive license to commercialize hGH-CTP worldwide. OPKO will lead the clinical activities and will be responsible for funding the development programs for the key indications, which include Adult and Pediatric GHD and Pediatric SGA. We will be responsible for all development costs for additional indications, all postmarketing studies, manufacturing and commercialization activities for all indications, and we will lead the manufacturing activities related to product development. In February 2015, we made an upfront payment of $295 million to OPKO, which was recorded in Research and development expenses, and OPKO is eligible to receive up to an additional $275 million upon the achievement of certain regulatory milestones. OPKO is also eligible to receive royalty payments associated with the commercialization of hGH-CTP for Adult GHD, which is subject to regulatory approval. Upon the launch of hGH-CTP for Pediatric GHD, which is subject to regulatory approval, the royalties will transition to tiered gross profit sharing for both hGH-CTP and our product, Genotropin. D. Equity-Method Investments Investment in Hisun Pfizer Pharmaceuticals Company Limited In 2016, we determined that we had other-than-temporary declines in the value of Hisun Pfizer, our 49% -owned equity-method investment in China, and, therefore, we recognized a loss of $211 million for the first nine months of 2016 in Other (income)/deductions––net (see Note 4 ) . The declines in value resulted from lower expectations as to the future cash flows to be generated by Hisun Pfizer, primarily as a result of an increase in risk due to the continued slowdown in the Chinese economy and changes in the expected timing and number of new product introductions by Hisun Pfizer. As of October 2, 2016 , the carrying value of our investment in Hisun Pfizer is $529 million , which is included in Long-term investments . In valuing our investment in Hisun Pfizer, we used discounted cash flow techniques, utilizing a 13.0% discount rate, reflecting our best estimate of the various risks inherent in the projected cash flows, and a nominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal, economic and/or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, including country risk. Changes in economic conditions or other factors underlying these assumptions could negatively impact the value of our investment in Hisun Pfizer in future periods. Investment in Laboratório Teuto Brasileiro S.A. In 2016, we determined that we had an other-than-temporary decline in the value of Teuto, a 40% -owned generics company in Brazil, and, therefore, we recognized a loss of $50 million for the first nine months of 2016 in Other (income)/deductions––net (see Note 4 ) related to our equity-method investment. The decline in value resulted from lower expectations as to the future cash flows to be generated by Teuto, primarily due to a slowdown in Brazilian economic conditions, which have been impacted by political risk, higher inflation, and the depreciation of the Brazilian real. In valuing our investment in Teuto, we used discounted cash flow techniques, utilizing a 17.5% discount rate, reflecting our best estimate of the various risks inherent in the projected cash flows, and a nominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal, economic and/or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, including country risk. We have an option to acquire the remaining 60% of Teuto, and Teuto’s shareholders have an option to sell their 60% stake in the company to us. Under the terms of our agreement with Teuto’s other shareholders, 2016 is the final year in which the call and put options may be exercised. Our investment in Teuto is accounted for under the equity method due to the significant influence we have over the operations of Teuto through our board representation, minority veto rights and 40% voting interest. E. Cost-Method Investment AM-Pharma B.V. In April 2015, we acquired a minority equity interest in AM-Pharma, a privately-held Dutch biopharmaceutical company focused on the development of recAP for inflammatory diseases, and secured an exclusive option to acquire the remaining equity in the company. The option becomes exercisable upon delivery of the clinical trial report after completion of a Phase II trial of recAP in the treatment of Acute Kidney Injury related to sepsis, which is expected to read out in 2017. Under the terms of the agreement, we paid $87.5 million for both the exclusive option and the minority equity interest, which was recorded as a cost-method investment in Long-term investments , and we may make additional payments of up to $512.5 million upon exercise of the option and potential launch of any product that may result from this investment.

Restructuring Charges and Other

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	9 Months Ended
	Oct. 02, 2016
Restructuring and Related Activities [Abstract]
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example: • In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and • In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems. All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as groups such as information technology, shared services and corporate operations. In connection with our acquisition of Hospira, we are focusing our efforts on achieving an appropriate cost structure for the combined company. For up to a three -year period post-acquisition, we expect to incur costs of approximately $1 billion (not including costs of $215 million for full-year 2015 associated with the return of acquired in-process research and development rights as described in the Current-Period Key Activities section of Notes to Consolidated Financial Statements–– Note 3 . Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives in our 2015 Financial Report) associated with the integration of Hospira. In early 2014, we announced that we would be incurring costs in 2014-2016 related to new programs: our new global commercial structure reorganization and additional cost-reduction/productivity initiatives. We have the following initiatives underway associated with these programs: • Manufacturing plant network rationalization and optimization, where execution timelines are necessarily long. Our plant network strategy is expected to result in the exit of seven sites over the next several years. In connection with these activities, during 2014-2016, we expect to incur costs of approximately $400 million associated with prior acquisition activity and costs of approximately $1.1 billion associated with new non-acquisition-related cost-reduction initiatives. Through October 2, 2016 , we incurred approximately $365 million and $828 million , respectively, associated with these initiatives. • The 2014 global commercial structure reorganization, which primarily includes the streamlining of certain functions, the realignment of regional locations and colleagues to support the businesses, as well as implementing the necessary system changes to support different reporting requirements. Through October 2, 2016 , we incurred costs of approximately $219 million and have completed this initiative. • Other new cost-reduction/productivity initiatives, primarily related to commercial property rationalization and other consolidation and savings opportunities. In connection with these cost-reduction activities, during 2014-2016, we expect to incur costs of approximately $1.3 billion . Through October 2, 2016 , we incurred approximately $895 million associated with these initiatives. The costs expected to be incurred during 2014-2016, of approximately $3 billion in total for the above-mentioned programs (but not including expected costs associated with the Hospira integration), include restructuring charges, implementation costs and additional depreciation––asset restructuring. Of this amount, we expect that about a quarter of the charges will be non-cash. Current-Period Key Activities In the first nine months of 2016 , we incurred approximately $1.2 billion in cost-reduction and acquisition-related costs (excluding transaction costs) primarily in connection with the integration of Hospira and the aforementioned programs. The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, Restructuring charges (a) : Employee terminations $ 347 $ 241 $ 464 $ 306 Asset impairments 27 198 45 209 Exit costs 29 30 64 40 Total restructuring charges 404 469 574 555 Transaction costs (b) 54 64 114 70 Integration costs (c) 74 48 300 102 Restructuring charges and certain acquisition-related costs 531 581 988 727 Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income as follows (d) : Cost of sales 46 23 145 67 Research and development expenses 1 1 5 3 Total additional depreciation––asset restructuring 47 24 151 71 Implementation costs recorded in our condensed consolidated statements of income as follows (e) : Cost of sales 46 23 127 64 Selling, informational and administrative expenses 23 16 56 55 Research and development expenses 8 2 17 13 Other (income)/deductions––net 1 2 2 3 Total implementation costs 78 42 202 135 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 655 $ 647 $ 1,341 $ 933 (a) In the nine months ended October 2, 2016 , Employee terminations represent the expected reduction of the workforce by approximately 2,100 employees, mainly in manufacturing, sales, research and corporate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. The restructuring charges for 2016 are associated with the following: • For the third quarter of 2016 , the IH segment ( $148 million ); the EH segment ( $28 million ); WRD, GPD and Medical (M) (WRD/GPD/M) ( $52 million ); manufacturing operations ( $108 million ); and Corporate ( $67 million ). • For the first nine months of 2016 , IH ( $162 million ); EH ( $19 million ); WRD/GPD/M ( $104 million ); manufacturing operations ( $181 million ); and Corporate ( $107 million ). The restructuring charges for 2015 are associated with the following: • For the third quarter of 2015 , IH ( $9 million ); EH ( $280 million ); WRD/GPD/M ( $50 million ); manufacturing operations ( $26 million ); and Corporate ( $104 million ). • For the first nine months of 2015 , IH ( $55 million ); EH ( $288 million ); WRD/GPD/M ( $66 million ); manufacturing operations ( $18 million ); and Corporate ( $127 million ). In September 2015, in order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, Pfizer opted to return rights to Celltrion that Hospira had previously acquired to potential biosimilars to Rituxan ® (rituximab) and Herceptin ® (trastuzumab). As such, upon return of the acquired rights, in the third quarter and first nine months of 2015, we incurred charges of $205 million , which are comprised of (i) a write-off of the applicable IPR&D assets, totaling $160 million , which is included in Asset impairments ; (ii) a write-off of amounts prepaid to Celltrion in the amount of $25 million , which is included in Asset impairments ; and (iii) a payment to Celltrion of $20 million , which is included in Exit costs . (b) Transaction costs represent external costs for banking, legal, accounting and other similar services, most of which in the third quarter of 2016 are directly related to our acquisition of Medivation, and most of which in the first nine months of 2016 are directly related to our acquisitions of Medivation and Anacor, and the terminated transaction with Allergan. Transaction costs in 2015 represent external costs directly related to the acquisition of Hospira and primarily include expenditures for banking, legal, accounting and other similar services. (c) Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the third quarter of 2016, integration costs mostly relate to our acquisition of Hospira and for the first nine months of 2016 , integration costs mostly relate to our acquisition of Hospira and the terminated transaction with Allergan. Integration costs in 2015 represent external incremental costs directly related to our acquisition of Hospira. (d) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (e) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives. The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, December 31, 2015 (a) $ 1,109 $ — $ 48 $ 1,157 Provision 464 45 64 574 Utilization and other (b) (360 ) (45 ) (50 ) (455 ) Balance, October 2, 2016 (c) $ 1,213 $ — $ 62 $ 1,275 (a) Included in Other current liabilities ( $776 million ) and Other noncurrent liabilities ( $381 million ). (b) Includes adjustments for foreign currency translation. (c) Included in Other current liabilities ( $714 million ) and Other noncurrent liabilities ( $561 million ).

Other (Income)_Deductions - Net

Other (Income)/Deductions - Net	9 Months Ended
	Oct. 02, 2016
Other Income and Expenses [Abstract]
Other (Income)/Deductions - Net	Other (Income)/Deductions—Net The following table provides components of Other (income)/deductions––net : Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, Interest income (a) $ (123 ) $ (121 ) $ (357 ) $ (332 ) Interest expense (a) 291 278 889 864 Net interest expense 168 157 532 533 Royalty-related income (233 ) (204 ) (695 ) (683 ) Certain legal matters, net (b) (40 ) — 494 99 Net gains on asset disposals (c) (47 ) (35 ) (81 ) (230 ) Impairment on remeasurement of HIS net assets (d) 1,422 — 1,422 — Certain asset impairments (e) 133 633 1,080 658 Business and legal entity alignment costs (f) 69 60 180 224 Other, net (g) (55 ) 50 (117 ) 70 Other (income)/deductions––net $ 1,417 $ 661 $ 2,815 $ 670 (a) Interest income increased in the first nine months of 2016 , primarily due to higher investment returns. Interest expense increased in the third quarter and first nine months of 2016 , primarily due to interest on legacy Hospira debt acquired in September 2015 and the addition of new fixed rate debt in the second quarter of 2016, partially offset by the maturity of other fixed rate debt in the second quarter of 2016. (b) In the first nine months of 2016, primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra pending against the Company in New York federal court for $486 million , which is subject to final court approval, partially offset by the reversal of a legal accrual where a loss is no longer deemed probable. In addition, the first nine months of 2016 includes a settlement related to a patent matter. See Note 12A2 for additional information. (c) In the first nine months of 2016 , includes gains on sales/out-licensing of product and compound rights (approximately $49 million ). In the first nine months of 2015 , primarily includes gains on sales/out-licensing of product and compound rights (approximately $76 million ) and gains on sales of investments in equity securities (approximately $160 million ). (d) In the third quarter and first nine months of 2016 , represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. In October 2016, ICU Medical and Pfizer announced that they entered into a definitive agreement under which ICU Medical will acquire all of Pfizer’s global infusion therapy net assets, HIS, for approximately $1 billion in cash and ICU Medical stock. HIS includes IV pumps, solutions and devices. See Note 2B for additional information . (e) In the third quarter of 2016 , primarily includes intangible asset impairment charges of $126 million , reflecting $97 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma and $29 million of other IPR&D assets acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the third quarter of 2016 are associated with the following: EH ( $97 million ) and IH ( $29 million ). In the first nine months of 2016 , primarily includes intangible asset impairment charges of $767 million , reflecting (i) $331 million related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) $265 million related to an IPR&D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) $97 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma; and (iv) $74 million of other IPR&D assets, $45 million of which were acquired in connection with our acquisition of Hospira and $29 million of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the first nine months of 2016 are associated with the following: EH ( $738 million ) and IH ( $29 million ). In addition, the first nine months of 2016 includes an impairment loss of $211 million related to Pfizer’s 49% -owned equity-method investment with Zhejiang Hisun Pharmaceuticals Co., Ltd. in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer's 40% -owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2D. The intangible asset impairment charge for 2016 for the IPR&D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a recent court ruling, requiring a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&D assets acquired in connection with our acquisition of King reflect changes in the competitive environment. In the third quarter and first nine months of 2015 , primarily includes an impairment loss of $470 million related to Pfizer's 49% -owned equity-method investment in Hisun Pfizer, and impairment charges for intangible assets of $163 million reflecting (i) $115 million related to developed technology rights for the treatment of attention deficit hyperactivity disorder; (ii) $28 million related to an IPR&D project for the treatment of attention deficit hyperactivity disorder; and (iii) $20 million related to an indefinite-lived Consumer Healthcare brand. The intangible asset impairment charges for the third quarter and first nine months of 2015 are associated with the following: IH ( $20 million ) and EH ( $143 million ). The intangible asset impairment charges for 2015 reflect, among other things, updated commercial forecasts due to increased competition. (f) In the third quarter and first nine months of 2016 and 2015 , represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. (g) In the first nine months of 2016 , includes among other things, $150 million paid to Allergan for reimbursement of Allergan’s expenses associated with the terminated transaction (see Note 1A ). The first nine months of 2016 , also includes income of $116 million from resolution of a contract disagreement. The following table provides additional information about the intangible assets that were impaired during 2016 in Other (income)/deductions––net: Fair Value (a) Nine Months Ended October 2, 2016 (MILLIONS OF DOLLARS) Amount Level 1 Level 2 Level 3 Impairment Intangible assets –– IPR&D (b) $ 50 $ — $ — $ 50 $ 436 Intangible assets –– Developed technology rights (b) 66 — — 66 331 Total $ 116 $ — $ — $ 116 $ 767 (a) The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1C . (b) Reflects intangible assets written down to fair value in the first nine months of 2016. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product and the impact of technological risk associated with IPR&D assets; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax Matters

Tax Matters	9 Months Ended
	Oct. 02, 2016
Income Tax Disclosure [Abstract]
Tax Matters	Tax Matters A. Taxes on Income from Continuing Operations Our effective tax rate for continuing operations was 17.7% for the third quarter of 2016 , compared to 21.0% for the third quarter of 2015 and was 15.8% for the first nine months of 2016 , compared to 23.4% for the first nine months of 2015 . The lower effective tax rate for the third quarter of 2016 in comparison with the same period in 2015 was primarily due to: • a favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business; as well as • an increase in benefits associated with the U.S. R&D tax credit, which was not in effect in the prior year quarter but was permanently extended on December 18, 2015, partially offset by: • a decrease in benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes of limitations; as well as • the unfavorable tax effects of an impairment charge related to the write-down of HIS net assets to fair value less estimated costs to sell, mainly related to goodwill, which is not deductible for tax purposes, and the jurisdictional mix of intangible assets. The lower effective tax rate for the first nine months of 2016 in comparison with the same period in 2015 was primarily due to: • a favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business; • benefits related to the final resolution of an agreement in principle reached in February 2016 and finalized in April 2016 to resolve certain claims related to Protonix, which resulted in the receipt of information that raised our assessment of the likelihood of prevailing on the technical merits of our tax position; • benefits associated with our Venezuela operations; as well as • an increase in benefits associated with the U.S. R&D tax credit, which was not in effect in the first nine months of the prior year but was permanently extended on December 18, 2015, partially offset by: • a decrease in benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes of limitations; as well as • the unfavorable tax effects of an impairment charge related to the write-down of HIS net assets to fair value less estimated costs to sell, mainly related to goodwill, which is not deductible for tax purposes, and the jurisdictional mix of intangible assets. B. Tax Contingencies We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS: • With respect to Pfizer, the IRS has issued a RAR for tax years 2009 -2010. We are not in agreement with the RAR and are currently appealing certain disputed issues. Tax years 2011-2013 are currently under audit. Tax years 2014 -2016 are open, but not under audit. All other tax years are closed. • With respect to Hospira, the federal income tax audit of tax years 2010-2011 was effectively settled in the second quarter of 2016. The IRS is currently auditing tax years 2012-2013 and 2014 through short-year 2015. All other tax years are closed. The tax years under audit for Hospira are not considered material to Pfizer. • With respect to Anacor and Medivation, the open tax years are not considered material to Pfizer. In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2010-2016), Japan (2015-2016), Europe (2007-2016, primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany), Latin America (1998-2016, primarily reflecting Brazil) and Puerto Rico (2010-2016). C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss) The following table provides the components of Tax provision/(benefit) on other comprehensive income/(loss): Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, Foreign currency translation adjustments, net (a) $ — $ (7 ) $ (15 ) $ 90 Unrealized holding losses on derivative financial instruments, net — (57 ) (192 ) (160 ) Reclassification adjustments for realized (gains)/losses 32 15 81 43 32 (42 ) (112 ) (117 ) Unrealized holding gains/(losses) on available-for-sale securities, net 40 6 106 (63 ) Reclassification adjustments for realized (gains)/losses (14 ) 1 (16 ) 63 26 7 90 — Benefit plans: actuarial losses, net (31 ) (51 ) (39 ) (43 ) Reclassification adjustments related to amortization 47 43 140 133 Reclassification adjustments related to settlements, net 10 12 27 35 Other 14 (9 ) 5 29 40 (4 ) 133 154 Benefit plans: prior service credits and other, net 35 (4 ) 66 188 Reclassification adjustments related to amortization (17 ) (36 ) (47 ) (42 ) Reclassification adjustments related to curtailments, net (3 ) 18 (5 ) (8 ) Other 2 2 1 2 18 (19 ) 15 139 Tax provision/(benefit) on other comprehensive income/(loss) $ 116 $ (65 ) $ 111 $ 267 (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	9 Months Ended
	Oct. 02, 2016
Equity [Abstract]
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gains/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/Credits and Other Accumulated Other Comprehensive Loss Balance, December 31, 2015 $ (5,863 ) $ 421 $ (227 ) $ (4,733 ) $ 880 $ (9,522 ) Other comprehensive income/(loss) (a) 1,016 (578 ) 522 310 39 1,308 Balance, October 2, 2016 $ (4,847 ) $ (157 ) $ 295 $ (4,423 ) $ 919 $ (8,214 ) (a) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $1 million loss for the first nine months of 2016 . As of October 2, 2016 , with respect to derivative financial instruments, the amount of unrealized pre-tax losses estimated to be reclassified into income within the next 12 months is $129 million (which is expected to be offset primarily by gains resulting from reclassification adjustments related to available-for-sale securities).

Financial Instruments

Financial Instruments	9 Months Ended
	Oct. 02, 2016
Financial Instruments [Abstract]
Financial Instruments	Financial Instruments A. Selected Financial Assets and Liabilities The following table provides additional information about certain of our financial assets and liabilities: (MILLIONS OF DOLLARS) October 2, December 31, Selected financial assets measured at fair value on a recurring basis (a) Trading funds and securities (b) $ 304 $ 287 Available-for-sale debt securities (c) 17,522 32,078 Money market funds 1,724 934 Available-for-sale equity securities (c) 590 603 Derivative financial instruments in a receivable position (d) : Interest rate swaps 1,923 837 Foreign currency swaps 90 135 Foreign currency forward-exchange contracts 186 559 22,340 35,433 Other selected financial assets Held-to-maturity debt securities, carried at amortized cost (c), (e) 1,270 1,388 Private equity securities, carried at equity-method or at cost (e), (f) 1,003 1,336 2,272 2,724 Total selected financial assets $ 24,613 $ 38,157 Selected financial liabilities measured at fair value on a recurring basis (a) Derivative financial instruments in a liability position (g) : Interest rate swaps $ 3 $ 139 Foreign currency swaps 1,349 1,489 Foreign currency forward-exchange contracts 503 81 1,855 1,709 Other selected financial liabilities Short-term borrowings: Principal amount 13,602 10,160 Net fair value adjustments related to hedging and purchase accounting 47 2 Net unamortized discounts, premiums and debt issuance costs (h) (16 ) (3 ) Total short-term borrowings, carried at historical proceeds, as adjusted (e) 13,633 10,159 Long-term debt: Principal amount 28,073 27,573 Net fair value adjustments related to hedging and purchase accounting 2,447 1,294 Net unamortized discounts, premiums and debt issuance costs (h) (83 ) (127 ) Total long-term debt, carried at historical proceeds, as adjusted (i) 30,437 28,740 44,071 38,899 Total selected financial liabilities $ 45,926 $ 40,608 (a) We use a market approach in valuing financial instruments on a recurring basis. For additional information, see Note 1C. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except less than 2% that use Level 1 inputs and money market funds measured at net asset value. (b) As of October 2, 2016 , trading funds and securities are composed of $196 million of trading equity funds, $12 million of trading securities and $96 million of trading debt funds. As of December 31, 2015 , trading funds and securities are composed of $185 million of trading equity funds and $102 million of trading debt funds. As of October 2, 2016 and December 31, 2015 , trading equity funds of $69 million and $85 million , respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. (c) Gross unrealized gains and losses are not significant. (d) Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $91 million as of October 2, 2016 ; and foreign currency forward-exchange contracts with fair values of $136 million as of December 31, 2015 . (e) The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities at cost and short-term borrowings not measured at fair value on a recurring basis were not significant as of October 2, 2016 or December 31, 2015 . The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our priv ate equity securities carried at cost are based on Level 3 inputs. Short-term borrowings include foreign currency short-term borrowings with fair values of $547 million as of December 31, 2015 , which are used as hedging instruments. (f) Our private equity securities represent investments in the life sciences sector. (g) Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency swaps with fair values of $211 million and foreign currency forward-exchange contracts with fair values of $145 million as of October 2, 2016 ; and foreign currency swaps with fair values of $234 million and foreign currency forward-exchange contracts with fair values of $59 million as of December 31, 2015 . (h) We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. See Note 1B for additional information. (i) The fair value of our long-term debt (not including the current portion of long-term debt) was $34.3 billion as of October 2, 2016 and $32.7 billion as of December 31, 2015 . The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Generally, the difference between the fair value of our long-term debt and the amount reported on the condensed consolidated balance sheet is due to a decline in relative market interest rates since the debt issuance. The following table provides the classification of these selected financial assets and liabilities in our condensed consolidated balance sheets: (MILLIONS OF DOLLARS) October 2, December 31, Assets Cash and cash equivalents $ 628 $ 978 Short-term investments 12,277 19,649 Other current assets (a) 293 587 Long-term investments 9,507 15,999 Other noncurrent assets (b) 1,907 944 $ 24,613 $ 38,157 Liabilities Short-term borrowings, including current portion of long-term debt (c) $ 13,633 $ 10,159 Other current liabilities (d) 805 645 Long-term debt (c) 30,437 28,740 Other noncurrent liabilities (e) 1,050 1,064 $ 45,926 $ 40,608 (a) As of October 2, 2016 , derivative instruments at fair value include interest rate swaps ( $49 million ), foreign currency swaps ( $67 million ) and foreign currency forward-exchange contracts ( $177 million ) and, as of December 31, 2015 , include interest rate swaps ( $2 million ), foreign currency swaps ( $46 million ) and foreign currency forward-exchange contracts ( $538 million ). (b) As of October 2, 2016 , derivative instruments at fair value include interest rate swaps ( $1.9 billion ), foreign currency swaps ( $23 million ) and foreign currency forward-exchange contracts ( $9 million ) and, as of December 31, 2015 , include interest rate swaps ( $835 million ), foreign currency swaps ( $89 million ) and foreign currency forward-exchange contracts ( $20 million ). (c) We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. See Note 1B for additional information. (d) As of October 2, 2016 , derivative instruments at fair value include interest rate swaps ( $1 million ), foreign currency swaps ( $320 million ) and foreign currency forward-exchange contracts ( $483 million ) and, as of December 31, 2015 , include interest rate swaps ( $5 million ), foreign currency swaps ( $560 million ) and foreign currency forward-exchange contracts ( $80 million ). (e) As of October 2, 2016 , derivative instruments at fair value include interest rate swaps ( $2 million ), foreign currency swaps ( $1.0 billion ) and foreign currency forward-exchange contracts ( $20 million ) and, as of December 31, 2015 , include interest rate swaps ( $134 million ), foreign currency swaps ( $928 million ) and foreign currency forward-exchange contracts ( $1 million ). There were no significant impairments of financial assets recognized in any period presented. B. Investments in Debt Securities The following table provides the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: Years October 2, (MILLIONS OF DOLLARS) Within 1 Over 1 to 5 Over 5 to 10 Over 10 Total Available-for-sale debt securities Corporate debt (a) $ 2,399 $ 3,824 $ 2,088 $ 25 $ 8,336 Western European, Asian, Scandinavian and other government debt (b) 4,247 661 8 — 4,916 Federal Home Loan Mortgage Corporation and Federal National Mortgage Association asset-backed securities 3 56 1 — 61 U.S. government debt 702 93 — — 795 Western European, Scandinavian and other government agency debt (b) 1,245 137 — — 1,383 Supranational debt (b) 306 346 — — 652 Other asset-backed debt (c) 449 331 20 3 803 Government National Mortgage Association and other U.S. government guaranteed asset-backed securities 575 1 — — 576 Held-to-maturity debt securities Time deposits and other 1,046 1 — — 1,048 Western European government debt (b) 222 — — — 222 Total debt securities $ 11,195 $ 5,451 $ 2,118 $ 29 $ 18,792 (a) Issued by a diverse group of corporations, largely consisting of financial institutions, virtually all of which are investment-grade. (b) Issued by governments, government agencies or supranational entities, as applicable, all of which are investment-grade. (c) Includes loan-backed, receivable-backed, and mortgage-backed securities, all of which are investment-grade and in senior positions in the capital structure of the security. Loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans, and receivable-backed securities are collateralized by credit cards receivables. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages. These securities are valued by third party models that use significant inputs derived from observable market data like prepayment rates, default rates, and recovery rates. C. Short-Term Borrowings Short-term borrowings include amounts for commercial paper of $8.0 billion as of October 2, 2016 and $4.9 billion as of December 31, 2015 . On June 24, 2016, we acquired Anacor and assumed its short-term debt with an acquisition date fair value of $698 million , which was redeemed in the second and third quarters of 2016. D. Long-Term Debt On June 3, 2016, we completed a public offering of $5.0 billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of 2.09% . The notes are redeemable, in whole or in part, at any time at our option, at a redemption price equal to the greater of 100% of the principal amount of the notes or the sum of the present value of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate, plus an incremental spread ranging between 0.5% and 0.15% , depending on the maturity; plus, in each case, accrued and unpaid interest. Interest is payable semi-annually. The following table provides the principal amounts and components of unsecured long-term debt issued in the second quarter of 2016: (MILLIONS OF DOLLARS) Maturity Date As of October 2, 2016 1.20% Notes (2018 Notes) June 1, 2018 $ 1,250 1.45% Notes (2019 Notes) June 3, 2019 850 1.95% Notes (2021 Notes) June 3, 2021 1,150 2.75% Notes (2026 Notes) June 3, 2026 1,250 4.40% Notes (2044 Notes) May 15, 2044 500 Total long-term debt issued in the second quarter of 2016 $ 5,000 The following table provides the maturity schedule of our Long-term debt outstanding as of October 2, 2016: (MILLIONS OF DOLLARS) 2017 2018 2019 2020 After 2020 Total Maturities $ — $ 3,618 $ 5,678 $ 383 $ 20,758 $ 30,437 E. Derivative Financial Instruments and Hedging Activities Foreign Exchange Risk As of October 2, 2016 , the aggregate notional amount of foreign exchange derivative financial instruments hedging or offsetting foreign currency exposures was $36.4 billion . The derivative financial instruments primarily hedge or offset exposures in the euro, Japanese yen and U.K. pound. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our 1.9 billion U.K. pound debt maturing in 2038. Interest Rate Risk As of October 2, 2016 , the aggregate notional amount of interest rate derivative financial instruments was $19.5 billion . The derivative financial instruments primarily hedge U.S. dollar and euro fixed-rate debt. The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Three Months Ended Amount of Gains/(Losses) Recognized in OID (a), (b), (c) Amount of Gains/(Losses) Recognized in OCI (Effective Portion) (a), (d) Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion) (a), (d) (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, October 2, September 27, Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign currency swaps $ — $ — $ 87 $ (96 ) $ (39 ) $ (86 ) Foreign currency forward-exchange contracts 2 — (212 ) (89 ) (111 ) 120 Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency forward-exchange contracts — — — (5 ) — — Derivative Financial Instruments Not Designated as Hedges: Foreign currency forward-exchange contracts 20 50 — — — — Foreign currency swaps (4 ) — — — — — Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings — — — (12 ) — — All other net — — — (32 ) — — $ 18 $ 49 $ (126 ) $ (235 ) $ (150 ) $ 35 Nine Months Ended Amount of Gains/(Losses) Recognized in OID (a), (b), (c) Amount of Gains/(Losses) Recognized in OCI (Effective Portion) (a), (d) Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion) (a), (d) (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, October 2, September 27, Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign currency swaps $ — $ — $ (204 ) $ (594 ) $ (165 ) $ (451 ) Foreign currency forward-exchange contracts 1 — (770 ) 532 (118 ) 996 Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency forward-exchange contracts 1 2 (15 ) 254 — — Derivative Financial Instruments Not Designated as Hedges: Foreign currency forward-exchange contracts (49 ) (64 ) — — — — Foreign currency swaps (9 ) (2 ) — — — — Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings — — (26 ) 6 — — All other net — — 1 (18 ) — — $ (56 ) $ (64 ) $ (1,014 ) $ 180 $ (283 ) $ 545 (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income . (b) Also, includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges, as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships. (c) There was no significant ineffectiveness for any period presented. (d) For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income/(loss)––Unrealized holding losses on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income/(loss)––Foreign currency translation adjustments, net. For information about the fair value of our derivative financial instruments, and the impact on our condensed consolidated balance sheets, see Note 7A above . Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce our counterparties’ exposure to our risk of defaulting on amounts owed. As of October 2, 2016 , the aggregate fair value of these derivative instruments that are in a net liability position was $542 million , for which we have posted collateral of $551 million in the normal course of business. If there had been a downgrade to below an A rating by S&P or the equivalent rating by Moody ’ s, we would not have been required to post any collateral to our counterparties . F. Credit Risk On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty. As of October 2, 2016 , we had $2.1 billion due from a well-diversified, highly rated group (S&P ratings of mostly A or better) of bank counterparties around the world. For details about our investments, see Note 7B above. In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request collateral payments depending on levels of exposure. As of October 2, 2016 , we received cash collateral of $1.3 billion from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, the obligations are reported in Short-term borrowings, including current portion of long-term debt.

Inventories

Inventories	9 Months Ended
	Oct. 02, 2016
Inventory Disclosure [Abstract]
Inventories	Inventories The following table provides the components of Inventories : (MILLIONS OF DOLLARS) October 2, December 31, Finished goods $ 2,680 $ 2,714 Work-in-process 3,965 3,932 Raw materials and supplies 862 867 Inventories (a) $ 7,507 $ 7,513 Noncurrent inventories not included above (b) $ 583 $ 594 (a) The change from December 31, 2015 reflects, among other things, the reclassification of $369 million to Assets held for sale during the third quarter of 2016 (see Note 2B) . (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Identifiable Intangible Assets

Identifiable Intangible Assets and Goodwill	9 Months Ended
	Oct. 02, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Identifiable Intangible Assets and Goodwill	Identifiable Intangible Assets and Goodwill A. Identifiable Intangible Assets Balance Sheet Information The following table provides the components of Identifiable intangible assets : October 2, 2016 December 31, 2015 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights $ 83,935 $ (49,105 ) $ 34,830 $ 77,613 $ (47,193 ) $ 30,419 Brands 2,117 (1,013 ) 1,104 1,973 (928 ) 1,044 Licensing agreements and other 1,801 (985 ) 816 1,619 (918 ) 701 87,854 (51,103 ) 36,750 81,205 (49,040 ) 32,165 Indefinite-lived intangible assets Brands and other 6,918 6,918 7,021 7,021 In-process research and development 10,569 10,569 1,171 1,171 17,487 17,487 8,192 8,192 Identifiable intangible assets (a) $ 105,341 $ (51,103 ) $ 54,238 $ 89,396 $ (49,040 ) $ 40,356 (a) The increase in I dentifiable intangible assets, less accumulated amortization , is primarily related to assets acquired as part of the acquisitions of Medivation, Anacor and Bamboo (see Note 2A ), the impact of foreign exchange and the impact of measurement period adjustments related to our acquisition of Hospira (see Note 2A ), partially offset by amortization, impairments and the reclassification of $1.3 billion to Assets held for sale during the third quarter of 2016 (see Note 2B ). For information about impairments, see Note 4 . Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: October 2, 2016 IH EH WRD Developed technology rights 64 % 35 % — % Brands, finite-lived 74 % 26 % — % Brands, indefinite-lived 71 % 29 % — % In-process research and development 92 % 5 % 3 % Amortization Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets, as these intangible assets benefit multiple business functions. Amortization expense related to intangible assets that are associated with a single function is included in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses , as appropriate. Total amortization expense for finite-lived intangible assets was $988 million for the third quarter of 2016 and $950 million for the third quarter of 2015 , and $3.0 billion for the first nine months of 2016 and $2.8 billion for the first nine months of 2015 . I n-Process Research and Development For IPR&D assets, the risk of failure is significant and there can be no certainty that these assets ultimately will yield successful products. The nature of the biopharmaceutical business is high-risk and, as such, we expect that many of these IPR&D assets will become impaired and be written off at some time in the future. B. Goodwill The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) IH EH Total Balance, December 31, 2015 $ 23,809 $ 24,433 $ 48,242 Additions (a) 7,403 12 7,415 Other (b) 494 130 624 Balance, October 2, 2016 $ 31,706 $ 24,575 $ 56,281 (a) IH additions primarily relate to our acquisitions of Medivation, Anacor and Bamboo and are subject to change until we complete the valuations of assets acquired and liabilities assumed from Medivation, Anacor and Bamboo (see Note 2A ). (b) Primarily reflects the impact of foreign exchange and, with respect to EH, the impact of the reclassification of $243 million to Assets held for sale during the third quarter of 2016 (see Note 2B ). Effective in the second quarter of 2016, our segments were reorganized to reflect that we now manage our innovative pharmaceutical and consumer healthcare operations as one business segment, IH (previously these businesses were managed as two segments: the GIP segment and the VOC segment). As a result of this change, our goodwill associated with our former GIP segment is required to be reallocated to new reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit. Therefore, we have not yet completed the allocation, but we expect that it will be completed in the current year.

Pension and Postretirement Bene

Pension and Postretirement Benefit Plans	9 Months Ended
	Oct. 02, 2016
Compensation and Retirement Disclosure [Abstract]
Pension and Postretirement Benefit Plans	Pension and Postretirement Benefit Plans The following table provides the components of net periodic benefit cost: Three Months Ended Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) (b) International (c) Postretirement Plans (d) (MILLIONS OF DOLLARS) Oct 2, 2016 Sep 27, 2015 Oct 2, 2016 Sep 27, 2015 Oct 2, 2016 Sep 27, 2015 Oct 2, 2016 Sep 27, 2015 Net periodic benefit cost/(credit): Service cost (e) $ 69 $ 71 $ 5 $ 5 $ 41 $ 46 $ 11 $ 14 Interest cost (e) 218 169 18 13 58 77 33 26 Expected return on plan assets (239 ) (272 ) — — (95 ) (105 ) (8 ) (13 ) Amortization of: Actuarial losses 99 89 9 11 23 31 9 9 Prior service costs (credits) 1 (2 ) — — (1 ) (2 ) (45 ) (43 ) Curtailments 2 1 1 — — — (8 ) (4 ) Settlements 21 32 7 4 1 1 — — Special termination benefits — — — — — 1 — — $ 170 $ 88 $ 39 $ 33 $ 27 $ 49 $ (9 ) $ (11 ) Nine Months Ended Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) (b) International (c) Postretirement Plans (d) (MILLIONS OF DOLLARS) Oct 2, 2016 Sep 27, 2015 Oct 2, 2016 Sep 27, 2015 Oct 2, 2016 Sep 27, 2015 Oct 2, 2016 Sep 27, 2015 Net periodic benefit cost/(credit): Service cost (e) $ 193 $ 216 $ 14 $ 17 $ 126 $ 140 $ 31 $ 41 Interest cost (e) 486 505 40 41 178 232 77 91 Expected return on plan assets (721 ) (813 ) — — (291 ) (314 ) (25 ) (39 ) Amortization of: Actuarial losses 297 253 27 34 70 94 23 28 Prior service costs (credits) 4 (5 ) (1 ) (1 ) (2 ) (5 ) (127 ) (104 ) Curtailments 5 2 1 — (1 ) — (14 ) (20 ) Settlements 52 76 23 21 2 1 — — Special termination benefits — — — — — 1 — — $ 316 $ 235 $ 105 $ 110 $ 81 $ 150 $ (36 ) $ (5 ) (a) The increase in net periodic benefit costs for the three months ended October 2, 2016 , compared to the three months ended September 27, 2015 , for our U.S. qualified pension plans was primarily due to (i) higher interest costs resulting from a change in our approach in the third quarter of 2016 for measuring service and interest costs (the adjustment increased interest costs by $57 million related to prior periods in 2016 (see (e) below)), (ii) a lower expected return on plan assets resulting from a lower expected rate of return, as well as a net decrease of approximately $1.1 billion in the asset base, due in part to lump-sum payments made in 2015 to certain terminated vested colleagues to settle Pfizer’s pension obligation, partially offset by a voluntary contribution of $1.0 billion made at the beginning of January 2016, and (iii) an increase in the amounts amortized for actuarial losses, primarily as a result of the addition of Hospira qualified plans. The aforementioned increases were partially offset by lower settlement activity in 2016. The increase in net periodic benefit costs for the nine months ended October 2, 2016 , compared to the nine months ended September 27, 2015 , for our U.S. qualified pension plans was primarily driven by (i) a lower expected return on plan assets resulting from a lower expected rate of return, as well as a net decrease of approximately $1.1 billion in the asset base, due in part to lump-sum payments made in 2015 to certain terminated vested colleagues to settle Pfizer’s pension obligation, partially offset by a voluntary contribution of $1.0 billion made at the beginning of January 2016, and (ii) an increase in the amounts amortized for actuarial losses, primarily as a result of the addition of Hospira qualified plans. The aforementioned increases were partially offset by (i) lower service costs resulting from a higher discount rate, (ii) lower settlement activity, and (iii) lower interest costs resulting from a lower beginning benefit obligation. (b) The increase in net periodic benefit costs for the three months ended October 2, 2016 , compared to the three months ended September 27, 2015 , for our U.S. non-qualified pension plans was primarily due to (i) higher interest costs resulting from a change in our approach in the third quarter for measuring service and interest costs (the adjustment increased interest costs by $4 million related to prior periods in 2016 (see (e) below)), and (ii) higher settlement activity. The aforementioned increases were partially offset by a decrease in the amounts amortized for actuarial losses resulting from the increase in 2015 in the discount rate used to determine the benefit obligation. The decrease in net periodic benefit costs for the nine months ended October 2, 2016 , compared to the nine months ended September 27, 2015 , for our U.S. non-qualified pension plans was primarily driven by (i) a decrease in the amounts amortized for actuarial losses resulting from the increase in 2015 in the discount rate used to determine the benefit obligation, and (ii) lower service costs resulting from a higher discount rate. The aforementioned decreases were partially offset by an increase in settlement activity. (c) The decrease in net periodic benefit costs for the three and nine months ended October 2, 2016 , compared to the three and nine months ended September 27, 2015 , for our international pension plans was primarily driven by (i) lower service and interest costs, resulting from a change in our approach for measuring service and interest costs (see (e) below), and (ii) a decrease in the amounts amortized for actuarial losses resulting from large gains in 2015, which decreased the plan net loss position. The aforementioned decreases to our net periodic benefit costs were partially offset by a decrease in the expected return on plan assets due to a lower expected rate of return on plan assets. (d) The decrease in net periodic benefit credit for the three months ended October 2, 2016 , compared to the three months ended September 27, 2015 , for our postretirement plans was primarily driven by (i) higher interest costs resulting from a change in our approach in the third quarter of 2016 for measuring service and interest costs (the adjustment increased interest costs by $8 million related to prior periods in 2016 (see (e) below)), and (ii) a decrease in expected return on plan assets, resulting from a decrease in plan assets, reflecting payments by the plan for IRC 401(h) reimbursements to Pfizer for eligible 2014 and 2015 prescription drug expenses for certain retirees. The aforementioned changes were partially offset by (i) higher curtailment gains and (ii) lower service costs resulting from a higher discount rate. The increase in net periodic benefit credit for the nine months ended October 2, 2016 , compared to the nine months ended September 27, 2015 , for our postretirement plans was primarily driven by (i) an increase in prior service credits due to the postretirement medical plan cap changes during 2016 and 2015, (ii) lower interest costs resulting from a lower benefit obligation, and (iii) lower service costs resulting from a higher discount rate. The aforementioned changes were partially offset by (i) a decrease in expected return on plan assets, primarily resulting from a decrease in plan assets, reflecting payments by the plan for IRC 401(h) reimbursements to Pfizer for eligible 2014 and 2015 prescription drug expenses for certain retirees, (ii) lower curtailment gains, and (iii) a decrease in the amounts amortized for actuarial losses resulting from the increase in 2015 in the discount rate used to determine the benefit obligation. (e) Effective January 1, 2016, the Company changed the approach used to measure service and interest costs for certain international pension and other postretirement benefit plans. For fiscal 2015, the Company measured service and interest costs utilizing a single weighted-average discount rate derived from the yield curve used to measure the respective plan obligations. For fiscal 2016, we elected to measure service and interest costs by applying the spot rates along the yield curve for certain international plans to the plans' liability cash flows. The Company believes the new approach provides a more precise measurement of service and interest costs by aligning the timing of the plans’ liability cash flows to the corresponding spot rates on the yield curve. This change does not affect the measurement of our plan obligations. We have accounted for this change as a change in accounting estimate and, accordingly, have accounted for it on a prospective basis. The expected reduction in expense for 2016 associated with this change in estimate is $42 million , which is recognized evenly over each quarter of the year. Effective January 1, 2016, the Company made a similar change for its U.S. pension and other postretirement benefit plans, but in the third quarter of 2016, we determined that our use of the bond model required the measurement of such costs to be conceptually aligned with the measurement of the pension benefit obligation. As such, 2016 service and interest costs for the U.S. plans were measured utilizing a single weighted-average discount rate derived from the bond model consistent with the approach used in 2015, resulting in an adjustment to increase net periodic pension cost by $112 million in the third quarter of 2016. As of and for the nine months ended October 2, 2016 , we contributed and expect to contribute from our general assets as follows: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from/(reimbursements of) our general assets for the nine months ended October 2, 2016 (a) $ 1,000 $ 123 $ 145 $ (28 ) Expected contributions from our general assets during 2016 (b) $ 1,000 $ 146 $ 194 $ 20 (a) Contributions to the postretirement plans reflect IRC 401(h) reimbursements totaling $198 million received for eligible 2014 and 2015 prescription drug expenses for certain retirees. (b) Contributions expected to be made for 2016 are inclusive of amounts contributed during the nine months ended October 2, 2016 , including the $1.0 billion voluntary contribution that was made in January 2016 for the U.S. qualified plans, which was considered pre-funding for future anticipated mandatory contributions and is also expected to reduce Pension Benefit Guaranty Corporation variable rate premiums. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.

Earnings Per Common Share Attri

Earnings Per Common Share Attributable to Common Shareholders	9 Months Ended
	Oct. 02, 2016
Earnings Per Share [Abstract]
Earnings Per Common Share Attributable to Common Shareholders	Earnings Per Common Share Attributable to Common Shareholders The following table provides the detailed calculation of Earnings per common share (EPS) : Three Months Ended Nine Months Ended (IN MILLIONS) October 2, September 27, October 2, September 27, EPS Numerator––Basic Income from continuing operations $ 1,320 $ 2,130 $ 6,380 $ 7,141 Less: Net income attributable to noncontrolling interests — 9 25 23 Income from continuing operations attributable to Pfizer Inc. 1,320 2,122 6,355 7,118 Less: Preferred stock dividends––net of tax — — 1 1 Income from continuing operations attributable to Pfizer Inc. common shareholders 1,320 2,121 6,354 7,117 Discontinued operations––net of tax — 8 — 14 Less: Discontinued operations––net of tax, attributable to noncontrolling interests — — — — Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders — 8 — 14 Net income attributable to Pfizer Inc. common shareholders $ 1,319 $ 2,130 $ 6,355 $ 7,131 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 1,320 $ 2,121 $ 6,355 $ 7,117 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions — 8 — 14 Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 1,320 $ 2,130 $ 6,355 $ 7,131 EPS Denominator Weighted-average number of common shares outstanding––Basic 6,066 6,168 6,095 6,176 Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements 72 75 68 83 Weighted-average number of common shares outstanding––Diluted 6,138 6,243 6,164 6,259 Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (a) 36 55 56 48 (a) These common stock equivalents were outstanding for the nine months ended October 2, 2016 and September 27, 2015 , but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Oct. 02, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see Note 5B. On March 8, 2016, we entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. (GS&Co.) to repurchase $5 billion of our common stock. Pursuant to the terms of the agreement, on March 10, 2016, we paid $5 billion to GS&Co. and received an initial delivery of approximately 136 million shares of our common stock from GS&Co. based on a price of $29.36 per share, which represented, based on the closing share price of our common stock on the NYSE on March 8, 2016, approximately 80% of the notional amount of the accelerated share repurchase agreement. On June 20, 2016, the accelerated share repurchase agreement with GS&Co. was completed, which, per the terms of the agreement, resulted in GS&Co. owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement’s settlement terms, we received an additional 18 million shares of our common stock from GS&Co. on June 20, 2016. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was $32.38 per share. The common stock received is included in Treasury stock . This agreement was entered into pursuant to our previously announced share repurchase authorization. After giving effect to this accelerated share repurchase agreement, our remaining share-purchase authorization is approximately $11.4 billion at October 2, 2016 . A. Legal Proceedings Our non-tax contingencies include, but are not limited to, the following: • Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the vast majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets. • Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters. • Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter. • Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other countries. Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial. We believe that our claims and defenses in these matters are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid. We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote. A1. Legal Proceedings––Patent Litigation Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other countries. We are also party to other patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for alleged delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering several of their products that may impact our licenses or co-promotion rights to such products. We are also subject to patent litigation pursuant to which one or more third parties seeks damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our subsidiary, Hospira, is involved in patent and patent-related disputes over its attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party. Actions In Which We Are The Plaintiff EpiPen In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz, Inc., a division of Novartis AG (Sandoz), in the U.S. District Court for the District of New Jersey in connection with Sandoz’s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name. Toviaz (fesoterodine) We have an exclusive, worldwide license to market Toviaz from UCB Pharma GmbH (UCB), which owns the patents relating to Toviaz. Beginning in May 2013, several generic drug manufacturers notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the FDA’s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the “Orange Book”. Beginning in June 2013, we filed actions against all of those generic drug manufacturers in the U.S. District Court for the District of Delaware, asserting the infringement of five of the patents for Toviaz: three composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. In June and July 2015, we settled with four of the generic defendants. The trial relating to the four remaining defendants occurred in July 2015. In April 2016, the District Court held that the patents that were the subject of the lawsuit were valid and infringed. The defendants’ deadline to appeal this decision expired in June 2016. In December 2014, Mylan Pharmaceuticals, Inc. (Mylan Pharmaceuticals) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the Orange Book. In January 2015, we filed an action against Mylan Pharmaceuticals in the U.S. District Court for the District of Delaware, asserting the infringement of five of the patents for Toviaz: three composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. Tygacil (tigecycline) In November 2014, Mylan Laboratories Limited (formerly Agila Specialties Private Limited) (Mylan Laboratories) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Tygacil. Mylan Laboratories asserts the invalidity and non-infringement of the polymorph patent for Tygacil and the formulation patent for Tygacil. Mylan Laboratories has not challenged the composition-of-matter patent. In January 2015, we filed suit against Mylan Laboratories in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the polymorph patent and the formulation patent for Tygacil. In addition, in September 2015 and December 2015, we received notices of Section 505(b)(2) new drug applications filed by each of Mylan Laboratories and Accord Healthcare Inc. (Accord) for tigecycline injectable products. Mylan Laboratories and Accord assert the invalidity and non-infringement of the polymorph patent for Tygacil and two formulation patents for Tygacil that expire in 2028 and 2029, respectively. In October 2015, we filed suit against Mylan Laboratories in the U.S. District Court for the District of Delaware and in the U.S. District Court for the District of West Virginia asserting the validity and infringement of the patents that are the subject of the lawsuit. In February 2016, we filed suit against Accord in the U.S. District Court for the District of Delaware and in the U.S. District Court for the Middle District of North Carolina asserting the validity and infringement of the patents that are the subject of the lawsuit. Precedex Premix In June 2014, Ben Venue Laboratories, Inc. (Ben Venue) notified our subsidiary, Hospira, that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that a patent relating to the use of Precedex in an intensive care unit setting, which expires in March 2019, was invalid or not infringed. In August 2014, Hospira and Orion Corporation (co-owner of the patent that is the subject of the lawsuit) filed suit against Ben Venue, Hikma Pharmaceuticals PLC (Hikma), and West-Ward Pharmaceutical Corp. in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patent that is the subject of the lawsuit. In October 2014, Eurohealth International Sarl was substituted for Ben Venue and Hikma. In June 2016, this case was settled on terms not material to Pfizer. In June 2015, Amneal Pharmaceuticals LLC (Amneal) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In August 2015, Hospira filed suit against Amneal in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit. In December 2015, Fresenius Kabi USA LLC (Fresenius) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In January 2016, Hospira filed suit against Fresenius in the U.S. District Court for the Northern District of Illinois asserting the validity and infringement of the patents that are the subject of the lawsuit. In August 2016, Par Sterile Products, LLC (Par) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In September 2016, Hospira filed suit against Par in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit. Matters Involving Our Collaboration/Licensing Partners Nexium 24HR (esomeprazole) We have an exclusive license from AstraZeneca PLC (AstraZeneca) to market in the U.S. the OTC version of Nexium (Nexium 24HR). Beginning in October 2014, Actavis Laboratories FL, Inc., and subsequently Andrx Labs, LLC (Andrx), Perrigo Company plc (Perrigo), Lupin Limited and, in October 2015, Dr. Reddy’s Laboratories, Inc. & Ltd. (Dr. Reddy’s) notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Nexium 24HR prior to the expiration of one or more of AstraZeneca’s patents listed in the Orange Book for Nexium 24HR. From November 2014 through November 2015, AstraZeneca filed actions against each of Actavis Laboratories FL, Inc., Andrx, Perrigo, Lupin Limited and Dr. Reddy’s in the U.S. District Court for the District of New Jersey asserting the infringement of the challenged patents. We are not a party to AstraZeneca’s patent-infringement actions. Toviaz (fesoterodine)––Inter-Partes Reviews In January 2016, Mylan Pharmaceuticals and Mylan Laboratories filed petitions with the U.S. Patent & Trademark Office requesting Inter Partes Reviews of five of the patents covering fesoterodine, the active ingredient in Toviaz: three composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. The patents are owned by UCB, and we have an exclusive, worldwide license to market Toviaz from UCB. In July 2016, the Patent Trial and Appeal Board agreed to institute Inter Partes Reviews of all five patents. Action In Which We Are The Defendant Inflectra (infliximab-dyyb) In March 2015, Janssen and New York University, together, brought a patent-infringement action in the U.S. District Court for the District of Massachusetts against Hospira, Celltrion Healthcare Co. Ltd. and Celltrion Inc. alleging that infliximab-dyyb, to be marketed by Hospira in the U.S. under the brand name Inflectra, would infringe six patents relating to infliximab, its manufacture and use. Four of the patents have since been dismissed by the plaintiffs, leaving two patents at issue in the ongoing action: the infliximab antibody patent and a patent relating to cell culture media. In August 2016, the U.S. District Court for the District of Massachusetts ruled that the antibody patent was invalid, and Janssen has appealed that ruling to the Court of Appeals for the Federal Circuit. A2. Legal Proceedings––Product Litigation Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. Asbestos Between 1967 and 1982, Warner-Lambert owned American Optical Corporation, which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. As of October 2, 2016 , approximately 56,000 claims naming American Optical and numerous other defendants were pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly-owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims. Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products containing asbestos and other allegedly hazardous materials sold by Gibsonburg Lime Products Company (Gibsonburg). Gibsonburg was acquired by Pfizer in the 1960s and sold products containing small amounts of asbestos until the early 1970s. There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries. Celebrex and Bextra Beginning in late 2004, several purported class actions were filed in federal and state courts alleging that Pfizer and certain of our current and former officers violated federal securities laws by misrepresenting the safety of Celebrex and Bextra. In June 2005, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation ( In re Pfizer Inc. Securities, Derivative and “ERISA” Litigation MDL-1688 ) in the U.S. District Court for the Southern District of New York. In March 2012, the court in the Multi-District Litigation certified a class consisting of all persons who purchased or acquired Pfizer stock between October 31, 2000 and October 19, 2005. In May 2014, the court in the Multi-District Litigation granted Pfizer’s motion to exclude the testimony of the plaintiffs’ loss causation and damages expert. We subsequently filed a motion for summary judgment seeking dismissal of the litigation, and the plaintiffs filed a motion for leave to submit an amended report by their expert. In July 2014, the court denied the plaintiffs’ motion for leave to submit an amended report and granted our motion for summary judgment, dismissing the plaintiffs’ claims in their entirety. In August 2014, the plaintiffs appealed the District Court’s decision to the U.S. Court of Appeals for the Second Circuit. In April 2016, the U.S. Court of Appeals for the Second Circuit reversed the District Court’s decision and remanded the case to the District Court for further proceedings. In July 2016, the parties reached an agreement in principle to resolve this matter for all defendants for $486 million , which was recorded in Other (income)/deductions––net for the nine months ended October 2, 2016 . The agreement is subject to final court approval, and the payment will be made in accordance with the terms of the settlement agreement. Effexor • Personal Injury Actions A number of individual lawsuits and multi-plaintiff lawsuits have been filed against us and/or our subsidiaries in various federal and state courts alleging personal injury as a result of the purported ingestion of Effexor. Among other types of actions, the Effexor personal injury litigation includes actions alleging a variety of birth defects as a result of the purported ingestion of Effexor by women during pregnancy. Plaintiffs in these birth-defect actions seek compensatory and punitive damages. In August 2013, the federal birth-defect cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation ( In re Effexor ( Venlafaxine Hydrochloride) Products Liability Litigation MDL-2458 ) in the U.S. District Court for the Eastern District of Pennsylvania. Almost all plaintiffs have voluntarily dismissed their actions. The Multi-District Litigation, as well as the coordinated state court proceedings in California, have been administratively stayed. • Antitrust Actions Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. In October 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs have appealed to the U.S. Court of Appeals for the Third Circuit. Motions to dismiss remain pending as to the end-payer plaintiffs’ remaining claims. Zoloft A number of individual lawsuits and multi-plaintiff lawsuits have been filed against us and/or our subsidiaries in various federal and state courts alleging personal injury as a result of the purported ingestion of Zoloft. Among other types of actions, the Zoloft personal injury litigation includes actions alleging a variety of birth defects as a result of the purported ingestion of Zoloft by women during pregnancy. Plaintiffs in these birth-defect actions seek compensatory and punitive damages and the disgorgement of profits resulting from the sale of Zoloft. In April 2012, the federal birth-defect cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation ( In re Zoloft Products Liability Litigation MDL-2342 ) in the U.S. District Court for the Eastern District of Pennsylvania. A number of plaintiffs have voluntarily dismissed their actions. In April 2016, the District Court granted our motion for summary judgment, dismissing the claims of almost all of the remaining plaintiffs. In May 2016, the plaintiffs appealed the District Court’s decision to the U.S. Court of Appeals for the Third Circuit. Lipitor • Whistleblower Action In 2004, a former employee filed a “whistleblower” action against us in the U.S. District Court for the Eastern District of New York. The complaint remained under seal until September 2007, at which time the U.S. Attorney for the Eastern District of New York declined to intervene in the case. We were served with the complaint in December 2007. Plaintiff alleges off-label promotion of Lipitor in violation of the Federal Civil False Claims Act and the false claims acts of certain states, and he seeks treble damages and civil penalties on behalf of the federal government and the specified states as the result of their purchase, or reimbursement of patients for the purchase, of Lipitor allegedly for such off-label uses. Plaintiff also seeks compensation as a whistleblower under those federal and state statutes. In addition, plaintiff alleges that he was wrongfully terminated, in violation of the anti-retaliation provisions of applicable federal and New York law, and he seeks damages and the reinstatement of his employment. In 2009, the District Court dismissed without prejudice the off-label promotion claims and, in 2010, plaintiff filed an amended complaint containing off-label promotion allegations that are substantially similar to the allegations in the original complaint. In November 2012, the District Court dismissed the amended complaint. In December 2012, plaintiff appealed the District Court’s decision to the U.S. Court of Appeals for the Second Circuit. In August 2014, the U.S. Court of Appeals for the Second Circuit dismissed the appeal for lack of jurisdiction and sent the case back to the District Court for clarification of its ruling regarding the plaintiff’s employment claims. In November 2014, the District Court granted plaintiff’s motion for a partial final judgment certifying the dismissal of the false claims counts, and plaintiff appealed the order dismissing those claims to the U.S. Court of Appeals for the Second Circuit. In May 2016, the U.S. Court of Appeals for the Second Circuit affirmed the District Court’s dismissal of the false claims counts, and it subsequently denied a petition for panel rehearing. In November 2016, the District Court administratively closed Plaintiff’s employment law claims, subject to plaintiff requesting to reopen them by January 2017. • Antitrust Actions Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants’ allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation (MDL) ( In re Lipitor Antitrust Litigation MDL-2332 ) in the U.S. District Court for the District of New Jersey. In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other MDL plaintiffs. All plaintiffs have appealed the District Court’s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit. Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. • Personal Injury Actions A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes as a result of the purported ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation ( In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502 ) in the U.S. District Court for the District of South Carolina. Viagra A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed melanoma and/or the exacerbation of melanoma as a result of the purported ingestion of Viagra. Plaintiffs seek compensatory and punitive damages. In April 2016, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation ( In Re: Viagra (Sildenafil Citrate) Products Liability Litigation, MDL-2691 ) in the U.S. District Court for the Northern District of California. Chantix/Champix Beginning in December 2008, purported class actions were filed against us in the Ontario Superior Court of Justice (Toronto Region), the Superior Court of Quebec (District of Montreal), the Court of Queen’s Bench of Alberta, Judicial District of Calgary, and the Superior Court of British Columbia (Vancouver Registry) on behalf of all individuals and third-party payers in Canada who have purchased and ingested Champix or reimbursed patients for the purchase of Champix. Each of these actions asserts claims under Canadian product liability law, including with respect to the safety and efficacy of Champix, and, on behalf of the putative class, seeks monetary relief, including punitive damages. In June 2012, the Ontario Superior Court of Justice certified the Ontario proceeding as a class action, defining the class as consisting of the following: (i) all persons in Canada who ingested

Segment, Geographic and Other R

Segment, Geographic and Other Revenue Information	9 Months Ended
	Oct. 02, 2016
Segment Reporting [Abstract]
Segment, Geographic and Other Revenue Information	Segment, Geographic and Other Revenue Information A. Segment Information We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Effective in the second quarter of 2016, our segments were reorganized to reflect that we now manage our innovative pharmaceutical and consumer healthcare operations as one business segment, IH (previously these businesses were managed as two segments: the GIP segment and the VOC segment). We have revised prior-period information (Revenues and Earnings, as defined by management) to reflect the reorganization. Also, in the second quarter of 2016, we changed the name of our Established Products business to Pfizer Essential Health. The IH and EH segments are each led by a single manager. Each operating segment has responsibility for its commercial activities and for certain IPR&D projects for new investigational products and additional indications for in-line products that generally have achieved proof-of-concept. Each business has a geographic footprint across developed and emerging markets. We regularly review our segments and the approach used by management to evaluate performance and allocate resources. Operating Segments Some additional information about our business segments follows: IH Segment EH Segment IH focuses on developing and commercializing novel, value-creating medicines and vaccines that significantly improve patients’ lives, as well as products for consumer healthcare. Key therapeutic areas include internal medicine, vaccines, oncology, inflammation & immunology, rare diseases and consumer healthcare and include leading brands, such as Prevnar/Prevenar 13, Xeljanz, Eliquis, Lyrica (U.S., Japan and certain other markets), Enbrel (outside the U.S. and Canada), Viagra (U.S. and Canada), Ibrance and Xtandi, as well as several well-known, OTC consumer products. EH includes legacy brands that have lost or will soon lose market exclusivity in both developed and emerging markets, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a new EH research and development organization as well as our contract manufacturing business. Effective as of the beginning of 2016, the following changes impact EH: • Our entire contract manufacturing business, Pfizer CentreOne (previously known as Pfizer CentreSource or PCS), is part of EH. Pfizer CentreOne consists of (i) the revenues and expenses of legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including the revenues and expenses related to our manufacturing and supply agreements with Zoetis; and (ii) the revenues and expenses of legacy Hospira's One-2-One sterile injectables contract manufacturing operation, which has been included in EH since we acquired Hospira on September 3, 2015. Prior to 2016, PCS was managed outside our operating segments as part of PGS and reported as "Other Business Activities". We have reclassified prior period PCS operating results ( $116 million of PCS revenues and $15 million of PCS earnings in the third quarter of 2015, and $360 million of PCS revenues and $66 million of PCS earnings in the first nine months of 2015) to conform to the current period presentation as part of EH. • In connection with the formation of a new EH R&D organization, certain functions transferred from Pfizer’s WRD organization to the new EH R&D organization. The new R&D organization within EH expects to develop potential new sterile injectable drugs and therapeutic solutions, as well as biosimilars. We have reclassified approximately $68 million of costs in the third quarter of 2015 and $202 million of costs in the first nine months of 2015 from WRD to EH to conform to the current period presentation as part of EH. Effective as of the beginning of the second quarter of 2016, the following changes impact IH: • In connection with the formation of the GPD organization, a new unified center for late-stage development for our innovative products, which is generally responsible for the clinical development of assets that are in clinical trials for our WRD and Innovative portfolios, certain development-related functions transferred from IH to GPD. We have reclassified approximately $76 million of costs in the first quarter of 2016, approximately $77 million of costs in the third quarter of 2015 and approximately $223 million of costs in the first nine months of 2015 from IH to GPD to conform to the current period presentation as part of GPD. Our chief operating decision maker uses the revenues and earnings of the two operating segments, among other factors, for performance evaluation and resource allocation. Other Costs and Business Activities Certain costs are not allocated to our operating segment results, such as costs associated with the following: • WRD, which is generally responsible for research projects for our IH business until proof-of-concept is achieved and then for transitioning those projects to the IH segment via the newly formed GPD organization for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. The WRD organization also has responsibility for certain science-based and other platform-services organizations, which provide technical expertise and other services to the various R&D projects, including EH R&D projects. WRD is also responsible for facilitating all regulatory submissions and interactions with regulatory agencies, including all safety-event activities. • GPD, which is generally responsible for the clinical development of assets that are in clinical trials for our WRD and Innovative portfolios. GPD also provides technical support and other services to Pfizer R&D projects. In connection with the formation of the GPD organization, certain development-related functions transferred from WRD and IH to GPD. In addition to the costs transferred from IH to GPD described above, we reclassified costs from WRD of approximately $78 million in the first quarter of 2016, approximately $86 million in the third quarter of 2015 and approximately $244 million in the first nine months of 2015 to GPD to conform to the current period presentation as part of GPD. • Pfizer Medical, which is responsible for the provision of medical information to healthcare providers, patients and other parties, transparency and disclosure activities, clinical trial results publication, grants for healthcare quality improvement and medical education, and partnerships with global public health and medical associations. • Corporate, representing platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement) and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments. • Other unallocated costs, representing overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment. • Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, which are substantive and in some cases recurring, or unusual items that are evaluated on an individual basis by management and which include non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities. Segment Assets We manage our assets on a total company basis, not by operating segment, as many of our operating assets are shared (such as our plant network assets) or commingled (such as accounts receivable, as many of our customers are served by both operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $178 billion as of October 2, 2016 and approximately $167 billion as of December 31, 2015 . Selected Income Statement Information The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, Reportable Segments: IH (b) $ 7,332 $ 6,752 $ 4,187 $ 4,018 EH (c) 5,712 5,335 3,128 3,181 Total reportable segments 13,045 12,087 7,315 7,199 Other business activities (d) — — (786 ) (715 ) Reconciling Items: Corporate (e) — — (1,504 ) (1,376 ) Purchase accounting adjustments (e) — — (966 ) (960 ) Acquisition-related costs (e) — — (280 ) (541 ) Certain significant items (f) — — (1,969 ) (837 ) Other unallocated — — (206 ) (73 ) $ 13,045 $ 12,087 $ 1,604 $ 2,697 Nine Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, Reportable Segments: IH (b) $ 21,471 $ 19,120 $ 12,470 $ 10,831 EH (c) 17,725 15,683 9,985 9,540 Total reportable segments 39,196 34,804 22,454 20,371 Other business activities (d) — — (2,190 ) (2,127 ) Reconciling Items: Corporate (e) — — (4,123 ) (3,949 ) Purchase accounting adjustments (e) — — (3,103 ) (2,698 ) Acquisition-related costs (e) — — (598 ) (631 ) Certain significant items (f) — — (4,112 ) (1,369 ) Other unallocated — — (753 ) (278 ) $ 39,196 $ 34,804 $ 7,575 $ 9,319 (a) Income from continuing operations before provision for taxes on income. (b) Effective as of the beginning of the second quarter of 2016, in connection with the formation of the GPD organization, certain development-related functions transferred from IH to GPD. We have reclassified approximately $76 million of costs in the first quarter of 2016, approximately $77 million of costs in the third quarter of 2015 and approximately $223 million of costs in the first nine months of 2015 from IH to GPD to conform to the current period presentation as part of GPD. Additionally, Anacor's and Medivations’s commercial operations are included in IH's operating results in our condensed consolidated statements of income. As a result, commencing from the acquisition date of June 24, 2016, IH's operating results for the third quarter and first nine months of 2016 include approximately three months of legacy Anacor operations, which were immaterial, and commencing from the acquisition date of September, 28, 2016, IH's operating results for the third quarter and first nine months of 2016 reflect three business days of legacy Medivation operations, which were immaterial. (c) On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Hospira. As a result, legacy Hospira commercial operations, including the legacy Hospira One-2-One contract manufacturing business, are included in EH’s operating results in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. See Note 2A for additional information. Effective as of the beginning of 2016, our entire contract manufacturing business, Pfizer CentreOne (previously known as Pfizer CentreSource or PCS), is part of EH. Pfizer CentreOne consists of (i) the revenues and expenses of legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including the revenues and expenses related to our manufacturing and supply agreements with Zoetis; and (ii) the revenues and expenses of legacy Hospira's One-2-One sterile injectables contract manufacturing operation, which has been included in EH since we acquired Hospira on September 3, 2015. Prior to 2016, PCS was managed outside our operating segments as part of PGS and reported as "Other Business Activities". We have reclassified prior period PCS operating results ( $116 million of PCS revenues and $15 million of PCS earnings in the third quarter of 2015, and $360 million of PCS revenues and $66 million of PCS earnings in the first nine months of 2015) to conform to the current period presentation as part of EH. As noted above, also effective as of the beginning of 2016, in connection with the formation of a new EH R&D organization, certain functions transferred from Pfizer’s WRD organization to the new EH R&D organization. We have reclassified approximately $68 million of costs in the third quarter of 2015 and $202 million of costs in the first nine months of 2015 from WRD to EH to conform to the current period presentation as part of EH. (d) Other business activities includes the costs managed by our WRD, GPD and Pfizer Medical organizations. (e) For a description, see the “Other Costs and Business Activities” section above. (f) Certain significant items are substantive and in some cases recurring (such as restructuring or legal charges), or unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the third quarter of 2016, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $375 million , (ii) income for certain legal matters of $40 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion , (iv) certain asset impairment charges of $126 million , (v) charges for business and legal entity alignment of $69 million and (vi) other charges of $17 million . For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the third quarter of 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $107 million , (ii) certain asset impairment charges of $633 million , (iii) charges for business and legal entity alignment of $60 million and (iv) other charges of $36 million . For additional information, see Note 3 and Note 4. For Earnings in the first nine months of 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $743 million , (ii) charges for certain legal matters of $506 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion , (iv) certain asset impairment charges of $1.1 billion , (v) charges for business and legal entity alignment of $180 million and (vi) other charges of $189 million . For additional information, see Note 2B , Note 3 and Note 4. For Earnings in the first nine months of 2015 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $302 million , (ii) certain asset impairment charges of $633 million , (iii) charges for business and legal entity alignment of $224 million , (iv) charges for certain legal matters of $92 million , and (v) other charges of $117 million . For additional information, see Note 3 and Note 4. Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments. The operating segment information does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented. B. Geographic Information The following table provides revenues by geographic area (a) : Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 2, September 27, % Change October 2, September 27, % Change U.S. $ 6,530 $ 5,565 17 $ 19,561 $ 14,993 30 Developed Europe (b) 2,218 2,315 (4 ) 6,982 7,006 — Developed Rest of World (c) 1,711 1,513 13 4,940 4,562 8 Emerging Markets (d) 2,586 2,694 (4 ) 7,714 8,243 (6 ) Revenues $ 13,045 $ 12,087 8 $ 39,196 $ 34,804 13 (a) On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Hospira. As a result, legacy Hospira operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016 . In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. On June 24, 2016, we acquired Anacor. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Anacor. As a result, legacy Anacor operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016 . In accordance with our domestic reporting period, our results of operations and IH's operating results for the third quarter and first nine months of 2016 include approximately three months of legacy Anacor operations. Additionally, on September 28, 2016, we acquired Medivation. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Medivation. As a result, legacy Medivation operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016 . In accordance with our domestic and international reporting periods, our results of operations and IH's operating results for the third quarter and first nine months of 2016 reflect three business days of legacy Medivation operations, which were immaterial. See Note 2A for additional information. (b) Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries. Revenues denominated in euros were $1.7 billion and $1.8 billion in the third quarter of 2016 and 2015 , respectively, and $5.3 billion and $5.4 billion in the first nine months of 2016 and 2015 , respectively. (c) Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea. (d) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey. C. Other Revenue Information Significant Product Revenues The following table provides detailed revenue information: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, PFIZER INNOVATIVE HEALTH (IH) (a) $ 7,332 $ 6,752 $ 21,471 $ 19,120 Internal Medicine $ 2,243 $ 1,954 $ 6,557 $ 5,500 Lyrica IH (b) 1,049 947 3,107 2,701 Viagra IH (c) 297 333 897 955 Chantix/Champix 198 159 631 491 Toviaz 60 59 191 193 BMP2 63 57 175 169 Alliance revenues (d) 417 343 1,139 841 All other Internal Medicine (m) 159 56 416 149 Vaccines $ 1,641 $ 1,629 $ 4,576 $ 4,536 Prevnar/Prevenar 13 1,536 1,576 4,302 4,384 FSME/IMMUN-TicoVac 33 28 102 93 All other Vaccines 72 26 172 60 Oncology $ 1,104 $ 786 $ 3,206 $ 2,026 Ibrance 550 230 1,492 408 Sutent 260 279 823 815 Xalkori 140 122 415 353 Inlyta 95 105 304 311 All other Oncology 60 50 172 139 Inflammation & Immunology (I&I) $ 960 $ 987 $ 2,907 $ 2,816 Enbrel (Outside the U.S. and Canada) 701 844 2,201 2,426 Xeljanz 235 127 649 351 All othe r I&I 24 16 57 40 Rare Disease $ 585 $ 579 $ 1,768 $ 1,776 BeneFIX 176 194 543 561 Genotropin 147 142 425 447 Refacto AF/Xyntha 140 130 408 392 Somavert 59 54 173 158 Rapamune 38 32 131 138 All other Rare Disease 25 27 88 80 Consumer Healthcare $ 798 $ 817 $ 2,457 $ 2,465 PFIZER ESSENTIAL HEALTH (EH) ( e) $ 5,712 $ 5,335 $ 17,725 $ 15,683 Legacy Established Products (LEP) (f) $ 2,708 $ 2,919 $ 8,373 $ 8,701 Lipitor 422 454 1,294 1,404 Premarin family 244 263 751 753 Norvasc 238 241 714 744 EpiPen 110 107 300 268 Xalatan/Xalacom 91 98 273 299 Relpax 83 91 248 254 Zoloft 72 95 228 274 Effexor 70 66 207 213 Zithromax/Zmax (g) 56 63 203 203 Xanax/Xanax XR 55 55 163 164 Cardura 49 52 143 158 Neurontin 45 45 136 148 Tikosyn 20 44 136 123 Depo-Provera 36 45 103 133 All other LEP 1,119 1,199 3,473 3,563 Sterile Injectable Pharmaceuticals (SIP) (h) $ 1,461 $ 957 $ 4,481 $ 2,436 Medrol (g) 102 98 330 284 Sulperazon 102 72 304 251 Fragmin 80 84 240 246 Tygacil 69 81 203 231 All other SIP 1,108 621 3,405 1,424 Peri-LOE Products (i) $ 1,023 $ 1,229 $ 3,224 $ 4,073 Lyrica EH (b) 191 273 623 925 Celebrex 194 212 550 640 Pristiq 174 185 546 523 Vfend 140 165 459 510 Zyvox 94 165 334 696 Viagra EH (c) 89 97 286 318 Revatio 73 53 213 181 All Other Peri-LOE Products 68 79 214 280 Infusion Systems (j) $ 281 $ 94 $ 879 $ 94 Biosimilars (k) $ 83 $ — $ 228 $ — Pfizer CentreOne (l) $ 156 $ 136 $ 540 $ 380 Revenues $ 13,045 $ 12,087 $ 39,196 $ 34,804 Total Lyrica (b) $ 1,240 $ 1,220 $ 3,730 $ 3,626 Total Viagra (c) $ 387 $ 430 $ 1,183 $ 1,274 Total Alliance revenues $ 419 $ 349 $ 1,155 $ 881 (a) The IH business, previously known as the Innovative Products business, encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare and includes all legacy Medivation and Anacor commercial operations. Medivation’s and Anacor’s commercial operations are included in IH’s operating results in our condensed consolidated statements of income, commencing from the acquisition date of September 28, 2016 for Medivation and from the acquisition date of June 24, 2016 for Anacor. As a result, IH’s revenues for the third quarter and first nine months of 2016 include three business days of legacy Medivation operations and approximately three months of legacy Anacor operations, which were immaterial. (b) Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH. (c) Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH. (d) Includes Eliquis (2016 and 2015) and Rebif (2015 only). (e) The EH business, previously known as the Established Products business, encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Infusion Systems, Biosimilars and Pfizer CentreOne and includes all legacy Hospira commercial operations. Hospira's commercial operations, including the legacy Hospira One-2-One sterile injectables contract manufacturing business, are included in EH’s operating results in our condensed consolidated statements of income, commencing from the acquisition date of September 3, 2015. Therefore, in accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. Also, effective as of the beginning of 2016, our entire contract manufacturing business, Pfizer CentreOne (previously known as Pfizer CentreSource or PCS), is part of EH. Pfizer CentreOne consists of (i) legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including our manufacturing and supply agreements with Zoetis; and (ii) legacy Hospira's One-2-One sterile injectables contract manufacturing operation. Prior to 2016, PCS was managed outside our operating segments and its revenues were reported as other business activities. We have reclassified prior period PCS revenues ( $116 million in the third quarter of 2015 and $360 million in the first nine months of 2015 ) to conform to the current period presentation as part of EH. (f) Legacy Established Products include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). (g) Prior period revenues for Medrol and Zithromax/Zmax may not agree to previously-disclosed revenues because revenues for those products are now split between the Legacy Established Products and the Sterile Injectable Pharmaceuticals categories. (h) Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products). (i) Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products primarily include Lyrica in certain developed Europe markets, Pristiq globally, Celebrex, Zyvox and Revatio in most developed markets, Vfend and Viagra in certain developed Europe markets and Japan, and Inspra in the EU. (j) Infusion Systems include Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets. (k) Biosimilars include Inflectra (biosimilar infliximab) in certain European markets, Nivestim (biosimilar filgrastim) in certain Asian markets and Retacrit (biosimilar epoetin zeta) in certain international markets. (l) Pfizer CentreOne (previously known as Pfizer CentreSource or PCS) includes (i) revenues from legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including revenues related to our manufacturing and supply agreements with Zoetis; and (ii) revenues from legacy Hospira’s One-2-One sterile injectables contract manufacturing operation. (m) Includes Eliquis direct sales markets. We performed certain reclassifications, primarily between Legacy Established Products and Sterile Injectable Pharmaceuticals, to conform to current period presentation.

Subsequent Event Regarding Equi

Subsequent Event Regarding Equity	9 Months Ended
	Oct. 02, 2016
Subsequent Events [Abstract]
Subsequent Event Regarding Equity	Subsequent Event Regarding Equity On October 26, 2016, the Compensation Committee approved the modification of current outstanding grants of TSRU awards, to permit a holder who is "retiree eligible" (at least age 55 with at least 10 years of service), to elect to exercise and convert his/her TSRUs when vested, into PTUs. The value received upon the election and conversion is calculated by taking the change in stock price ( 20 trading day average ending on the exercise date (Election Price) less the grant price) plus accumulated dividends from the grant date, times the number of TSRUs exercised. This value is divided by the Election Price to determine the number of PTUs. The PTUs will be entitled to earn DEUs, and the PTUs and DEUs will be settled in Pfizer common stock on the TSRUs original settlement date (i.e., the fifth or seventh anniversary of grant), and will be subject to all of the terms and conditions of the original grant including forfeiture provisions. This modification applies to approximately 2,900 employees, including members of senior management. There was no incremental compensation cost resulting from the modification.

Basis of Presentation and Sig21

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Oct. 02, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q. We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 28, 2016 and August 23, 2015 . The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and nine months ended October 2, 2016 and September 27, 2015 . Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2015 Form 10-K. Unless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this Quarterly Report on Form 10-Q refer to Pfizer Inc. and its subsidiaries. Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts. Effective in the second quarter of 2016, our segments were reorganized to reflect that we now manage our innovative pharmaceutical and consumer healthcare operations as one business segment, Pfizer Innovative Health (IH) (previously these businesses were managed as two segments: the GIP segment and the VOC segment). Also, in the second quarter of 2016, we changed the name of our Established Products business to Pfizer Essential Health (EH). We have revised prior-period segment information to reflect the reorganization. For additional information, see Note 13 . In the condensed consolidated balance sheet as of December 31, 2015, we performed certain reclassifications to conform to the current period presentation of Other current assets , Other noncurrent assets , Short-term borrowings, including current portion of long-term debt and Long-term debt , and in the condensed consolidated statement of cash flows for the nine months ended September 27, 2015, we performed certain reclassifications to conform to the current presentation of Other changes in assets and liabilities, net of acquisitions and divestitures , Principal payments on short-term borrowings, and Principal payments on long-term debt, for debt issuance costs in accordance with the adoption of a new accounting standard. For additional information, see Note 1B .
Adoption of New Accounting Standards	Adoption of New Accounting Standards We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. The update does not impact the measurement or recognition of debt issuance costs. As of October 2, 2016 , debt issuance costs were $89 million and are presented as contra-liabilities to Short-term borrowings, including current portion of long-term debt ( $1 million ) and Long-term debt ( $88 million ). In the December 31, 2015 condensed consolidated balance sheet, we have reclassified debt issuance costs of $79 million ( $1 million from Other current assets and $79 million from Other noncurrent assets ) and have presented them as contra-liabilities to Short-term borrowings, including current portion of long-term debt ( $1 million ) and Long-term debt ( $79 million ) to conform to the current period presentation. For additional information, see Note 7A. We adopted a new standard as of January 1, 2016 that requires an acquirer to recognize adjustments made in the measurement period to provisional amounts of assets acquired and liabilities assumed in a business combination in the reporting period in which the adjustment amounts are determined. There was no material impact to our condensed consolidated financial statements in the third quarter and first nine months of 2016 from adopting this standard. For additional information, see Note 2A. We adopted a new standard as of January 1, 2016 related to the accounting for hybrid financial instruments issued or held as investments and there was no material impact to our condensed consolidated financial statements from adopting this standard.
Fair Value	Fair Value Our fair value methodologies depend on the following types of inputs: • Quoted prices for identical assets or liabilities in active markets (Level 1 inputs). • Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs). • Unobservable inputs that reflect estimates and assumptions (Level 3 inputs). A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.

Acquisitions, Assets and Liab22

Acquisitions, Assets and Liabilities Held for Sale, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment (Tables)	9 Months Ended
	Oct. 02, 2016
Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]
Schedule of Amounts Recognized for Assets Acquired and Liabilities Assumed	The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as adjustments made in the first nine months of 2016 to the amounts initially recorded in 2015 (measurement period adjustments) with a corresponding change to goodwill. The measurement period adjustments did not have a material impact on our earnings in any period. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed. (MILLIONS OF DOLLARS) Amounts Recognized as of Acquisition Date (as previously reported as of December 31, 2015) Measurement Period Adjustments (a) Amounts Recognized as of Acquisition Date (as adjusted) Final Working capital, excluding inventories $ 274 $ 68 $ 342 Inventories 1,924 (23 ) 1,901 PP&E 2,410 (57 ) 2,352 Identifiable intangible assets, excluding IPR&D 8,270 20 8,290 IPR&D 995 35 1,030 Other noncurrent assets 408 (46 ) 362 Long-term debt (1,928 ) — (1,928 ) Benefit obligations (117 ) — (117 ) Net income tax accounts (3,394 ) 14 (3,380 ) Other noncurrent liabilities (39 ) (23 ) (61 ) Total identifiable net assets 8,803 (12 ) 8,791 Goodwill 7,284 12 7,295 Net assets acquired/total consideration transferred $ 16,087 $ — $ 16,087 (a) The changes in the estimated fair values are primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.
Summary of Pro Forma Information	The following table provides supplemental pro forma information as if the acquisition of Hospira had occurred on January 1, 2014: Unaudited Supplemental Pro Forma Consolidated Results Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS, EXCEPT PER SHARE DATA) September 27, September 27, Revenues $ 12,957 $ 38,034 Net income attributable to Pfizer Inc. common shareholders 2,513 7,577 Diluted EPS attributable to Pfizer Inc. common shareholders 0.40 1.21
Summary of Assets and Liabilities Held for Sale	The amounts associated with HIS, as well as other assets classified as held for sale as of October 2, 2016 and December 31, 2015 , consisted of the following: (MILLIONS OF DOLLARS) October 2, December 31, Assets Held for Sale Inventories $ 369 $ — Property, plant and equipment 441 — Identifiable intangible assets 1,322 — Goodwill 243 — Other assets 60 — Less: adjustment to HIS assets for net realizable value (a) (1,394 ) — Total HIS assets held for sale 1,042 — Other assets held for sale (b) 77 9 Assets held for sale $ 1,119 $ 9 Liabilities Held for Sale Accrued compensation and related items $ 42 $ — Other liabilities 68 — Total HIS liabilities held for sale $ 110 $ — (a) For the quarter ending October 2, 2016 , we recorded an adjustment to HIS assets for net realizable value of $1,394 million plus estimated costs to sell of $28 million for a total impairment on HIS net assets of $1,422 million . (b) Other assets held for sale consist primarily of property, plant and equipment and other assets.

Restructuring Charges and Oth23

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)	9 Months Ended
	Oct. 02, 2016
Restructuring and Related Activities [Abstract]
Schedule of Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, Restructuring charges (a) : Employee terminations $ 347 $ 241 $ 464 $ 306 Asset impairments 27 198 45 209 Exit costs 29 30 64 40 Total restructuring charges 404 469 574 555 Transaction costs (b) 54 64 114 70 Integration costs (c) 74 48 300 102 Restructuring charges and certain acquisition-related costs 531 581 988 727 Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income as follows (d) : Cost of sales 46 23 145 67 Research and development expenses 1 1 5 3 Total additional depreciation––asset restructuring 47 24 151 71 Implementation costs recorded in our condensed consolidated statements of income as follows (e) : Cost of sales 46 23 127 64 Selling, informational and administrative expenses 23 16 56 55 Research and development expenses 8 2 17 13 Other (income)/deductions––net 1 2 2 3 Total implementation costs 78 42 202 135 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 655 $ 647 $ 1,341 $ 933 (a) In the nine months ended October 2, 2016 , Employee terminations represent the expected reduction of the workforce by approximately 2,100 employees, mainly in manufacturing, sales, research and corporate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. The restructuring charges for 2016 are associated with the following: • For the third quarter of 2016 , the IH segment ( $148 million ); the EH segment ( $28 million ); WRD, GPD and Medical (M) (WRD/GPD/M) ( $52 million ); manufacturing operations ( $108 million ); and Corporate ( $67 million ). • For the first nine months of 2016 , IH ( $162 million ); EH ( $19 million ); WRD/GPD/M ( $104 million ); manufacturing operations ( $181 million ); and Corporate ( $107 million ). The restructuring charges for 2015 are associated with the following: • For the third quarter of 2015 , IH ( $9 million ); EH ( $280 million ); WRD/GPD/M ( $50 million ); manufacturing operations ( $26 million ); and Corporate ( $104 million ). • For the first nine months of 2015 , IH ( $55 million ); EH ( $288 million ); WRD/GPD/M ( $66 million ); manufacturing operations ( $18 million ); and Corporate ( $127 million ). In September 2015, in order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, Pfizer opted to return rights to Celltrion that Hospira had previously acquired to potential biosimilars to Rituxan ® (rituximab) and Herceptin ® (trastuzumab). As such, upon return of the acquired rights, in the third quarter and first nine months of 2015, we incurred charges of $205 million , which are comprised of (i) a write-off of the applicable IPR&D assets, totaling $160 million , which is included in Asset impairments ; (ii) a write-off of amounts prepaid to Celltrion in the amount of $25 million , which is included in Asset impairments ; and (iii) a payment to Celltrion of $20 million , which is included in Exit costs . (b) Transaction costs represent external costs for banking, legal, accounting and other similar services, most of which in the third quarter of 2016 are directly related to our acquisition of Medivation, and most of which in the first nine months of 2016 are directly related to our acquisitions of Medivation and Anacor, and the terminated transaction with Allergan. Transaction costs in 2015 represent external costs directly related to the acquisition of Hospira and primarily include expenditures for banking, legal, accounting and other similar services. (c) Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the third quarter of 2016, integration costs mostly relate to our acquisition of Hospira and for the first nine months of 2016 , integration costs mostly relate to our acquisition of Hospira and the terminated transaction with Allergan. Integration costs in 2015 represent external incremental costs directly related to our acquisition of Hospira. (d) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (e) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
Schedule of Components of and Changes in Restructuring Accruals	The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, December 31, 2015 (a) $ 1,109 $ — $ 48 $ 1,157 Provision 464 45 64 574 Utilization and other (b) (360 ) (45 ) (50 ) (455 ) Balance, October 2, 2016 (c) $ 1,213 $ — $ 62 $ 1,275 (a) Included in Other current liabilities ( $776 million ) and Other noncurrent liabilities ( $381 million ). (b) Includes adjustments for foreign currency translation. (c) Included in Other current liabilities ( $714 million ) and Other noncurrent liabilities ( $561 million ).

Other (Income)_Deductions - N24

Other (Income)/Deductions - Net (Tables)	9 Months Ended
	Oct. 02, 2016
Other Income and Expenses [Abstract]
Schedule of Other (Income)/Deductions - Net	The following table provides components of Other (income)/deductions––net : Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, Interest income (a) $ (123 ) $ (121 ) $ (357 ) $ (332 ) Interest expense (a) 291 278 889 864 Net interest expense 168 157 532 533 Royalty-related income (233 ) (204 ) (695 ) (683 ) Certain legal matters, net (b) (40 ) — 494 99 Net gains on asset disposals (c) (47 ) (35 ) (81 ) (230 ) Impairment on remeasurement of HIS net assets (d) 1,422 — 1,422 — Certain asset impairments (e) 133 633 1,080 658 Business and legal entity alignment costs (f) 69 60 180 224 Other, net (g) (55 ) 50 (117 ) 70 Other (income)/deductions––net $ 1,417 $ 661 $ 2,815 $ 670 (a) Interest income increased in the first nine months of 2016 , primarily due to higher investment returns. Interest expense increased in the third quarter and first nine months of 2016 , primarily due to interest on legacy Hospira debt acquired in September 2015 and the addition of new fixed rate debt in the second quarter of 2016, partially offset by the maturity of other fixed rate debt in the second quarter of 2016. (b) In the first nine months of 2016, primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra pending against the Company in New York federal court for $486 million , which is subject to final court approval, partially offset by the reversal of a legal accrual where a loss is no longer deemed probable. In addition, the first nine months of 2016 includes a settlement related to a patent matter. See Note 12A2 for additional information. (c) In the first nine months of 2016 , includes gains on sales/out-licensing of product and compound rights (approximately $49 million ). In the first nine months of 2015 , primarily includes gains on sales/out-licensing of product and compound rights (approximately $76 million ) and gains on sales of investments in equity securities (approximately $160 million ). (d) In the third quarter and first nine months of 2016 , represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. In October 2016, ICU Medical and Pfizer announced that they entered into a definitive agreement under which ICU Medical will acquire all of Pfizer’s global infusion therapy net assets, HIS, for approximately $1 billion in cash and ICU Medical stock. HIS includes IV pumps, solutions and devices. See Note 2B for additional information . (e) In the third quarter of 2016 , primarily includes intangible asset impairment charges of $126 million , reflecting $97 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma and $29 million of other IPR&D assets acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the third quarter of 2016 are associated with the following: EH ( $97 million ) and IH ( $29 million ). In the first nine months of 2016 , primarily includes intangible asset impairment charges of $767 million , reflecting (i) $331 million related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) $265 million related to an IPR&D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) $97 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma; and (iv) $74 million of other IPR&D assets, $45 million of which were acquired in connection with our acquisition of Hospira and $29 million of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the first nine months of 2016 are associated with the following: EH ( $738 million ) and IH ( $29 million ). In addition, the first nine months of 2016 includes an impairment loss of $211 million related to Pfizer’s 49% -owned equity-method investment with Zhejiang Hisun Pharmaceuticals Co., Ltd. in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer's 40% -owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2D. The intangible asset impairment charge for 2016 for the IPR&D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a recent court ruling, requiring a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&D assets acquired in connection with our acquisition of King reflect changes in the competitive environment. In the third quarter and first nine months of 2015 , primarily includes an impairment loss of $470 million related to Pfizer's 49% -owned equity-method investment in Hisun Pfizer, and impairment charges for intangible assets of $163 million reflecting (i) $115 million related to developed technology rights for the treatment of attention deficit hyperactivity disorder; (ii) $28 million related to an IPR&D project for the treatment of attention deficit hyperactivity disorder; and (iii) $20 million related to an indefinite-lived Consumer Healthcare brand. The intangible asset impairment charges for the third quarter and first nine months of 2015 are associated with the following: IH ( $20 million ) and EH ( $143 million ). The intangible asset impairment charges for 2015 reflect, among other things, updated commercial forecasts due to increased competition. (f) In the third quarter and first nine months of 2016 and 2015 , represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. (g) In the first nine months of 2016 , includes among other things, $150 million paid to Allergan for reimbursement of Allergan’s expenses associated with the terminated transaction (see Note 1A ). The first nine months of 2016 , also includes income of $116 million from resolution of a contract disagreement.
Schedule of Additional Information About Intangible Assets Impaired	The following table provides additional information about the intangible assets that were impaired during 2016 in Other (income)/deductions––net: Fair Value (a) Nine Months Ended October 2, 2016 (MILLIONS OF DOLLARS) Amount Level 1 Level 2 Level 3 Impairment Intangible assets –– IPR&D (b) $ 50 $ — $ — $ 50 $ 436 Intangible assets –– Developed technology rights (b) 66 — — 66 331 Total $ 116 $ — $ — $ 116 $ 767 (a) The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1C . (b) Reflects intangible assets written down to fair value in the first nine months of 2016. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product and the impact of technological risk associated with IPR&D assets; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax Matters (Tables)

Tax Matters (Tables)	9 Months Ended
	Oct. 02, 2016
Income Tax Disclosure [Abstract]
Schedule of Tax Provision (Benefit) on Other Comprehensive Income/(Loss)	The following table provides the components of Tax provision/(benefit) on other comprehensive income/(loss): Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, Foreign currency translation adjustments, net (a) $ — $ (7 ) $ (15 ) $ 90 Unrealized holding losses on derivative financial instruments, net — (57 ) (192 ) (160 ) Reclassification adjustments for realized (gains)/losses 32 15 81 43 32 (42 ) (112 ) (117 ) Unrealized holding gains/(losses) on available-for-sale securities, net 40 6 106 (63 ) Reclassification adjustments for realized (gains)/losses (14 ) 1 (16 ) 63 26 7 90 — Benefit plans: actuarial losses, net (31 ) (51 ) (39 ) (43 ) Reclassification adjustments related to amortization 47 43 140 133 Reclassification adjustments related to settlements, net 10 12 27 35 Other 14 (9 ) 5 29 40 (4 ) 133 154 Benefit plans: prior service credits and other, net 35 (4 ) 66 188 Reclassification adjustments related to amortization (17 ) (36 ) (47 ) (42 ) Reclassification adjustments related to curtailments, net (3 ) 18 (5 ) (8 ) Other 2 2 1 2 18 (19 ) 15 139 Tax provision/(benefit) on other comprehensive income/(loss) $ 116 $ (65 ) $ 111 $ 267 (a) Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.

Accumulated Other Comprehensi26

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)	9 Months Ended
	Oct. 02, 2016
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax	The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gains/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/Credits and Other Accumulated Other Comprehensive Loss Balance, December 31, 2015 $ (5,863 ) $ 421 $ (227 ) $ (4,733 ) $ 880 $ (9,522 ) Other comprehensive income/(loss) (a) 1,016 (578 ) 522 310 39 1,308 Balance, October 2, 2016 $ (4,847 ) $ (157 ) $ 295 $ (4,423 ) $ 919 $ (8,214 ) (a) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $1 million loss for the first nine months of 2016 .

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Oct. 02, 2016
Financial Instruments [Abstract]
Information about Certain Financial Assets and Liabilities	The following table provides additional information about certain of our financial assets and liabilities: (MILLIONS OF DOLLARS) October 2, December 31, Selected financial assets measured at fair value on a recurring basis (a) Trading funds and securities (b) $ 304 $ 287 Available-for-sale debt securities (c) 17,522 32,078 Money market funds 1,724 934 Available-for-sale equity securities (c) 590 603 Derivative financial instruments in a receivable position (d) : Interest rate swaps 1,923 837 Foreign currency swaps 90 135 Foreign currency forward-exchange contracts 186 559 22,340 35,433 Other selected financial assets Held-to-maturity debt securities, carried at amortized cost (c), (e) 1,270 1,388 Private equity securities, carried at equity-method or at cost (e), (f) 1,003 1,336 2,272 2,724 Total selected financial assets $ 24,613 $ 38,157 Selected financial liabilities measured at fair value on a recurring basis (a) Derivative financial instruments in a liability position (g) : Interest rate swaps $ 3 $ 139 Foreign currency swaps 1,349 1,489 Foreign currency forward-exchange contracts 503 81 1,855 1,709 Other selected financial liabilities Short-term borrowings: Principal amount 13,602 10,160 Net fair value adjustments related to hedging and purchase accounting 47 2 Net unamortized discounts, premiums and debt issuance costs (h) (16 ) (3 ) Total short-term borrowings, carried at historical proceeds, as adjusted (e) 13,633 10,159 Long-term debt: Principal amount 28,073 27,573 Net fair value adjustments related to hedging and purchase accounting 2,447 1,294 Net unamortized discounts, premiums and debt issuance costs (h) (83 ) (127 ) Total long-term debt, carried at historical proceeds, as adjusted (i) 30,437 28,740 44,071 38,899 Total selected financial liabilities $ 45,926 $ 40,608 (a) We use a market approach in valuing financial instruments on a recurring basis. For additional information, see Note 1C. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except less than 2% that use Level 1 inputs and money market funds measured at net asset value. (b) As of October 2, 2016 , trading funds and securities are composed of $196 million of trading equity funds, $12 million of trading securities and $96 million of trading debt funds. As of December 31, 2015 , trading funds and securities are composed of $185 million of trading equity funds and $102 million of trading debt funds. As of October 2, 2016 and December 31, 2015 , trading equity funds of $69 million and $85 million , respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. (c) Gross unrealized gains and losses are not significant. (d) Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $91 million as of October 2, 2016 ; and foreign currency forward-exchange contracts with fair values of $136 million as of December 31, 2015 . (e) The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities at cost and short-term borrowings not measured at fair value on a recurring basis were not significant as of October 2, 2016 or December 31, 2015 . The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our priv ate equity securities carried at cost are based on Level 3 inputs. Short-term borrowings include foreign currency short-term borrowings with fair values of $547 million as of December 31, 2015 , which are used as hedging instruments. (f) Our private equity securities represent investments in the life sciences sector. (g) Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency swaps with fair values of $211 million and foreign currency forward-exchange contracts with fair values of $145 million as of October 2, 2016 ; and foreign currency swaps with fair values of $234 million and foreign currency forward-exchange contracts with fair values of $59 million as of December 31, 2015 . (h) We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. See Note 1B for additional information. (i) The fair value of our long-term debt (not including the current portion of long-term debt) was $34.3 billion as of October 2, 2016 and $32.7 billion as of December 31, 2015 . The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Generally, the difference between the fair value of our long-term debt and the amount reported on the condensed consolidated balance sheet is due to a decline in relative market interest rates since the debt issuance.
Selected Financial Assets and Liabilities Presented in the Condensed Consolidated Balance Sheets	The following table provides the classification of these selected financial assets and liabilities in our condensed consolidated balance sheets: (MILLIONS OF DOLLARS) October 2, December 31, Assets Cash and cash equivalents $ 628 $ 978 Short-term investments 12,277 19,649 Other current assets (a) 293 587 Long-term investments 9,507 15,999 Other noncurrent assets (b) 1,907 944 $ 24,613 $ 38,157 Liabilities Short-term borrowings, including current portion of long-term debt (c) $ 13,633 $ 10,159 Other current liabilities (d) 805 645 Long-term debt (c) 30,437 28,740 Other noncurrent liabilities (e) 1,050 1,064 $ 45,926 $ 40,608 (a) As of October 2, 2016 , derivative instruments at fair value include interest rate swaps ( $49 million ), foreign currency swaps ( $67 million ) and foreign currency forward-exchange contracts ( $177 million ) and, as of December 31, 2015 , include interest rate swaps ( $2 million ), foreign currency swaps ( $46 million ) and foreign currency forward-exchange contracts ( $538 million ). (b) As of October 2, 2016 , derivative instruments at fair value include interest rate swaps ( $1.9 billion ), foreign currency swaps ( $23 million ) and foreign currency forward-exchange contracts ( $9 million ) and, as of December 31, 2015 , include interest rate swaps ( $835 million ), foreign currency swaps ( $89 million ) and foreign currency forward-exchange contracts ( $20 million ). (c) We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. See Note 1B for additional information. (d) As of October 2, 2016 , derivative instruments at fair value include interest rate swaps ( $1 million ), foreign currency swaps ( $320 million ) and foreign currency forward-exchange contracts ( $483 million ) and, as of December 31, 2015 , include interest rate swaps ( $5 million ), foreign currency swaps ( $560 million ) and foreign currency forward-exchange contracts ( $80 million ). (e) As of October 2, 2016 , derivative instruments at fair value include interest rate swaps ( $2 million ), foreign currency swaps ( $1.0 billion ) and foreign currency forward-exchange contracts ( $20 million ) and, as of December 31, 2015 , include interest rate swaps ( $134 million ), foreign currency swaps ( $928 million ) and foreign currency forward-exchange contracts ( $1 million ).
Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities	The following table provides the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: Years October 2, (MILLIONS OF DOLLARS) Within 1 Over 1 to 5 Over 5 to 10 Over 10 Total Available-for-sale debt securities Corporate debt (a) $ 2,399 $ 3,824 $ 2,088 $ 25 $ 8,336 Western European, Asian, Scandinavian and other government debt (b) 4,247 661 8 — 4,916 Federal Home Loan Mortgage Corporation and Federal National Mortgage Association asset-backed securities 3 56 1 — 61 U.S. government debt 702 93 — — 795 Western European, Scandinavian and other government agency debt (b) 1,245 137 — — 1,383 Supranational debt (b) 306 346 — — 652 Other asset-backed debt (c) 449 331 20 3 803 Government National Mortgage Association and other U.S. government guaranteed asset-backed securities 575 1 — — 576 Held-to-maturity debt securities Time deposits and other 1,046 1 — — 1,048 Western European government debt (b) 222 — — — 222 Total debt securities $ 11,195 $ 5,451 $ 2,118 $ 29 $ 18,792 (a) Issued by a diverse group of corporations, largely consisting of financial institutions, virtually all of which are investment-grade. (b) Issued by governments, government agencies or supranational entities, as applicable, all of which are investment-grade. (c) Includes loan-backed, receivable-backed, and mortgage-backed securities, all of which are investment-grade and in senior positions in the capital structure of the security. Loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans, and receivable-backed securities are collateralized by credit cards receivables. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages. These securities are valued by third party models that use significant inputs derived from observable market data like prepayment rates, default rates, and recovery rates.
Schedule of Principal Amounts and Components of Unsecured Long-term Debt Issued	The following table provides the principal amounts and components of unsecured long-term debt issued in the second quarter of 2016: (MILLIONS OF DOLLARS) Maturity Date As of October 2, 2016 1.20% Notes (2018 Notes) June 1, 2018 $ 1,250 1.45% Notes (2019 Notes) June 3, 2019 850 1.95% Notes (2021 Notes) June 3, 2021 1,150 2.75% Notes (2026 Notes) June 3, 2026 1,250 4.40% Notes (2044 Notes) May 15, 2044 500 Total long-term debt issued in the second quarter of 2016 $ 5,000
Maturity Schedule of Long-term Debt Outstanding	The following table provides the maturity schedule of our Long-term debt outstanding as of October 2, 2016: (MILLIONS OF DOLLARS) 2017 2018 2019 2020 After 2020 Total Maturities $ — $ 3,618 $ 5,678 $ 383 $ 20,758 $ 30,437
Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk	The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Three Months Ended Amount of Gains/(Losses) Recognized in OID (a), (b), (c) Amount of Gains/(Losses) Recognized in OCI (Effective Portion) (a), (d) Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion) (a), (d) (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, October 2, September 27, Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign currency swaps $ — $ — $ 87 $ (96 ) $ (39 ) $ (86 ) Foreign currency forward-exchange contracts 2 — (212 ) (89 ) (111 ) 120 Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency forward-exchange contracts — — — (5 ) — — Derivative Financial Instruments Not Designated as Hedges: Foreign currency forward-exchange contracts 20 50 — — — — Foreign currency swaps (4 ) — — — — — Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings — — — (12 ) — — All other net — — — (32 ) — — $ 18 $ 49 $ (126 ) $ (235 ) $ (150 ) $ 35 Nine Months Ended Amount of Gains/(Losses) Recognized in OID (a), (b), (c) Amount of Gains/(Losses) Recognized in OCI (Effective Portion) (a), (d) Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion) (a), (d) (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, October 2, September 27, Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign currency swaps $ — $ — $ (204 ) $ (594 ) $ (165 ) $ (451 ) Foreign currency forward-exchange contracts 1 — (770 ) 532 (118 ) 996 Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency forward-exchange contracts 1 2 (15 ) 254 — — Derivative Financial Instruments Not Designated as Hedges: Foreign currency forward-exchange contracts (49 ) (64 ) — — — — Foreign currency swaps (9 ) (2 ) — — — — Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings — — (26 ) 6 — — All other net — — 1 (18 ) — — $ (56 ) $ (64 ) $ (1,014 ) $ 180 $ (283 ) $ 545 (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income . OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income . (b) Also, includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges, as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships. (c) There was no significant ineffectiveness for any period presented. (d) For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income/(loss)––Unrealized holding losses on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income/(loss)––Foreign currency translation adjustments, net.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Oct. 02, 2016
Inventory Disclosure [Abstract]
Schedule of Components of Inventories, Current	The following table provides the components of Inventories : (MILLIONS OF DOLLARS) October 2, December 31, Finished goods $ 2,680 $ 2,714 Work-in-process 3,965 3,932 Raw materials and supplies 862 867 Inventories (a) $ 7,507 $ 7,513 Noncurrent inventories not included above (b) $ 583 $ 594 (a) The change from December 31, 2015 reflects, among other things, the reclassification of $369 million to Assets held for sale during the third quarter of 2016 (see Note 2B) . (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.
Schedule of Components of Inventories, Noncurrent	The following table provides the components of Inventories : (MILLIONS OF DOLLARS) October 2, December 31, Finished goods $ 2,680 $ 2,714 Work-in-process 3,965 3,932 Raw materials and supplies 862 867 Inventories (a) $ 7,507 $ 7,513 Noncurrent inventories not included above (b) $ 583 $ 594 (a) The change from December 31, 2015 reflects, among other things, the reclassification of $369 million to Assets held for sale during the third quarter of 2016 (see Note 2B) . (b) Included in Other noncurrent assets . There are no recoverability issues associated with these amounts.

Identifiable Intangible Asset29

Identifiable Intangible Assets and Goodwill (Tables)	9 Months Ended
	Oct. 02, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : October 2, 2016 December 31, 2015 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights $ 83,935 $ (49,105 ) $ 34,830 $ 77,613 $ (47,193 ) $ 30,419 Brands 2,117 (1,013 ) 1,104 1,973 (928 ) 1,044 Licensing agreements and other 1,801 (985 ) 816 1,619 (918 ) 701 87,854 (51,103 ) 36,750 81,205 (49,040 ) 32,165 Indefinite-lived intangible assets Brands and other 6,918 6,918 7,021 7,021 In-process research and development 10,569 10,569 1,171 1,171 17,487 17,487 8,192 8,192 Identifiable intangible assets (a) $ 105,341 $ (51,103 ) $ 54,238 $ 89,396 $ (49,040 ) $ 40,356 (a) The increase in I dentifiable intangible assets, less accumulated amortization , is primarily related to assets acquired as part of the acquisitions of Medivation, Anacor and Bamboo (see Note 2A ), the impact of foreign exchange and the impact of measurement period adjustments related to our acquisition of Hospira (see Note 2A ), partially offset by amortization, impairments and the reclassification of $1.3 billion to Assets held for sale during the third quarter of 2016 (see Note 2B ). For information about impairments, see Note 4 .
Schedule of Indefinite Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : October 2, 2016 December 31, 2015 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights $ 83,935 $ (49,105 ) $ 34,830 $ 77,613 $ (47,193 ) $ 30,419 Brands 2,117 (1,013 ) 1,104 1,973 (928 ) 1,044 Licensing agreements and other 1,801 (985 ) 816 1,619 (918 ) 701 87,854 (51,103 ) 36,750 81,205 (49,040 ) 32,165 Indefinite-lived intangible assets Brands and other 6,918 6,918 7,021 7,021 In-process research and development 10,569 10,569 1,171 1,171 17,487 17,487 8,192 8,192 Identifiable intangible assets (a) $ 105,341 $ (51,103 ) $ 54,238 $ 89,396 $ (49,040 ) $ 40,356 (a) The increase in I dentifiable intangible assets, less accumulated amortization , is primarily related to assets acquired as part of the acquisitions of Medivation, Anacor and Bamboo (see Note 2A ), the impact of foreign exchange and the impact of measurement period adjustments related to our acquisition of Hospira (see Note 2A ), partially offset by amortization, impairments and the reclassification of $1.3 billion to Assets held for sale during the third quarter of 2016 (see Note 2B ). For information about impairments, see Note 4 .
Identifiable Intangible Assets as a Percentage of Total Identifiable Intangible Assets Less Accumulated Amortization, By Segment	Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: October 2, 2016 IH EH WRD Developed technology rights 64 % 35 % — % Brands, finite-lived 74 % 26 % — % Brands, indefinite-lived 71 % 29 % — % In-process research and development 92 % 5 % 3 %
Schedule of Goodwill	The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) IH EH Total Balance, December 31, 2015 $ 23,809 $ 24,433 $ 48,242 Additions (a) 7,403 12 7,415 Other (b) 494 130 624 Balance, October 2, 2016 $ 31,706 $ 24,575 $ 56,281 (a) IH additions primarily relate to our acquisitions of Medivation, Anacor and Bamboo and are subject to change until we complete the valuations of assets acquired and liabilities assumed from Medivation, Anacor and Bamboo (see Note 2A ). (b) Primarily reflects the impact of foreign exchange and, with respect to EH, the impact of the reclassification of $243 million to Assets held for sale during the third quarter of 2016 (see Note 2B ).

Pension and Postretirement Be30

Pension and Postretirement Benefit Plans (Tables)	9 Months Ended
	Oct. 02, 2016
Compensation and Retirement Disclosure [Abstract]
Schedule of Net Periodic Benefit Costs	The following table provides the components of net periodic benefit cost: Three Months Ended Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) (b) International (c) Postretirement Plans (d) (MILLIONS OF DOLLARS) Oct 2, 2016 Sep 27, 2015 Oct 2, 2016 Sep 27, 2015 Oct 2, 2016 Sep 27, 2015 Oct 2, 2016 Sep 27, 2015 Net periodic benefit cost/(credit): Service cost (e) $ 69 $ 71 $ 5 $ 5 $ 41 $ 46 $ 11 $ 14 Interest cost (e) 218 169 18 13 58 77 33 26 Expected return on plan assets (239 ) (272 ) — — (95 ) (105 ) (8 ) (13 ) Amortization of: Actuarial losses 99 89 9 11 23 31 9 9 Prior service costs (credits) 1 (2 ) — — (1 ) (2 ) (45 ) (43 ) Curtailments 2 1 1 — — — (8 ) (4 ) Settlements 21 32 7 4 1 1 — — Special termination benefits — — — — — 1 — — $ 170 $ 88 $ 39 $ 33 $ 27 $ 49 $ (9 ) $ (11 ) Nine Months Ended Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) (b) International (c) Postretirement Plans (d) (MILLIONS OF DOLLARS) Oct 2, 2016 Sep 27, 2015 Oct 2, 2016 Sep 27, 2015 Oct 2, 2016 Sep 27, 2015 Oct 2, 2016 Sep 27, 2015 Net periodic benefit cost/(credit): Service cost (e) $ 193 $ 216 $ 14 $ 17 $ 126 $ 140 $ 31 $ 41 Interest cost (e) 486 505 40 41 178 232 77 91 Expected return on plan assets (721 ) (813 ) — — (291 ) (314 ) (25 ) (39 ) Amortization of: Actuarial losses 297 253 27 34 70 94 23 28 Prior service costs (credits) 4 (5 ) (1 ) (1 ) (2 ) (5 ) (127 ) (104 ) Curtailments 5 2 1 — (1 ) — (14 ) (20 ) Settlements 52 76 23 21 2 1 — — Special termination benefits — — — — — 1 — — $ 316 $ 235 $ 105 $ 110 $ 81 $ 150 $ (36 ) $ (5 ) (a) The increase in net periodic benefit costs for the three months ended October 2, 2016 , compared to the three months ended September 27, 2015 , for our U.S. qualified pension plans was primarily due to (i) higher interest costs resulting from a change in our approach in the third quarter of 2016 for measuring service and interest costs (the adjustment increased interest costs by $57 million related to prior periods in 2016 (see (e) below)), (ii) a lower expected return on plan assets resulting from a lower expected rate of return, as well as a net decrease of approximately $1.1 billion in the asset base, due in part to lump-sum payments made in 2015 to certain terminated vested colleagues to settle Pfizer’s pension obligation, partially offset by a voluntary contribution of $1.0 billion made at the beginning of January 2016, and (iii) an increase in the amounts amortized for actuarial losses, primarily as a result of the addition of Hospira qualified plans. The aforementioned increases were partially offset by lower settlement activity in 2016. The increase in net periodic benefit costs for the nine months ended October 2, 2016 , compared to the nine months ended September 27, 2015 , for our U.S. qualified pension plans was primarily driven by (i) a lower expected return on plan assets resulting from a lower expected rate of return, as well as a net decrease of approximately $1.1 billion in the asset base, due in part to lump-sum payments made in 2015 to certain terminated vested colleagues to settle Pfizer’s pension obligation, partially offset by a voluntary contribution of $1.0 billion made at the beginning of January 2016, and (ii) an increase in the amounts amortized for actuarial losses, primarily as a result of the addition of Hospira qualified plans. The aforementioned increases were partially offset by (i) lower service costs resulting from a higher discount rate, (ii) lower settlement activity, and (iii) lower interest costs resulting from a lower beginning benefit obligation. (b) The increase in net periodic benefit costs for the three months ended October 2, 2016 , compared to the three months ended September 27, 2015 , for our U.S. non-qualified pension plans was primarily due to (i) higher interest costs resulting from a change in our approach in the third quarter for measuring service and interest costs (the adjustment increased interest costs by $4 million related to prior periods in 2016 (see (e) below)), and (ii) higher settlement activity. The aforementioned increases were partially offset by a decrease in the amounts amortized for actuarial losses resulting from the increase in 2015 in the discount rate used to determine the benefit obligation. The decrease in net periodic benefit costs for the nine months ended October 2, 2016 , compared to the nine months ended September 27, 2015 , for our U.S. non-qualified pension plans was primarily driven by (i) a decrease in the amounts amortized for actuarial losses resulting from the increase in 2015 in the discount rate used to determine the benefit obligation, and (ii) lower service costs resulting from a higher discount rate. The aforementioned decreases were partially offset by an increase in settlement activity. (c) The decrease in net periodic benefit costs for the three and nine months ended October 2, 2016 , compared to the three and nine months ended September 27, 2015 , for our international pension plans was primarily driven by (i) lower service and interest costs, resulting from a change in our approach for measuring service and interest costs (see (e) below), and (ii) a decrease in the amounts amortized for actuarial losses resulting from large gains in 2015, which decreased the plan net loss position. The aforementioned decreases to our net periodic benefit costs were partially offset by a decrease in the expected return on plan assets due to a lower expected rate of return on plan assets. (d) The decrease in net periodic benefit credit for the three months ended October 2, 2016 , compared to the three months ended September 27, 2015 , for our postretirement plans was primarily driven by (i) higher interest costs resulting from a change in our approach in the third quarter of 2016 for measuring service and interest costs (the adjustment increased interest costs by $8 million related to prior periods in 2016 (see (e) below)), and (ii) a decrease in expected return on plan assets, resulting from a decrease in plan assets, reflecting payments by the plan for IRC 401(h) reimbursements to Pfizer for eligible 2014 and 2015 prescription drug expenses for certain retirees. The aforementioned changes were partially offset by (i) higher curtailment gains and (ii) lower service costs resulting from a higher discount rate. The increase in net periodic benefit credit for the nine months ended October 2, 2016 , compared to the nine months ended September 27, 2015 , for our postretirement plans was primarily driven by (i) an increase in prior service credits due to the postretirement medical plan cap changes during 2016 and 2015, (ii) lower interest costs resulting from a lower benefit obligation, and (iii) lower service costs resulting from a higher discount rate. The aforementioned changes were partially offset by (i) a decrease in expected return on plan assets, primarily resulting from a decrease in plan assets, reflecting payments by the plan for IRC 401(h) reimbursements to Pfizer for eligible 2014 and 2015 prescription drug expenses for certain retirees, (ii) lower curtailment gains, and (iii) a decrease in the amounts amortized for actuarial losses resulting from the increase in 2015 in the discount rate used to determine the benefit obligation. (e) Effective January 1, 2016, the Company changed the approach used to measure service and interest costs for certain international pension and other postretirement benefit plans. For fiscal 2015, the Company measured service and interest costs utilizing a single weighted-average discount rate derived from the yield curve used to measure the respective plan obligations. For fiscal 2016, we elected to measure service and interest costs by applying the spot rates along the yield curve for certain international plans to the plans' liability cash flows. The Company believes the new approach provides a more precise measurement of service and interest costs by aligning the timing of the plans’ liability cash flows to the corresponding spot rates on the yield curve. This change does not affect the measurement of our plan obligations. We have accounted for this change as a change in accounting estimate and, accordingly, have accounted for it on a prospective basis. The expected reduction in expense for 2016 associated with this change in estimate is $42 million , which is recognized evenly over each quarter of the year. Effective January 1, 2016, the Company made a similar change for its U.S. pension and other postretirement benefit plans, but in the third quarter of 2016, we determined that our use of the bond model required the measurement of such costs to be conceptually aligned with the measurement of the pension benefit obligation. As such, 2016 service and interest costs for the U.S. plans were measured utilizing a single weighted-average discount rate derived from the bond model consistent with the approach used in 2015, resulting in an adjustment to increase net periodic pension cost by $112 million in the third quarter of 2016.
Schedule of Employer Contributions to Pension and Postretirement Plans	As of and for the nine months ended October 2, 2016 , we contributed and expect to contribute from our general assets as follows: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from/(reimbursements of) our general assets for the nine months ended October 2, 2016 (a) $ 1,000 $ 123 $ 145 $ (28 ) Expected contributions from our general assets during 2016 (b) $ 1,000 $ 146 $ 194 $ 20 (a) Contributions to the postretirement plans reflect IRC 401(h) reimbursements totaling $198 million received for eligible 2014 and 2015 prescription drug expenses for certain retirees. (b) Contributions expected to be made for 2016 are inclusive of amounts contributed during the nine months ended October 2, 2016 , including the $1.0 billion voluntary contribution that was made in January 2016 for the U.S. qualified plans, which was considered pre-funding for future anticipated mandatory contributions and is also expected to reduce Pension Benefit Guaranty Corporation variable rate premiums. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.

Earnings Per Common Share Att31

Earnings Per Common Share Attributable to Common Shareholders (Tables)	9 Months Ended
	Oct. 02, 2016
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earning Per Share	The following table provides the detailed calculation of Earnings per common share (EPS) : Three Months Ended Nine Months Ended (IN MILLIONS) October 2, September 27, October 2, September 27, EPS Numerator––Basic Income from continuing operations $ 1,320 $ 2,130 $ 6,380 $ 7,141 Less: Net income attributable to noncontrolling interests — 9 25 23 Income from continuing operations attributable to Pfizer Inc. 1,320 2,122 6,355 7,118 Less: Preferred stock dividends––net of tax — — 1 1 Income from continuing operations attributable to Pfizer Inc. common shareholders 1,320 2,121 6,354 7,117 Discontinued operations––net of tax — 8 — 14 Less: Discontinued operations––net of tax, attributable to noncontrolling interests — — — — Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders — 8 — 14 Net income attributable to Pfizer Inc. common shareholders $ 1,319 $ 2,130 $ 6,355 $ 7,131 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions $ 1,320 $ 2,121 $ 6,355 $ 7,117 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions — 8 — 14 Net income attributable to Pfizer Inc. common shareholders and assumed conversions $ 1,320 $ 2,130 $ 6,355 $ 7,131 EPS Denominator Weighted-average number of common shares outstanding––Basic 6,066 6,168 6,095 6,176 Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements 72 75 68 83 Weighted-average number of common shares outstanding––Diluted 6,138 6,243 6,164 6,259 Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (a) 36 55 56 48 (a) These common stock equivalents were outstanding for the nine months ended October 2, 2016 and September 27, 2015 , but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Segment, Geographic and Other32

Segment, Geographic and Other Revenue Information (Tables)	9 Months Ended
	Oct. 02, 2016
Segment Reporting [Abstract]
Reconciliation of Revenue from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, Reportable Segments: IH (b) $ 7,332 $ 6,752 $ 4,187 $ 4,018 EH (c) 5,712 5,335 3,128 3,181 Total reportable segments 13,045 12,087 7,315 7,199 Other business activities (d) — — (786 ) (715 ) Reconciling Items: Corporate (e) — — (1,504 ) (1,376 ) Purchase accounting adjustments (e) — — (966 ) (960 ) Acquisition-related costs (e) — — (280 ) (541 ) Certain significant items (f) — — (1,969 ) (837 ) Other unallocated — — (206 ) (73 ) $ 13,045 $ 12,087 $ 1,604 $ 2,697 Nine Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, Reportable Segments: IH (b) $ 21,471 $ 19,120 $ 12,470 $ 10,831 EH (c) 17,725 15,683 9,985 9,540 Total reportable segments 39,196 34,804 22,454 20,371 Other business activities (d) — — (2,190 ) (2,127 ) Reconciling Items: Corporate (e) — — (4,123 ) (3,949 ) Purchase accounting adjustments (e) — — (3,103 ) (2,698 ) Acquisition-related costs (e) — — (598 ) (631 ) Certain significant items (f) — — (4,112 ) (1,369 ) Other unallocated — — (753 ) (278 ) $ 39,196 $ 34,804 $ 7,575 $ 9,319 (a) Income from continuing operations before provision for taxes on income. (b) Effective as of the beginning of the second quarter of 2016, in connection with the formation of the GPD organization, certain development-related functions transferred from IH to GPD. We have reclassified approximately $76 million of costs in the first quarter of 2016, approximately $77 million of costs in the third quarter of 2015 and approximately $223 million of costs in the first nine months of 2015 from IH to GPD to conform to the current period presentation as part of GPD. Additionally, Anacor's and Medivations’s commercial operations are included in IH's operating results in our condensed consolidated statements of income. As a result, commencing from the acquisition date of June 24, 2016, IH's operating results for the third quarter and first nine months of 2016 include approximately three months of legacy Anacor operations, which were immaterial, and commencing from the acquisition date of September, 28, 2016, IH's operating results for the third quarter and first nine months of 2016 reflect three business days of legacy Medivation operations, which were immaterial. (c) On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Hospira. As a result, legacy Hospira commercial operations, including the legacy Hospira One-2-One contract manufacturing business, are included in EH’s operating results in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. See Note 2A for additional information. Effective as of the beginning of 2016, our entire contract manufacturing business, Pfizer CentreOne (previously known as Pfizer CentreSource or PCS), is part of EH. Pfizer CentreOne consists of (i) the revenues and expenses of legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including the revenues and expenses related to our manufacturing and supply agreements with Zoetis; and (ii) the revenues and expenses of legacy Hospira's One-2-One sterile injectables contract manufacturing operation, which has been included in EH since we acquired Hospira on September 3, 2015. Prior to 2016, PCS was managed outside our operating segments as part of PGS and reported as "Other Business Activities". We have reclassified prior period PCS operating results ( $116 million of PCS revenues and $15 million of PCS earnings in the third quarter of 2015, and $360 million of PCS revenues and $66 million of PCS earnings in the first nine months of 2015) to conform to the current period presentation as part of EH. As noted above, also effective as of the beginning of 2016, in connection with the formation of a new EH R&D organization, certain functions transferred from Pfizer’s WRD organization to the new EH R&D organization. We have reclassified approximately $68 million of costs in the third quarter of 2015 and $202 million of costs in the first nine months of 2015 from WRD to EH to conform to the current period presentation as part of EH. (d) Other business activities includes the costs managed by our WRD, GPD and Pfizer Medical organizations. (e) For a description, see the “Other Costs and Business Activities” section above. (f) Certain significant items are substantive and in some cases recurring (such as restructuring or legal charges), or unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the third quarter of 2016, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $375 million , (ii) income for certain legal matters of $40 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion , (iv) certain asset impairment charges of $126 million , (v) charges for business and legal entity alignment of $69 million and (vi) other charges of $17 million . For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the third quarter of 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $107 million , (ii) certain asset impairment charges of $633 million , (iii) charges for business and legal entity alignment of $60 million and (iv) other charges of $36 million . For additional information, see Note 3 and Note 4. For Earnings in the first nine months of 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $743 million , (ii) charges for certain legal matters of $506 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion , (iv) certain asset impairment charges of $1.1 billion , (v) charges for business and legal entity alignment of $180 million and (vi) other charges of $189 million . For additional information, see Note 2B , Note 3 and Note 4. For Earnings in the first nine months of 2015 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $302 million , (ii) certain asset impairment charges of $633 million , (iii) charges for business and legal entity alignment of $224 million , (iv) charges for certain legal matters of $92 million , and (v) other charges of $117 million . For additional information, see Note 3 and Note 4.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, Reportable Segments: IH (b) $ 7,332 $ 6,752 $ 4,187 $ 4,018 EH (c) 5,712 5,335 3,128 3,181 Total reportable segments 13,045 12,087 7,315 7,199 Other business activities (d) — — (786 ) (715 ) Reconciling Items: Corporate (e) — — (1,504 ) (1,376 ) Purchase accounting adjustments (e) — — (966 ) (960 ) Acquisition-related costs (e) — — (280 ) (541 ) Certain significant items (f) — — (1,969 ) (837 ) Other unallocated — — (206 ) (73 ) $ 13,045 $ 12,087 $ 1,604 $ 2,697 Nine Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, Reportable Segments: IH (b) $ 21,471 $ 19,120 $ 12,470 $ 10,831 EH (c) 17,725 15,683 9,985 9,540 Total reportable segments 39,196 34,804 22,454 20,371 Other business activities (d) — — (2,190 ) (2,127 ) Reconciling Items: Corporate (e) — — (4,123 ) (3,949 ) Purchase accounting adjustments (e) — — (3,103 ) (2,698 ) Acquisition-related costs (e) — — (598 ) (631 ) Certain significant items (f) — — (4,112 ) (1,369 ) Other unallocated — — (753 ) (278 ) $ 39,196 $ 34,804 $ 7,575 $ 9,319 (a) Income from continuing operations before provision for taxes on income. (b) Effective as of the beginning of the second quarter of 2016, in connection with the formation of the GPD organization, certain development-related functions transferred from IH to GPD. We have reclassified approximately $76 million of costs in the first quarter of 2016, approximately $77 million of costs in the third quarter of 2015 and approximately $223 million of costs in the first nine months of 2015 from IH to GPD to conform to the current period presentation as part of GPD. Additionally, Anacor's and Medivations’s commercial operations are included in IH's operating results in our condensed consolidated statements of income. As a result, commencing from the acquisition date of June 24, 2016, IH's operating results for the third quarter and first nine months of 2016 include approximately three months of legacy Anacor operations, which were immaterial, and commencing from the acquisition date of September, 28, 2016, IH's operating results for the third quarter and first nine months of 2016 reflect three business days of legacy Medivation operations, which were immaterial. (c) On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Hospira. As a result, legacy Hospira commercial operations, including the legacy Hospira One-2-One contract manufacturing business, are included in EH’s operating results in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. See Note 2A for additional information. Effective as of the beginning of 2016, our entire contract manufacturing business, Pfizer CentreOne (previously known as Pfizer CentreSource or PCS), is part of EH. Pfizer CentreOne consists of (i) the revenues and expenses of legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including the revenues and expenses related to our manufacturing and supply agreements with Zoetis; and (ii) the revenues and expenses of legacy Hospira's One-2-One sterile injectables contract manufacturing operation, which has been included in EH since we acquired Hospira on September 3, 2015. Prior to 2016, PCS was managed outside our operating segments as part of PGS and reported as "Other Business Activities". We have reclassified prior period PCS operating results ( $116 million of PCS revenues and $15 million of PCS earnings in the third quarter of 2015, and $360 million of PCS revenues and $66 million of PCS earnings in the first nine months of 2015) to conform to the current period presentation as part of EH. As noted above, also effective as of the beginning of 2016, in connection with the formation of a new EH R&D organization, certain functions transferred from Pfizer’s WRD organization to the new EH R&D organization. We have reclassified approximately $68 million of costs in the third quarter of 2015 and $202 million of costs in the first nine months of 2015 from WRD to EH to conform to the current period presentation as part of EH. (d) Other business activities includes the costs managed by our WRD, GPD and Pfizer Medical organizations. (e) For a description, see the “Other Costs and Business Activities” section above. (f) Certain significant items are substantive and in some cases recurring (such as restructuring or legal charges), or unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the third quarter of 2016, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $375 million , (ii) income for certain legal matters of $40 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion , (iv) certain asset impairment charges of $126 million , (v) charges for business and legal entity alignment of $69 million and (vi) other charges of $17 million . For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the third quarter of 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $107 million , (ii) certain asset impairment charges of $633 million , (iii) charges for business and legal entity alignment of $60 million and (iv) other charges of $36 million . For additional information, see Note 3 and Note 4. For Earnings in the first nine months of 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $743 million , (ii) charges for certain legal matters of $506 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion , (iv) certain asset impairment charges of $1.1 billion , (v) charges for business and legal entity alignment of $180 million and (vi) other charges of $189 million . For additional information, see Note 2B , Note 3 and Note 4. For Earnings in the first nine months of 2015 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $302 million , (ii) certain asset impairment charges of $633 million , (iii) charges for business and legal entity alignment of $224 million , (iv) charges for certain legal matters of $92 million , and (v) other charges of $117 million . For additional information, see Note 3 and Note 4.
Schedule of Revenues by Geographic Region	The following table provides revenues by geographic area (a) : Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 2, September 27, % Change October 2, September 27, % Change U.S. $ 6,530 $ 5,565 17 $ 19,561 $ 14,993 30 Developed Europe (b) 2,218 2,315 (4 ) 6,982 7,006 — Developed Rest of World (c) 1,711 1,513 13 4,940 4,562 8 Emerging Markets (d) 2,586 2,694 (4 ) 7,714 8,243 (6 ) Revenues $ 13,045 $ 12,087 8 $ 39,196 $ 34,804 13 (a) On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Hospira. As a result, legacy Hospira operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016 . In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. On June 24, 2016, we acquired Anacor. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Anacor. As a result, legacy Anacor operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016 . In accordance with our domestic reporting period, our results of operations and IH's operating results for the third quarter and first nine months of 2016 include approximately three months of legacy Anacor operations. Additionally, on September 28, 2016, we acquired Medivation. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Medivation. As a result, legacy Medivation operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016 . In accordance with our domestic and international reporting periods, our results of operations and IH's operating results for the third quarter and first nine months of 2016 reflect three business days of legacy Medivation operations, which were immaterial. See Note 2A for additional information. (b) Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries. Revenues denominated in euros were $1.7 billion and $1.8 billion in the third quarter of 2016 and 2015 , respectively, and $5.3 billion and $5.4 billion in the first nine months of 2016 and 2015 , respectively. (c) Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea. (d) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.
Schedule of Significant Product Revenues	The following table provides detailed revenue information: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 2, September 27, October 2, September 27, PFIZER INNOVATIVE HEALTH (IH) (a) $ 7,332 $ 6,752 $ 21,471 $ 19,120 Internal Medicine $ 2,243 $ 1,954 $ 6,557 $ 5,500 Lyrica IH (b) 1,049 947 3,107 2,701 Viagra IH (c) 297 333 897 955 Chantix/Champix 198 159 631 491 Toviaz 60 59 191 193 BMP2 63 57 175 169 Alliance revenues (d) 417 343 1,139 841 All other Internal Medicine (m) 159 56 416 149 Vaccines $ 1,641 $ 1,629 $ 4,576 $ 4,536 Prevnar/Prevenar 13 1,536 1,576 4,302 4,384 FSME/IMMUN-TicoVac 33 28 102 93 All other Vaccines 72 26 172 60 Oncology $ 1,104 $ 786 $ 3,206 $ 2,026 Ibrance 550 230 1,492 408 Sutent 260 279 823 815 Xalkori 140 122 415 353 Inlyta 95 105 304 311 All other Oncology 60 50 172 139 Inflammation & Immunology (I&I) $ 960 $ 987 $ 2,907 $ 2,816 Enbrel (Outside the U.S. and Canada) 701 844 2,201 2,426 Xeljanz 235 127 649 351 All othe r I&I 24 16 57 40 Rare Disease $ 585 $ 579 $ 1,768 $ 1,776 BeneFIX 176 194 543 561 Genotropin 147 142 425 447 Refacto AF/Xyntha 140 130 408 392 Somavert 59 54 173 158 Rapamune 38 32 131 138 All other Rare Disease 25 27 88 80 Consumer Healthcare $ 798 $ 817 $ 2,457 $ 2,465 PFIZER ESSENTIAL HEALTH (EH) ( e) $ 5,712 $ 5,335 $ 17,725 $ 15,683 Legacy Established Products (LEP) (f) $ 2,708 $ 2,919 $ 8,373 $ 8,701 Lipitor 422 454 1,294 1,404 Premarin family 244 263 751 753 Norvasc 238 241 714 744 EpiPen 110 107 300 268 Xalatan/Xalacom 91 98 273 299 Relpax 83 91 248 254 Zoloft 72 95 228 274 Effexor 70 66 207 213 Zithromax/Zmax (g) 56 63 203 203 Xanax/Xanax XR 55 55 163 164 Cardura 49 52 143 158 Neurontin 45 45 136 148 Tikosyn 20 44 136 123 Depo-Provera 36 45 103 133 All other LEP 1,119 1,199 3,473 3,563 Sterile Injectable Pharmaceuticals (SIP) (h) $ 1,461 $ 957 $ 4,481 $ 2,436 Medrol (g) 102 98 330 284 Sulperazon 102 72 304 251 Fragmin 80 84 240 246 Tygacil 69 81 203 231 All other SIP 1,108 621 3,405 1,424 Peri-LOE Products (i) $ 1,023 $ 1,229 $ 3,224 $ 4,073 Lyrica EH (b) 191 273 623 925 Celebrex 194 212 550 640 Pristiq 174 185 546 523 Vfend 140 165 459 510 Zyvox 94 165 334 696 Viagra EH (c) 89 97 286 318 Revatio 73 53 213 181 All Other Peri-LOE Products 68 79 214 280 Infusion Systems (j) $ 281 $ 94 $ 879 $ 94 Biosimilars (k) $ 83 $ — $ 228 $ — Pfizer CentreOne (l) $ 156 $ 136 $ 540 $ 380 Revenues $ 13,045 $ 12,087 $ 39,196 $ 34,804 Total Lyrica (b) $ 1,240 $ 1,220 $ 3,730 $ 3,626 Total Viagra (c) $ 387 $ 430 $ 1,183 $ 1,274 Total Alliance revenues $ 419 $ 349 $ 1,155 $ 881 (a) The IH business, previously known as the Innovative Products business, encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare and includes all legacy Medivation and Anacor commercial operations. Medivation’s and Anacor’s commercial operations are included in IH’s operating results in our condensed consolidated statements of income, commencing from the acquisition date of September 28, 2016 for Medivation and from the acquisition date of June 24, 2016 for Anacor. As a result, IH’s revenues for the third quarter and first nine months of 2016 include three business days of legacy Medivation operations and approximately three months of legacy Anacor operations, which were immaterial. (b) Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH. (c) Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH. (d) Includes Eliquis (2016 and 2015) and Rebif (2015 only). (e) The EH business, previously known as the Established Products business, encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Infusion Systems, Biosimilars and Pfizer CentreOne and includes all legacy Hospira commercial operations. Hospira's commercial operations, including the legacy Hospira One-2-One sterile injectables contract manufacturing business, are included in EH’s operating results in our condensed consolidated statements of income, commencing from the acquisition date of September 3, 2015. Therefore, in accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. Also, effective as of the beginning of 2016, our entire contract manufacturing business, Pfizer CentreOne (previously known as Pfizer CentreSource or PCS), is part of EH. Pfizer CentreOne consists of (i) legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including our manufacturing and supply agreements with Zoetis; and (ii) legacy Hospira's One-2-One sterile injectables contract manufacturing operation. Prior to 2016, PCS was managed outside our operating segments and its revenues were reported as other business activities. We have reclassified prior period PCS revenues ( $116 million in the third quarter of 2015 and $360 million in the first nine months of 2015 ) to conform to the current period presentation as part of EH. (f) Legacy Established Products include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). (g) Prior period revenues for Medrol and Zithromax/Zmax may not agree to previously-disclosed revenues because revenues for those products are now split between the Legacy Established Products and the Sterile Injectable Pharmaceuticals categories. (h) Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products). (i) Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products primarily include Lyrica in certain developed Europe markets, Pristiq globally, Celebrex, Zyvox and Revatio in most developed markets, Vfend and Viagra in certain developed Europe markets and Japan, and Inspra in the EU. (j) Infusion Systems include Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets. (k) Biosimilars include Inflectra (biosimilar infliximab) in certain European markets, Nivestim (biosimilar filgrastim) in certain Asian markets and Retacrit (biosimilar epoetin zeta) in certain international markets. (l) Pfizer CentreOne (previously known as Pfizer CentreSource or PCS) includes (i) revenues from legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including revenues related to our manufacturing and supply agreements with Zoetis; and (ii) revenues from legacy Hospira’s One-2-One sterile injectables contract manufacturing operation. (m) Includes Eliquis direct sales markets.

Basis of Presentation and Sig33

Basis of Presentation and Significant Accounting Policies (Details) - USD ($) $ / shares in Units, $ in Millions		Sep. 28, 2016	Jun. 24, 2016	Apr. 08, 2016	Apr. 02, 2017	Oct. 02, 2016	Sep. 27, 2015	Oct. 06, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired	[1]					$ 17,679	$ 16,322
Payments of merger termination costs				$ 150		150
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs						89
Held-for-sale [Member] | Subsequent Event [Member] | HIS [Member] | ICU Medical [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration transferred								$ 1,000
Accounting Standards Update 2015-03 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs									$ (79)
Forecast [Member] | Held-for-sale [Member] | HIS [Member] | ICU Medical [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Minimum share transfer restriction term					18 months
Medivation [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share)		$ 81.50
Payments for acquisitions, cash portion		$ 14,300
Cash payments for acquisition, net of cash acquired		$ 13,900
Anacor [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share)			$ 99.25
Payments for acquisitions, cash portion			$ 4,900
Cash payments for acquisition, net of cash acquired			4,500
Debt assumed			$ 698
Short-term borrowings, including current portion of long-term debt [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs						1
Short-term borrowings, including current portion of long-term debt [Member] | Accounting Standards Update 2015-03 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs									1
Long-term debt [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs						$ 88
Long-term debt [Member] | Accounting Standards Update 2015-03 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs									79
Other current assets [Member] | Accounting Standards Update 2015-03 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs									(1)
Other noncurrent assets [Member] | Accounting Standards Update 2015-03 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs									$ (79)
[1]	Amounts may not add due to rounding.

Acquisitions, Assets and Liab34

Acquisitions, Assets and Liabilities Held for Sale, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Medivation (Details) - USD ($) $ / shares in Units, $ in Millions		Sep. 28, 2016	Oct. 02, 2016	Sep. 27, 2015	Dec. 31, 2015
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired	[1]		$ 17,679	$ 16,322
Goodwill	[2]		56,281		$ 48,242
Medivation [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share)		$ 81.50
Payments for acquisitions, cash portion		$ 14,300
Cash payments for acquisition, net of cash acquired		13,900
Identifiable intangible assets		13,200
Goodwill		5,500
Deferred tax liabilities		4,400
Contingent consideration assumed		374
Medivation [Member] | In Process Research and Development [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		4,800
Medivation [Member] | Developed Technology Rights [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		$ 8,500
Acquired intangible assets, average useful life		12 years
Other Current Liabilities [Member] | Medivation [Member]
Business Acquisition [Line Items]
Amount payable			$ 1,000
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.

Acquisitions, Assets and Liab35

Acquisitions, Assets and Liabilities Held for Sale, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Bamboo Therapeutics (Details) - USD ($) $ in Millions		Aug. 01, 2016	Apr. 03, 2016	Oct. 02, 2016	Sep. 27, 2015	Dec. 31, 2015
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired	[1]			$ 17,679	$ 16,322
Goodwill	[2]			$ 56,281		$ 48,242
Bamboo Therapeutics [Member]
Business Acquisition [Line Items]
Payment to acquire the remaining equity		$ 150
Maximum amount of potential milestone payments		495
Total fair value of consideration transferred		331
Payments for acquisitions, cash portion		130	$ 43
Cash payments for acquisition, net of cash acquired		101
Contingent consideration incurred		157
Fair value of previously held equity interest		44
Goodwill		130
Deferred tax liabilities		94
Other Income (Expense) [Member] | Bamboo Therapeutics [Member]
Business Acquisition [Line Items]
Gain recognized upon acquisition of remaining interest in acquiree		1
In Process Research and Development [Member] | Bamboo Therapeutics [Member]
Business Acquisition [Line Items]
IPR&D		$ 325
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.

Acquisitions, Assets and Liab36

Acquisitions, Assets and Liabilities Held for Sale, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Anacor Pharmaceuticals, Inc. (Details) - USD ($) $ / shares in Units, $ in Millions		Jun. 24, 2016	Oct. 02, 2016	Sep. 27, 2015	Dec. 31, 2015
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired	[1]		$ 17,679	$ 16,322
Goodwill	[2]		$ 56,281		$ 48,242
Anacor [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share)		$ 99.25
Payments for acquisitions, cash portion		$ 4,900
Cash payments for acquisition, net of cash acquired		4,500
Debt assumed		698
IPR&D		5,000
Goodwill		1,800
Deferred tax liabilities		1,600
Anacor [Member] | In Process Research and Development [Member]
Business Acquisition [Line Items]
IPR&D		$ 4,800
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.

Acquisitions, Assets and Liab37

Acquisitions, Assets and Liabilities Held for Sale, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Hospira Acquisition (Details) - USD ($) $ / shares in Units, $ in Millions		Sep. 03, 2015	Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015	Dec. 31, 2015
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired	[1]				$ 17,679	$ 16,322
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill	[2]		$ 56,281		56,281		$ 48,242
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)	[3]		$ 1,320	$ 2,130	6,355	7,132
Hospira [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share)		$ 90
Payments for acquisitions, cash portion		$ 16,100
Cash payments for acquisition, net of cash acquired		15,700
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Working capital, excluding inventories		342
Inventories		1,901
PP&E		2,352
Other noncurrent assets		362
Long-term debt		(1,928)
Benefit obligations		(117)
Net income tax accounts		(3,380)
Other noncurrent liabilities		(61)
Total identifiable net assets		8,791
Goodwill		7,295
Net assets acquired/total consideration transferred		16,087
Measurement Period Adjustments
Working capital, excluding inventories	[4]				68
Inventories	[4]				(23)
Property, plant and equipment	[4]				(57)
Other noncurrent assets	[4]				(46)
Long-term debt	[4]				0
Benefit obligations	[4]				0
Net income tax accounts	[4]				14
Other noncurrent liabilities	[4]				(23)
Total identifiable net assets	[4]				(12)
Goodwill	[4]				12
Net assets acquired/total consideration transferred	[4]				0
Unrecognized tax positions		109
Tax impact of fair value adjustments		3,200
Other tax matters		719
Business Acquisition, Pro Forma Information [Abstract]
Revenues				12,957		38,034
Net income attributable to Pfizer Inc. common shareholders				$ 2,513		$ 7,577
Diluted EPS attributable to Pfizer Inc. common shareholders (in dollars per share)				$ 0.40		$ 1.21
Additional amortization expense				$ 70		$ 321
Depreciation expense				14		57
Interest expense				(3)		(23)
Hospira [Member] | Fair Value Adjustment to Inventory [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)				75		66
Hospira [Member] | Eliminations [Member]
Business Acquisition, Pro Forma Information [Abstract]
Amortization expense				9		33
Hospira [Member] | Eliminations [Member] | Acquisition-related Costs [Member]
Business Acquisition, Pro Forma Information [Abstract]
Net income (loss)				$ 680		$ 724
Hospira [Member] | Previously Reported [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Working capital, excluding inventories		274
Inventories		1,924
PP&E		2,410
Other noncurrent assets		408
Long-term debt		(1,928)
Benefit obligations		(117)
Net income tax accounts		(3,394)
Other noncurrent liabilities		(39)
Total identifiable net assets		8,803
Goodwill		7,284
Net assets acquired/total consideration transferred		16,087
Developed Technology Rights and Other Intangible Assets [Member] | Hospira [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Identifiable intangible assets, excluding IPR&D		8,290
Measurement Period Adjustments
Identifiable intangible assets	[4]				20
Developed Technology Rights and Other Intangible Assets [Member] | Hospira [Member] | Previously Reported [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Identifiable intangible assets, excluding IPR&D		8,270
In Process Research and Development [Member] | Hospira [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
IPR&D		1,030
Measurement Period Adjustments
Identifiable intangible assets	[4]				$ 35
In Process Research and Development [Member] | Hospira [Member] | Previously Reported [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
IPR&D		$ 995
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	The changes in the estimated fair values are primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.

Acquisitions, Assets and Liab38

Acquisitions, Assets and Liabilities Held for Sale, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Additional Acquisitions (Details) - USD ($) $ in Millions		Dec. 01, 2014	Oct. 02, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill	[1]		$ 56,281	$ 48,242
Baxter International Inc. [Member]
Business Acquisition [Line Items]
Total consideration transferred		$ 648
Identifiable intangible assets, excluding IPR&D		376
Inventories		194
Goodwill		12
Baxter International Inc. [Member] | Developed Technology Rights [Member]
Business Acquisition [Line Items]
Identifiable intangible assets, excluding IPR&D		$ 371
[1]	Amounts may not add due to rounding.

Acquisitions, Assets and Liab39

Acquisitions, Assets and Liabilities Held for Sale, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Assets and Liabilities Held for Sale (Details) - USD ($) $ in Millions		Oct. 06, 2016	Apr. 02, 2017	Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016		Sep. 27, 2015	[2]	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment on remeasurement of HIS net assets	[1]			$ 1,422	$ 0	$ 1,422	[2]	$ 0
Assets Held for Sale
Assets held for sale	[3]			1,119		1,119				$ 9
HIS [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment on remeasurement of HIS net assets				1,422		1,400
Held-for-sale [Member]
Assets Held for Sale
Other assets	[4]			77		77				9
Assets held for sale				1,119		1,119				9
Held-for-sale [Member] | HIS [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment on remeasurement of HIS net assets				1,422
Assets Held for Sale
Inventories				369		369				0
Property, plant and equipment				441		441				0
Identifiable intangible assets				1,322		1,322				0
Goodwill				243		243				0
Other assets				60		60				0
Less: adjustment to HIS assets for net realizable value	[5]			(1,394)		(1,394)				0
Assets held for sale				1,042		1,042				0
Liabilities Held for Sale
Accrued compensation and related items				42		42				0
Other liabilities				68		68				0
Total HIS liabilities held for sale				110		110				$ 0
Selling costs				$ 28		$ 28
Held-for-sale [Member] | ICU Medical [Member] | Subsequent Event [Member] | HIS [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration transferred		$ 1,000
Shares issued from disposition		400
Cash received from disposition		$ 600
Held-for-sale [Member] | Forecast [Member] | ICU Medical [Member] | HIS [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Ownership percentage			16.60%
Minimum share transfer restriction term			18 months
[1]	In the third quarter and first nine months of 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. In October 2016, ICU Medical and Pfizer announced that they entered into a definitive agreement under which ICU Medical will acquire all of Pfizer’s global infusion therapy net assets, HIS, for approximately $1 billion in cash and ICU Medical stock. HIS includes IV pumps, solutions and devices. See Note 2B for additional information.
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Other assets held for sale consist primarily of property, plant and equipment and other assets.
[5]	For the quarter ending October 2, 2016, we recorded an adjustment to HIS assets for net realizable value of $1,394 million plus estimated costs to sell of $28 million for a total impairment on HIS net assets of $1,422 million.

Acquisitions, Assets and Liab40

Acquisitions, Assets and Liabilities Held for Sale, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Research and Development and Collaborative Arrangements (Details) patient in Thousands	1 Months Ended						3 Months Ended	9 Months Ended
	May 31, 2016USD ($)	Apr. 30, 2016USD ($)	Jan. 31, 2016USD ($)	Jul. 31, 2015studypatient	Mar. 31, 2015USD ($)	Feb. 28, 2015USD ($)	Oct. 02, 2016USD ($)	Oct. 02, 2016USD ($)
NovaQuest Co-Investment Fund II, L.P. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development arrangement, amount	$ 250,000,000
Research and development arrangement, percentage of costs to be reimbursed (up to)	40.00%
Funding to offset costs incurred under research and development arrangement							$ 67,600,000	$ 136,900,000
NovaQuest Co-Investment Fund V, L.P. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development arrangement, amount		$ 200,000,000
Research and development arrangement, contingent payments, maximum		$ 267,000,000
Research and development arrangement, term		8 years
Research and development arrangement, percentage of costs to be reimbursed (up to)		100.00%
Funding to offset costs incurred under research and development arrangement							14,500,000	29,500,000
RPI Finance Trust [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development arrangement, amount			$ 300,000,000
Research and development arrangement, contingent payments, maximum			$ 250,000,000
Research and development arrangement, term			7 years
Research and development arrangement, percentage of costs to be reimbursed (up to)			100.00%
Funding to offset costs incurred under research and development arrangement							$ 11,000,000	$ 32,700,000
Eli Lilly & Company (Lilly) [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of studies | study				6
Number of patients | patient				7
Eli Lilly & Company (Lilly) [Member] | Deferred Revenue [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payments received					$ 200,000,000
OPKO Health, Inc. [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payments and milestone payments						$ 295,000,000
Contingent collaborative arrangement payments						$ 275,000,000

Acquisitions, Assets and Liab41

Acquisitions, Assets and Liabilities Held for Sale, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Equity-Method Investments (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015	Apr. 03, 2016
Hisun Pfizer Pharmaceuticals Co. Ltd [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage		49.00%		49.00%
Equity method investment, impairment	$ 470	$ 211	$ 470
Equity Method Investments		$ 529
Hisun Pfizer Pharmaceuticals Co. Ltd [Member] | Discounted Cash Flows Technique [Member]
Schedule of Equity Method Investments [Line Items]
Discount rate		13.00%
Laboratorio Teuto Brasilero [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage		40.00%
Equity method investment, impairment		$ 50
Laboratorio Teuto Brasilero [Member] | Other Income (Expense) [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, impairment		$ 50
Laboratorio Teuto Brasilero [Member] | Discounted Cash Flows Technique [Member]
Schedule of Equity Method Investments [Line Items]
Discount rate		17.50%
Laboratorio Teuto Brasilero [Member] | Laboratorio Teuto Brasilero [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage		60.00%

Acquisitions, Assets and Liab42

Acquisitions, Assets and Liabilities Held for Sale, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Cost-Method Investments (Details) - AM Pharma BV [Member] $ in Millions	1 Months Ended
	Apr. 30, 2015USD ($)
Schedule of Cost-method Investments [Line Items]
Cost method, maximum payments	$ 512.5
Long-term Investments [Member]
Schedule of Cost-method Investments [Line Items]
Upfront And milestone payments	$ 87.5

Restructuring Charges and Oth43

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) $ in Millions		Sep. 03, 2015	Oct. 02, 2016USD ($)	Sep. 27, 2015USD ($)	Oct. 02, 2016USD ($)site	Sep. 27, 2015USD ($)	Dec. 31, 2015USD ($)	Sep. 03, 2018USD ($)
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost			$ 3,000		$ 3,000
Total costs associated with acquisitions and cost-reduction/productivity initiatives					1,200
Restructuring charges:
Employee terminations	[1]		347	$ 241	464	$ 306
Asset impairments	[1]		27	198	45	209
Exit costs	[1]		29	30	64	40
Total restructuring charges	[1]		404	469	574	555
Transaction costs	[2]		54	64	114	70
Integration costs	[3]		74	48	300	102
Restructuring charges and certain acquisition-related costs	[4]		531	581	988	727
Total additional depreciation––asset restructuring	[5]		47	24	151	71
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[6]		78	42	202	135
Total costs associated with acquisitions and cost-reduction/productivity initiatives			655	647	1,341	933
Cost of Sales [Member]
Restructuring charges:
Total additional depreciation––asset restructuring	[5]		46	23	145	67
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[6]		46	23	127	64
Selling, Informational and Administrative Expenses [Member]
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[6]		23	16	56	55
Research and Development Expense [Member]
Restructuring charges:
Total additional depreciation––asset restructuring	[5]		1	1	5	3
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[6]		8	2	17	13
Other (Income)/Deductions - net [Member]
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[6]		1	2	$ 2	3
Manufacturing Plant Network Rationalization And Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Expected number of sites exited | site					7
Acquisition-related Costs [Member] | Manufacturing Plant Network Rationalization And Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost			400		$ 400
Restructuring costs incurred			365		365
Facility Closing [Member] | Manufacturing Plant Network Rationalization And Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost			1,100		1,100
Restructuring costs incurred			828		828
Business Restructuring Reserves [Member] | Global Commercial Structure Reorganization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred			219		219
Commercial Real Estate [Member] | Other Cost Reduction / Productivity Initiatives [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost			1,300		1,300
Restructuring costs incurred			$ 895		$ 895
Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Expected integration related costs, period		3 years
Hospira [Member] | Return of Acquired Rights [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring cost incurred associated with the return of acquired in-process research and development rights				$ 205		$ 205	$ 215
Forecast [Member] | Hospira [Member]
Restructuring charges:
Integration costs								$ 1,000
[1]	In the nine months ended October 2, 2016, Employee terminations represent the expected reduction of the workforce by approximately 2,100 employees, mainly in manufacturing, sales, research and corporate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.The restructuring charges for 2016 are associated with the following:•For the third quarter of 2016, the IH segment ($148 million); the EH segment ($28 million); WRD, GPD and Medical (M) (WRD/GPD/M) ($52 million); manufacturing operations ($108 million); and Corporate ($67 million).•For the first nine months of 2016, IH ($162 million); EH ($19 million); WRD/GPD/M ($104 million); manufacturing operations ($181 million); and Corporate ($107 million).The restructuring charges for 2015 are associated with the following:•For the third quarter of 2015, IH ($9 million); EH ($280 million); WRD/GPD/M ($50 million); manufacturing operations ($26 million); and Corporate ($104 million).•For the first nine months of 2015, IH ($55 million); EH ($288 million); WRD/GPD/M ($66 million); manufacturing operations ($18 million); and Corporate ($127 million).In September 2015, in order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, Pfizer opted to return rights to Celltrion that Hospira had previously acquired to potential biosimilars to Rituxan® (rituximab) and Herceptin® (trastuzumab). As such, upon return of the acquired rights, in the third quarter and first nine months of 2015, we incurred charges of $205 million, which are comprised of (i) a write-off of the applicable IPR&D assets, totaling $160 million, which is included in Asset impairments; (ii) a write-off of amounts prepaid to Celltrion in the amount of $25 million, which is included in Asset impairments; and (iii) a payment to Celltrion of $20 million, which is included in Exit costs.
[2]	Transaction costs represent external costs for banking, legal, accounting and other similar services, most of which in the third quarter of 2016 are directly related to our acquisition of Medivation, and most of which in the first nine months of 2016 are directly related to our acquisitions of Medivation and Anacor, and the terminated transaction with Allergan. Transaction costs in 2015 represent external costs directly related to the acquisition of Hospira and primarily include expenditures for banking, legal, accounting and other similar services.
[3]	Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the third quarter of 2016, integration costs mostly relate to our acquisition of Hospira and for the first nine months of 2016, integration costs mostly relate to our acquisition of Hospira and the terminated transaction with Allergan. Integration costs in 2015 represent external incremental costs directly related to our acquisition of Hospira.
[4]	Amounts may not add due to rounding.
[5]	Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[6]	Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

Restructuring Charges and Oth44

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Details) $ in Millions		3 Months Ended		9 Months Ended		12 Months Ended
		Oct. 02, 2016USD ($)	Sep. 27, 2015USD ($)	Oct. 02, 2016USD ($)Employee	Sep. 27, 2015USD ($)	Dec. 31, 2015USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected number of positions eliminated (in number of employees) | Employee				2,100
Restructuring charges	[1]	$ 404	$ 469	$ 574	$ 555
Impairment of intangible assets		126	163	767	163
Corporate [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		67	104	107	127
IH [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		148	9	162	55
Impairment of intangible assets		29	20		20
EH [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		28	280	19	288
Impairment of intangible assets		97	143	738	143
WRD, GPD & Medical [Member] | Segment Reconciling Items [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		52	50	104	66
Manufacturing operations [Member] | Segment Reconciling Items [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 108	26	$ 181	18
Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Write off of prepaid amounts			25		25
Payments for the return of acquired rights			20		20
Hospira [Member] | Return of Acquired Rights [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring cost incurred			205		205	$ 215
In Process Research and Development [Member] | Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Impairment of intangible assets			$ 160		$ 160
[1]	In the nine months ended October 2, 2016, Employee terminations represent the expected reduction of the workforce by approximately 2,100 employees, mainly in manufacturing, sales, research and corporate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.The restructuring charges for 2016 are associated with the following:•For the third quarter of 2016, the IH segment ($148 million); the EH segment ($28 million); WRD, GPD and Medical (M) (WRD/GPD/M) ($52 million); manufacturing operations ($108 million); and Corporate ($67 million).•For the first nine months of 2016, IH ($162 million); EH ($19 million); WRD/GPD/M ($104 million); manufacturing operations ($181 million); and Corporate ($107 million).The restructuring charges for 2015 are associated with the following:•For the third quarter of 2015, IH ($9 million); EH ($280 million); WRD/GPD/M ($50 million); manufacturing operations ($26 million); and Corporate ($104 million).•For the first nine months of 2015, IH ($55 million); EH ($288 million); WRD/GPD/M ($66 million); manufacturing operations ($18 million); and Corporate ($127 million).In September 2015, in order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, Pfizer opted to return rights to Celltrion that Hospira had previously acquired to potential biosimilars to Rituxan® (rituximab) and Herceptin® (trastuzumab). As such, upon return of the acquired rights, in the third quarter and first nine months of 2015, we incurred charges of $205 million, which are comprised of (i) a write-off of the applicable IPR&D assets, totaling $160 million, which is included in Asset impairments; (ii) a write-off of amounts prepaid to Celltrion in the amount of $25 million, which is included in Asset impairments; and (iii) a payment to Celltrion of $20 million, which is included in Exit costs.

Restructuring Charges and Oth45

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
Restructuring Reserve [Roll Forward]
Balance, December 31, 2015	[1]			$ 1,157
Provision	[2]	$ 404	$ 469	574	$ 555
Utilization and other	[3]			(455)
Balance, October 2, 2016	[4]	1,275		1,275
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2015	[1]			1,109
Provision				464
Utilization and other	[3]			(360)
Balance, October 2, 2016	[4]	1,213		1,213
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2015	[1]			0
Provision				45
Utilization and other	[3]			(45)
Balance, October 2, 2016	[4]	0		0
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2015	[1]			48
Provision				64
Utilization and other	[3]			(50)
Balance, October 2, 2016	[4]	$ 62		$ 62
[1]	Included in Other current liabilities ($776 million) and Other noncurrent liabilities ($381 million).
[2]	In the nine months ended October 2, 2016, Employee terminations represent the expected reduction of the workforce by approximately 2,100 employees, mainly in manufacturing, sales, research and corporate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.The restructuring charges for 2016 are associated with the following:•For the third quarter of 2016, the IH segment ($148 million); the EH segment ($28 million); WRD, GPD and Medical (M) (WRD/GPD/M) ($52 million); manufacturing operations ($108 million); and Corporate ($67 million).•For the first nine months of 2016, IH ($162 million); EH ($19 million); WRD/GPD/M ($104 million); manufacturing operations ($181 million); and Corporate ($107 million).The restructuring charges for 2015 are associated with the following:•For the third quarter of 2015, IH ($9 million); EH ($280 million); WRD/GPD/M ($50 million); manufacturing operations ($26 million); and Corporate ($104 million).•For the first nine months of 2015, IH ($55 million); EH ($288 million); WRD/GPD/M ($66 million); manufacturing operations ($18 million); and Corporate ($127 million).In September 2015, in order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, Pfizer opted to return rights to Celltrion that Hospira had previously acquired to potential biosimilars to Rituxan® (rituximab) and Herceptin® (trastuzumab). As such, upon return of the acquired rights, in the third quarter and first nine months of 2015, we incurred charges of $205 million, which are comprised of (i) a write-off of the applicable IPR&D assets, totaling $160 million, which is included in Asset impairments; (ii) a write-off of amounts prepaid to Celltrion in the amount of $25 million, which is included in Asset impairments; and (iii) a payment to Celltrion of $20 million, which is included in Exit costs.
[3]	Includes adjustments for foreign currency translation.
[4]	Included in Other current liabilities ($714 million) and Other noncurrent liabilities ($561 million).

Restructuring Charges and Oth46

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) - USD ($) $ in Millions	Oct. 02, 2016		Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 1,275	[1]	$ 1,157	[2]
Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	714		776
Other Noncurrent Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 561		$ 381
[1]	Included in Other current liabilities ($714 million) and Other noncurrent liabilities ($561 million).
[2]	Included in Other current liabilities ($776 million) and Other noncurrent liabilities ($381 million).

Other (Income)_Deductions - N47

Other (Income)/Deductions - Net (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016		Sep. 27, 2015
Other Income and Expenses [Abstract]
Interest income	[1]	$ (123)	$ (121)	$ (357)		$ (332)
Interest expense	[1]	291	278	889		864
Net interest expense		168	157	532		533
Royalty-related income		(233)	(204)	(695)		(683)
Certain legal matters, net	[2]	(40)	0	494		99
Net gains on asset disposals	[3]	(47)	(35)	(81)		(230)
Impairment on remeasurement of HIS net assets	[4]	1,422	0	1,422	[5]	0	[5]
Certain asset impairments	[6]	133	633	1,080		658
Business and legal entity alignment costs	[7]	69	60	180		224
Other, net	[8]	(55)	50	(117)		70
Other (income)/deductions––net	[9]	$ 1,417	$ 661	$ 2,815		$ 670
[1]	Interest income increased in the first nine months of 2016, primarily due to higher investment returns. Interest expense increased in the third quarter and first nine months of 2016, primarily due to interest on legacy Hospira debt acquired in September 2015 and the addition of new fixed rate debt in the second quarter of 2016, partially offset by the maturity of other fixed rate debt in the second quarter of 2016.
[2]	In the first nine months of 2016, primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra pending against the Company in New York federal court for $486 million, which is subject to final court approval, partially offset by the reversal of a legal accrual where a loss is no longer deemed probable. In addition, the first nine months of 2016 includes a settlement related to a patent matter. See Note 12A2 for additional information.
[3]	In the first nine months of 2016, includes gains on sales/out-licensing of product and compound rights (approximately $49 million). In the first nine months of 2015, primarily includes gains on sales/out-licensing of product and compound rights (approximately $76 million) and gains on sales of investments in equity securities (approximately $160 million).
[4]	In the third quarter and first nine months of 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. In October 2016, ICU Medical and Pfizer announced that they entered into a definitive agreement under which ICU Medical will acquire all of Pfizer’s global infusion therapy net assets, HIS, for approximately $1 billion in cash and ICU Medical stock. HIS includes IV pumps, solutions and devices. See Note 2B for additional information.
[5]	Amounts may not add due to rounding.
[6]	In the third quarter of 2016, primarily includes intangible asset impairment charges of $126 million, reflecting $97 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma and $29 million of other IPR&D assets acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the third quarter of 2016 are associated with the following: EH ($97 million) and IH ($29 million). In the first nine months of 2016, primarily includes intangible asset impairment charges of $767 million, reflecting (i) $331 million related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) $265 million related to an IPR&D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) $97 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma; and (iv) $74 million of other IPR&D assets, $45 million of which were acquired in connection with our acquisition of Hospira and $29 million of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the first nine months of 2016 are associated with the following: EH ($738 million) and IH ($29 million). In addition, the first nine months of 2016 includes an impairment loss of $211 million related to Pfizer’s 49%-owned equity-method investment with Zhejiang Hisun Pharmaceuticals Co., Ltd. in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer's 40%-owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2D. The intangible asset impairment charge for 2016 for the IPR&D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a recent court ruling, requiring a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&D assets acquired in connection with our acquisition of King reflect changes in the competitive environment.In the third quarter and first nine months of 2015, primarily includes an impairment loss of $470 million related to Pfizer's 49%-owned equity-method investment in Hisun Pfizer, and impairment charges for intangible assets of $163 million reflecting (i) $115 million related to developed technology rights for the treatment of attention deficit hyperactivity disorder; (ii) $28 million related to an IPR&D project for the treatment of attention deficit hyperactivity disorder; and (iii) $20 million related to an indefinite-lived Consumer Healthcare brand. The intangible asset impairment charges for the third quarter and first nine months of 2015 are associated with the following: IH ($20 million) and EH ($143 million). The intangible asset impairment charges for 2015 reflect, among other things, updated commercial forecasts due to increased competition.
[7]	In the third quarter and first nine months of 2016 and 2015, represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.
[8]	In the first nine months of 2016, includes among other things, $150 million paid to Allergan for reimbursement of Allergan’s expenses associated with the terminated transaction (see Note 1A). The first nine months of 2016, also includes income of $116 million from resolution of a contract disagreement.
[9]	Amounts may not add due to rounding.

Other (Income)_Deductions - N48

Other (Income)/Deductions - Net (Footnotes) (Details) - USD ($) $ in Millions		Apr. 08, 2016	Jul. 31, 2016	Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016		Sep. 27, 2015	Oct. 06, 2016	Apr. 03, 2016
Loss Contingencies [Line Items]
Gain on sale of investments								$ 160
Impairment of intangible assets				$ 126	$ 163	$ 767		163
Payments of merger termination costs		$ 150				150
Income from contract resolution						116
Hisun Pfizer Pharmaceuticals Co. Ltd [Member]
Loss Contingencies [Line Items]
Equity method investment, impairment					470	$ 211		470
Equity method investment, ownership percentage				49.00%		49.00%				49.00%
Laboratorio Teuto Brasilero [Member]
Loss Contingencies [Line Items]
Equity method investment, impairment						$ 50
Equity method investment, ownership percentage				40.00%		40.00%
Pending Litigation [Member] | Celebrex and Bextra [Member] | Product Safety Misrepresentation [Member]
Loss Contingencies [Line Items]
Litigation settlement			$ 486			$ 486
In Process Research and Development [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets					28			28
Impairment, indefinite-lived intangible assets	[1]					436
In Process Research and Development [Member] | Hospira [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets						265
In Process Research and Development [Member] | InnoPharma [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets				$ 97
Other In Process Research and Development [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets						74
Other In Process Research and Development [Member] | Hospira [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets						45
Other In Process Research and Development [Member] | King [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets						29
Trade Names [Member]
Loss Contingencies [Line Items]
Impairment, indefinite-lived intangible assets					20			20
Operating Segments [Member] | EH [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets				97	143	738		143
Operating Segments [Member] | IH [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets				$ 29	20			20
Held-for-sale [Member] | ICU Medical [Member] | HIS [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Consideration transferred									$ 1,000
Developed Technology Rights [Member]
Loss Contingencies [Line Items]
Impairment, finite-lived intangible assets					$ 115	331	[1]	115
Developed Technology Rights [Member] | Hospira [Member]
Loss Contingencies [Line Items]
Impairment of intangible assets						331
Distribution Rights [Member]
Loss Contingencies [Line Items]
Gain on disposition of intangible assets						$ 49		$ 76
[1]	Reflects intangible assets written down to fair value in the first nine months of 2016. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product and the impact of technological risk associated with IPR&D assets; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Other (Income)_Deductions - N49

Other (Income)/Deductions - Net - Additional Information about Intangible Assets (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016		Sep. 27, 2015
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Intangible Assets, Total	[1]	$ 116		$ 116
Impairment, Total		126	$ 163	767		$ 163
In Process Research and Development [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Intangible assets, indefinite-lived	[1],[2]	50		50
Impairment, indefinite-lived intangible assets	[2]			436
Impairment, Total			28			28
Level 1 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Intangible Assets, Total	[1]	0		0
Level 1 [Member] | In Process Research and Development [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Intangible assets, indefinite-lived	[1],[2]	0		0
Level 2 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Intangible Assets, Total	[1]	0		0
Level 2 [Member] | In Process Research and Development [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Intangible assets, indefinite-lived	[1],[2]	0		0
Level 3 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Intangible Assets, Total	[1]	116		116
Level 3 [Member] | In Process Research and Development [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Intangible assets, indefinite-lived	[1],[2]	50		50
Developed Technology Rights [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Intangible assets, finite-lived	[1],[2]	66		66
Impairment, finite-lived intangible assets			$ 115	331	[2]	$ 115
Developed Technology Rights [Member] | Level 1 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Intangible assets, finite-lived	[1],[2]	0		0
Developed Technology Rights [Member] | Level 2 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Intangible assets, finite-lived	[1],[2]	0		0
Developed Technology Rights [Member] | Level 3 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Intangible assets, finite-lived	[1],[2]	$ 66		$ 66
[1]	The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1C.
[2]	Reflects intangible assets written down to fair value in the first nine months of 2016. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product and the impact of technological risk associated with IPR&D assets; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Tax Matters - Narrative (Detail

Tax Matters - Narrative (Detail)	3 Months Ended		9 Months Ended
	Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
Income Tax Disclosure [Abstract]
Effective tax rate for income from continuing operations	17.70%	21.00%	15.80%	23.40%

Tax Matters (Detail)

Tax Matters (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
Income Tax Disclosure [Abstract]
Foreign currency translation adjustments, net	[1]	$ 0	$ (7)	$ (15)	$ 90
Unrealized holding losses on derivative financial instruments, net		0	(57)	(192)	(160)
Reclassification adjustments for realized (gains)/losses		32	15	81	43
Derivatives qualifying as hedges, tax, total		32	(42)	(112)	(117)
Unrealized holding gains/(losses) on available-for-sale securities, net		40	6	106	(63)
Reclassification adjustments for realized (gains)/losses		(14)	1	(16)	63
Available-for-sale securities, tax, total		26	7	90	0
Benefit plans: actuarial losses, net		(31)	(51)	(39)	(43)
Reclassification adjustments related to amortization		47	43	140	133
Reclassification adjustments related to settlements, net		10	12	27	35
Other		14	(9)	5	29
Defined benefit plans, actuarial gain (loss), tax, total		40	(4)	133	154
Benefit plans: prior service credits and other, net		35	(4)	66	188
Reclassification adjustments related to amortization		(17)	(36)	(47)	(42)
Reclassification adjustments related to curtailments, net		(3)	18	(5)	(8)
Other		2	2	1	2
Pension and other postretirement benefit plans, net prior service cost (credit), tax		18	(19)	15	139
Tax provision/(benefit) on other comprehensive income/(loss)	[2],[3]	$ 116	$ (65)	$ 111	$ 267
[1]	Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.
[2]	Amounts may not add due to rounding.
[3]	See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income/(Loss).

Accumulated Other Comprehensi52

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail) $ in Millions	9 Months Ended
	Oct. 02, 2016USD ($)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2015	$ 64,720	[1]
Balance, October 2, 2016	63,306	[1]
Foreign currency translation adjustments attributable to noncontrolling interests	(1)
Accumulated Other Comprehensive Income (Loss) [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2015	(9,522)
Other comprehensive income/(loss)	1,308	[2]
Balance, October 2, 2016	(8,214)
Foreign Currency Translation Adjustment [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2015	(5,863)
Other comprehensive income/(loss)	1,016	[2]
Balance, October 2, 2016	(4,847)
Derivative Financial Instruments [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2015	421
Other comprehensive income/(loss)	(578)	[2]
Balance, October 2, 2016	(157)
Available-For-Sale Securities [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2015	(227)
Other comprehensive income/(loss)	522	[2]
Balance, October 2, 2016	295
Cash flow hedge gain (loss) to be reclassified within twelve months	(129)
Actuarial Gains/(Losses) [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2015	(4,733)
Other comprehensive income/(loss)	310	[2]
Balance, October 2, 2016	(4,423)
Prior Service (Costs)/Credits and Other [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2015	880
Other comprehensive income/(loss)	39	[2]
Balance, October 2, 2016	$ 919
[1]	Amounts may not add due to rounding.
[2]	Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $1 million loss for the first nine months of 2016.

Financial Instruments - Assets

Financial Instruments - Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($) $ in Millions		Oct. 02, 2016	Dec. 31, 2015
Other selected financial assets
Total selected financial assets		$ 24,613	$ 38,157
Short-term borrowings:
Total short-term borrowings, carried at historical proceeds, as adjusted	[1]	13,633	10,159
Long-term debt:
Total long-term debt, carried at historical proceeds, as adjusted	[1]	30,437	28,740
Total		44,071	38,899
Total selected financial liabilities		45,926	40,608
Reported Value Measurement [Member]
Other selected financial assets
Held-to-maturity debt securities, carried at amortized cost	[2],[3]	1,270	1,388
Private equity securities, carried at equity-method or at cost	[3],[4]	1,003	1,336
Total		2,272	2,724
Long-term debt [Member]
Short-term borrowings:
Net fair value adjustments related to hedging and purchase accounting		2,447	1,294
Net unamortized discounts, premiums and debt issuance costs	[5]	(83)	(127)
Long-term debt:
Principal amount		28,073	27,573
Total long-term debt, carried at historical proceeds, as adjusted	[6]	30,437	28,740
Short-term Debt [Member]
Short-term borrowings:
Principal amount		13,602	10,160
Net fair value adjustments related to hedging and purchase accounting		47	2
Net unamortized discounts, premiums and debt issuance costs	[5]	(16)	(3)
Total short-term borrowings, carried at historical proceeds, as adjusted	[3]	13,633	10,159
Fair Value, Measurements, Recurring [Member]
Assets, Fair Value Disclosure [Abstract]
Trading funds and securities	[7],[8]	304	287
Selected financial assets measured at fair value on a recurring basis	[8],[9]	22,340	35,433
Selected financial liabilities measured at fair value on a recurring basis
Derivative financial instruments in a liability position	[8],[10]	1,855	1,709
Fair Value, Measurements, Recurring [Member] | Interest Rate Swaps [Member]
Assets, Fair Value Disclosure [Abstract]
Derivative financial instruments in a receivable position	[8],[9]	1,923	837
Selected financial liabilities measured at fair value on a recurring basis
Derivative financial instruments in a liability position	[8],[10]	3	139
Fair Value, Measurements, Recurring [Member] | Foreign Currency Swap [Member]
Assets, Fair Value Disclosure [Abstract]
Derivative financial instruments in a receivable position	[8],[9]	90	135
Selected financial liabilities measured at fair value on a recurring basis
Derivative financial instruments in a liability position	[8],[10]	1,349	1,489
Fair Value, Measurements, Recurring [Member] | Foreign Currency Forward-Exchange Contracts [Member]
Assets, Fair Value Disclosure [Abstract]
Derivative financial instruments in a receivable position	[8],[9]	186	559
Selected financial liabilities measured at fair value on a recurring basis
Derivative financial instruments in a liability position	[8],[10]	503	81
Fair Value, Measurements, Recurring [Member] | Debt Securities [Member]
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	[2],[8]	17,522	32,078
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	[8]	1,724	934
Fair Value, Measurements, Recurring [Member] | Equity Securities [Member]
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	[2],[8]	$ 590	$ 603
[1]	Amounts may not add due to rounding.
[2]	Gross unrealized gains and losses are not significant.
[3]	The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities at cost and short-term borrowings not measured at fair value on a recurring basis were not significant as of October 2, 2016 or December 31, 2015. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our private equity securities carried at cost are based on Level 3 inputs. Short-term borrowings include foreign currency short-term borrowings with fair values of $547 million as of December 31, 2015, which are used as hedging instruments.
[4]	Our private equity securities represent investments in the life sciences sector.
[5]	We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. See Note 1B for additional information.
[6]	The fair value of our long-term debt (not including the current portion of long-term debt) was $34.3 billion as of October 2, 2016 and $32.7 billion as of December 31, 2015. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Generally, the difference between the fair value of our long-term debt and the amount reported on the condensed consolidated balance sheet is due to a decline in relative market interest rates since the debt issuance.
[7]	As of October 2, 2016, trading funds and securities are composed of $196 million of trading equity funds, $12 million of trading securities and $96 million of trading debt funds. As of December 31, 2015, trading funds and securities are composed of $185 million of trading equity funds and $102 million of trading debt funds. As of October 2, 2016 and December 31, 2015, trading equity funds of $69 million and $85 million, respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.
[8]	We use a market approach in valuing financial instruments on a recurring basis. For additional information, see Note 1C. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except less than 2% that use Level 1 inputs and money market funds measured at net asset value.
[9]	Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $91 million as of October 2, 2016; and foreign currency forward-exchange contracts with fair values of $136 million as of December 31, 2015.
[10]	Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency swaps with fair values of $211 million and foreign currency forward-exchange contracts with fair values of $145 million as of October 2, 2016; and foreign currency swaps with fair values of $234 million and foreign currency forward-exchange contracts with fair values of $59 million as of December 31, 2015.

Financial Instruments - Asset54

Financial Instruments - Assets and Liabilities Measured on Recurring Basis (Footnotes) (Detail) - USD ($) $ in Millions	Oct. 02, 2016	Dec. 31, 2015
Fair Value, Measurements, Recurring [Member]
Footnotes to selected financial assets and liabilities:
Percentage of financial assets and liabilities measured at fair value inputs Level 1 and Level 3 inputs (less than)	2.00%
Trading equity funds	$ 196	$ 185
Trading securities	12
Trading debt funds	96	102
Trading securities held in trust	69	85
Not Designated as Hedging Instrument [Member] | Foreign Currency Swap [Member] | Fair Value, Measurements, Recurring [Member]
Footnotes to selected financial assets and liabilities:
Instruments used as offsets (liabilities)	211	234
Not Designated as Hedging Instrument [Member] | Foreign Currency Forward-Exchange Contracts [Member] | Fair Value, Measurements, Recurring [Member]
Footnotes to selected financial assets and liabilities:
Instruments used as offsets (assets)	91	136
Instruments used as offsets (liabilities)	145	59
Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Footnotes to selected financial assets and liabilities:
Fair value of long-term debt	$ 34,300	32,700
Foreign Currency Short Term Borrowings [Member] | Designated as Hedging Instrument [Member] | Estimate of Fair Value Measurement [Member]
Footnotes to selected financial assets and liabilities:
Fair value of short-term debt		$ 547

Financial Instruments - Balance

Financial Instruments - Balance Sheet Grouping (Detail) - USD ($) $ in Millions		Oct. 02, 2016	Dec. 31, 2015
Assets
Selected financial assets		$ 24,613	$ 38,157
Liabilities
Selected financial liabilities		45,926	40,608
Cash and Cash Equivalents [Member]
Assets
Selected financial assets		628	978
Short-term Investments [Member]
Assets
Selected financial assets		12,277	19,649
Other Current Assets [Member]
Assets
Selected financial assets	[1]	293	587
Long-term Investments [Member]
Assets
Selected financial assets		9,507	15,999
Other Noncurrent Assets [Member]
Assets
Selected financial assets	[2]	1,907	944
Short-Term Borrowings, Including Current Portion of Long-Term Debt [Member]
Liabilities
Selected financial liabilities	[3]	13,633	10,159
Other Current Liabilities [Member]
Liabilities
Selected financial liabilities	[4]	805	645
Long-term debt [Member]
Liabilities
Selected financial liabilities	[3]	30,437	28,740
Other Noncurrent Liabilities [Member]
Liabilities
Selected financial liabilities	[5]	$ 1,050	$ 1,064
[1]	As of October 2, 2016, derivative instruments at fair value include interest rate swaps ($49 million), foreign currency swaps ($67 million) and foreign currency forward-exchange contracts ($177 million) and, as of December 31, 2015, include interest rate swaps ($2 million), foreign currency swaps ($46 million) and foreign currency forward-exchange contracts ($538 million).
[2]	As of October 2, 2016, derivative instruments at fair value include interest rate swaps ($1.9 billion), foreign currency swaps ($23 million) and foreign currency forward-exchange contracts ($9 million) and, as of December 31, 2015, include interest rate swaps ($835 million), foreign currency swaps ($89 million) and foreign currency forward-exchange contracts ($20 million).
[3]	We adopted a new standard as of January 1, 2016 that changed the presentation of debt issuance costs related to a recognized debt liability as a direct deduction from the carrying value of that associated debt, consistent with the presentation of a debt discount. See Note 1B for additional information.
[4]	As of October 2, 2016, derivative instruments at fair value include interest rate swaps ($1 million), foreign currency swaps ($320 million) and foreign currency forward-exchange contracts ($483 million) and, as of December 31, 2015, include interest rate swaps ($5 million), foreign currency swaps ($560 million) and foreign currency forward-exchange contracts ($80 million).
[5]	As of October 2, 2016, derivative instruments at fair value include interest rate swaps ($2 million), foreign currency swaps ($1.0 billion) and foreign currency forward-exchange contracts ($20 million) and, as of December 31, 2015, include interest rate swaps ($134 million), foreign currency swaps ($928 million) and foreign currency forward-exchange contracts ($1 million).

Financial Instruments - Balan56

Financial Instruments - Balance Sheet Grouping - Footnotes (Detail) - USD ($) $ in Millions		Oct. 02, 2016	Dec. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		$ 24,613	$ 38,157
Selected financial liabilities		45,926	40,608
Other Current Assets [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	[1]	293	587
Other Current Assets [Member] | Interest Rate Swaps [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		49	2
Other Current Assets [Member] | Foreign Currency Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		67	46
Other Current Assets [Member] | Foreign Currency Forward-Exchange Contracts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		177	538
Other Noncurrent Assets [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	[2]	1,907	944
Other Noncurrent Assets [Member] | Interest Rate Swaps [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		1,900	835
Other Noncurrent Assets [Member] | Foreign Currency Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		23	89
Other Noncurrent Assets [Member] | Foreign Currency Forward-Exchange Contracts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		9	20
Other Current Liabilities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	[3]	805	645
Other Current Liabilities [Member] | Interest Rate Swaps [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities		1	5
Other Current Liabilities [Member] | Foreign Currency Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities		320	560
Other Current Liabilities [Member] | Foreign Currency Forward-Exchange Contracts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities		483	80
Other Noncurrent Liabilities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	[4]	1,050	1,064
Other Noncurrent Liabilities [Member] | Interest Rate Swaps [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities		2	134
Other Noncurrent Liabilities [Member] | Foreign Currency Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities		1,000	928
Other Noncurrent Liabilities [Member] | Foreign Currency Forward-Exchange Contracts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities		$ 20	$ 1
[1]	As of October 2, 2016, derivative instruments at fair value include interest rate swaps ($49 million), foreign currency swaps ($67 million) and foreign currency forward-exchange contracts ($177 million) and, as of December 31, 2015, include interest rate swaps ($2 million), foreign currency swaps ($46 million) and foreign currency forward-exchange contracts ($538 million).
[2]	As of October 2, 2016, derivative instruments at fair value include interest rate swaps ($1.9 billion), foreign currency swaps ($23 million) and foreign currency forward-exchange contracts ($9 million) and, as of December 31, 2015, include interest rate swaps ($835 million), foreign currency swaps ($89 million) and foreign currency forward-exchange contracts ($20 million).
[3]	As of October 2, 2016, derivative instruments at fair value include interest rate swaps ($1 million), foreign currency swaps ($320 million) and foreign currency forward-exchange contracts ($483 million) and, as of December 31, 2015, include interest rate swaps ($5 million), foreign currency swaps ($560 million) and foreign currency forward-exchange contracts ($80 million).
[4]	As of October 2, 2016, derivative instruments at fair value include interest rate swaps ($2 million), foreign currency swaps ($1.0 billion) and foreign currency forward-exchange contracts ($20 million) and, as of December 31, 2015, include interest rate swaps ($134 million), foreign currency swaps ($928 million) and foreign currency forward-exchange contracts ($1 million).

Financial Instruments - Investm

Financial Instruments - Investments in Debt Securities (Detail) $ in Millions	Oct. 02, 2016USD ($)
Total Debt Securities [Line Items]
Debt securities maturities within one year	$ 11,195
Debt securities maturities over 1 to 5 years	5,451
Debt securities maturities over 5 to 10 years	2,118
Debt securities maturities over 10 years	29
Total debt securities	18,792
Corporate debt [Member]
Total Debt Securities [Line Items]
Available-for-sale debt securities maturities within 1 year	2,399	[1]
Available-for-sale debt securities maturities over 1 to 5 years	3,824	[1]
Available-for-sale debt securities maturities over 5 to 10 years	2,088	[1]
Available-for-sale debt securities maturities over 10 years	25	[1]
Available-for-sale debt securities maturities total	8,336	[1]
Western European, Asian, Scandinavian and other government debt [Member]
Total Debt Securities [Line Items]
Available-for-sale debt securities maturities within 1 year	4,247	[2]
Available-for-sale debt securities maturities over 1 to 5 years	661	[2]
Available-for-sale debt securities maturities over 5 to 10 years	8	[2]
Available-for-sale debt securities maturities over 10 years	0	[2]
Available-for-sale debt securities maturities total	4,916	[2]
Federal Home Loan Mortgage Corporation and Federal National Mortgage Association asset-backed securities [Member]
Total Debt Securities [Line Items]
Available-for-sale debt securities maturities within 1 year	3
Available-for-sale debt securities maturities over 1 to 5 years	56
Available-for-sale debt securities maturities over 5 to 10 years	1
Available-for-sale debt securities maturities over 10 years	0
Available-for-sale debt securities maturities total	61
U.S. government debt [Member]
Total Debt Securities [Line Items]
Available-for-sale debt securities maturities within 1 year	702
Available-for-sale debt securities maturities over 1 to 5 years	93
Available-for-sale debt securities maturities over 5 to 10 years	0
Available-for-sale debt securities maturities over 10 years	0
Available-for-sale debt securities maturities total	795
Western European, Scandinavian and other government agency debt [Member]
Total Debt Securities [Line Items]
Available-for-sale debt securities maturities within 1 year	1,245	[2]
Available-for-sale debt securities maturities over 1 to 5 years	137	[2]
Available-for-sale debt securities maturities over 5 to 10 years	0	[2]
Available-for-sale debt securities maturities over 10 years	0	[2]
Available-for-sale debt securities maturities total	1,383	[2]
Supranational debt [Member]
Total Debt Securities [Line Items]
Available-for-sale debt securities maturities within 1 year	306	[2]
Available-for-sale debt securities maturities over 1 to 5 years	346	[2]
Available-for-sale debt securities maturities over 5 to 10 years	0	[2]
Available-for-sale debt securities maturities over 10 years	0	[2]
Available-for-sale debt securities maturities total	652	[2]
Other asset-backed debt [Member]
Total Debt Securities [Line Items]
Available-for-sale debt securities maturities within 1 year	449	[3]
Available-for-sale debt securities maturities over 1 to 5 years	331	[3]
Available-for-sale debt securities maturities over 5 to 10 years	20	[3]
Available-for-sale debt securities maturities over 10 years	3	[3]
Available-for-sale debt securities maturities total	803	[3]
Government National Mortgage Association and other U.S. government guaranteed asset-back securities [Member]
Total Debt Securities [Line Items]
Available-for-sale debt securities maturities within 1 year	575
Available-for-sale debt securities maturities over 1 to 5 years	1
Available-for-sale debt securities maturities over 5 to 10 years	0
Available-for-sale debt securities maturities over 10 years	0
Available-for-sale debt securities maturities total	576
Time deposits and other [Member]
Total Debt Securities [Line Items]
Held-to-maturity debt securities maturities within 1 year	1,046
Held-to-maturity debt securities with maturities over 1 to 5 years	1
Held-to-maturity debt securities maturities over 5 to 10 years	0
Held-to-maturity debt securities maturities over 10 years	0
Held-to-maturity debt securities maturities total	1,048
Western European government debt [Member]
Total Debt Securities [Line Items]
Held-to-maturity debt securities maturities within 1 year	222	[2]
Held-to-maturity debt securities with maturities over 1 to 5 years	0	[2]
Held-to-maturity debt securities maturities over 5 to 10 years	0	[2]
Held-to-maturity debt securities maturities over 10 years	0	[2]
Held-to-maturity debt securities maturities total	$ 222	[2]
[1]	Issued by a diverse group of corporations, largely consisting of financial institutions, virtually all of which are investment-grade.
[2]	Issued by governments, government agencies or supranational entities, as applicable, all of which are investment-grade.
[3]	Includes loan-backed, receivable-backed, and mortgage-backed securities, all of which are investment-grade and in senior positions in the capital structure of the security. Loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans, and receivable-backed securities are collateralized by credit cards receivables. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages. These securities are valued by third party models that use significant inputs derived from observable market data like prepayment rates, default rates, and recovery rates.

Financial Instruments - Short-T

Financial Instruments - Short-Term Borrowings (Details) - USD ($) $ in Millions	Oct. 02, 2016	Jun. 24, 2016	Dec. 31, 2015
Commercial Paper [Member]
Short-term Debt [Line Items]
Commercial paper	$ 8,000		$ 4,900
Anacor [Member]
Short-term Debt [Line Items]
Debt assumed		$ 698

Financial Instruments - Long-Te

Financial Instruments - Long-Term Debt (Details) - USD ($)	Jun. 03, 2016	Oct. 02, 2016
Debt Instrument [Line Items]
Long-term debt		$ 30,437,000,000
Senior Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount of public offering	$ 5,000,000,000
Weighted average effective interest rate	2.09%
Percentage of original principal amount of notes at which notes can be redeemed	100.00%
Long-term debt		$ 5,000,000,000
Senior Notes [Member] | 1.20% Notes (2018 Notes) [Member]
Debt Instrument [Line Items]
Stated interest rate		1.20%
Long-term debt		$ 1,250,000,000
Senior Notes [Member] | 1.45% Notes (2019 Notes) [Member]
Debt Instrument [Line Items]
Stated interest rate		1.45%
Long-term debt		$ 850,000,000
Senior Notes [Member] | 1.95% Notes (2021 Notes) [Member]
Debt Instrument [Line Items]
Stated interest rate		1.95%
Long-term debt		$ 1,150,000,000
Senior Notes [Member] | 2.75% Notes (2026 Notes) [Member]
Debt Instrument [Line Items]
Stated interest rate		2.75%
Long-term debt		$ 1,250,000,000
Senior Notes [Member] | 4.40% Notes (2044 Notes) [Member]
Debt Instrument [Line Items]
Stated interest rate		4.40%
Long-term debt		$ 500,000,000
US Treasury Rate [Member] | Minimum [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument redemption price, incremental spread	0.50%
US Treasury Rate [Member] | Maximum [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument redemption price, incremental spread	0.15%

Financial Instruments - Long-60

Financial Instruments - Long-Term Debt - Maturities (Details) $ in Millions	Oct. 02, 2016USD ($)
Financial Instruments [Abstract]
2,017	$ 0
2,018	3,618
2,019	5,678
2,020	383
After 2,020	20,758
Total	$ 30,437

Financial Instruments - Derivat

Financial Instruments - Derivative Financial Instruments and Hedging Activities (Detail) $ in Millions, £ in Billions		3 Months Ended		9 Months Ended
		Oct. 02, 2016USD ($)	Sep. 27, 2015USD ($)	Oct. 02, 2016USD ($)	Sep. 27, 2015USD ($)	Oct. 02, 2016GBP (£)	Dec. 31, 2015USD ($)
Derivative Instruments, Gain (Loss) [Line Items]
Long-term debt	[1]	$ 30,437		$ 30,437			$ 28,740
Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[2],[3]	(126)	$ (235)	(1,014)	$ 180
Other Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3],[4],[5]	18	49	(56)	(64)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Other Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[2],[3]	(150)	35	(283)	545
Other Derivative Instruments [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[2],[3]	0	(32)	1	(18)
Other Derivative Instruments [Member] | Other Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3],[4],[5]	0	0	0	0
Other Derivative Instruments [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[2],[3]	0	0	0	0
Interest Rate Contract [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative asset, notional amount		19,500		19,500
Foreign Currency Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative asset, notional amount		36,400		36,400
Foreign Currency Swap [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[2],[3]	87	(96)	(204)	(594)
Foreign Currency Swap [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Other Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3],[4],[5]	0	0	0	0
Foreign Currency Swap [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[2],[3]	(39)	(86)	(165)	(451)
Foreign Currency Swap [Member] | Not Designated as Hedging Instrument [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[2],[3]	0	0	0	0
Foreign Currency Swap [Member] | Not Designated as Hedging Instrument [Member] | Other Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3],[4],[5]	(4)	0	(9)	(2)
Foreign Currency Swap [Member] | Not Designated as Hedging Instrument [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[2],[3]	0	0	0	0
Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[2],[3]	(212)	(89)	(770)	532
Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Other Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3],[4],[5]	2	0	1	0
Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[2],[3]	(111)	120	(118)	996
Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[2],[3]	0	(5)	(15)	254
Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Other Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3],[4],[5]	0	0	1	2
Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[2],[3]	0	0	0	0
Foreign Currency Forward-Exchange Contracts [Member] | Not Designated as Hedging Instrument [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[2],[3]	0	0	0	0
Foreign Currency Forward-Exchange Contracts [Member] | Not Designated as Hedging Instrument [Member] | Other Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3],[4],[5]	20	50	(49)	(64)
Foreign Currency Forward-Exchange Contracts [Member] | Not Designated as Hedging Instrument [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[2],[3]	0	0	0	0
Foreign Currency Short Term Borrowings [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[2],[3]	0	(12)	(26)	6
Foreign Currency Short Term Borrowings [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Other Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[3],[4],[5]	0	0	0	0
Foreign Currency Short Term Borrowings [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other Income (Expense) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID (Effective Portion)	[2],[3]	$ 0	$ 0	$ 0	$ 0
Unsecured Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Long-term debt | £						£ 1.9
[1]	Amounts may not add due to rounding.
[2]	For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income/(loss)––Unrealized holding losses on derivative financial instruments, net. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income/(loss)––Foreign currency translation adjustments, net.
[3]	OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income.
[4]	Also, includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges, as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships.
[5]	There was no significant ineffectiveness for any period presented.

Financial Instruments - Narrati

Financial Instruments - Narrative (Detail) $ in Millions	9 Months Ended
	Oct. 02, 2016USD ($)
Short-term Debt [Line Items]
Net liability position	$ 542
Posted collateral, amount	551
Derivative [Member]
Short-term Debt [Line Items]
Maximum exposure, amount	2,100
Cash and Cash Equivalents [Member]
Short-term Debt [Line Items]
Collateral received	$ 1,300

Inventories (Detail)

Inventories (Detail) - USD ($) $ in Millions		Oct. 02, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Finished goods		$ 2,680	$ 2,714
Work-in-process		3,965	3,932
Raw materials and supplies		862	867
Inventories	[1],[2]	7,507	7,513
Noncurrent inventories not included above	[3]	583	594
Held-for-sale [Member] | HIS [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Reclassification of inventories to assets held for sale		$ 369	$ 0
[1]	Amounts may not add due to rounding.
[2]	The change from December 31, 2015 reflects, among other things, the reclassification of $369 million to Assets held for sale during the third quarter of 2016 (see Note 2B).
[3]	Included in Other noncurrent assets. There are no recoverability issues associated with these amounts.

Identifiable Intangible Asset64

Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Detail) - USD ($) $ in Millions		Oct. 02, 2016	Dec. 31, 2015
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets		$ 17,487	$ 8,192
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		87,854	81,205
Finite-lived intangible assets, accumulated amortization	[1]	(51,103)	(49,040)
Finite-lived Intangible Assets, less Accumulated Amortization		36,750	32,165
Intangible assets, gross carrying amount	[1]	105,341	89,396
Identifiable Intangible Assets, less Accumulated Amortization	[1],[2]	54,238	40,356
Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets		6,918	7,021
In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets		10,569	1,171
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		83,935	77,613
Finite-lived intangible assets, accumulated amortization		(49,105)	(47,193)
Finite-lived Intangible Assets, less Accumulated Amortization		34,830	30,419
Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		2,117	1,973
Finite-lived intangible assets, accumulated amortization		(1,013)	(928)
Finite-lived Intangible Assets, less Accumulated Amortization		1,104	1,044
License Agreements and Other [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		1,801	1,619
Finite-lived intangible assets, accumulated amortization		(985)	(918)
Finite-lived Intangible Assets, less Accumulated Amortization		816	701
Held-for-sale [Member] | HIS [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible assets reclassified to assets held for sale		$ 1,322	$ 0
[1]	The increase in Identifiable intangible assets, less accumulated amortization, is primarily related to assets acquired as part of the acquisitions of Medivation, Anacor and Bamboo (see Note 2A), the impact of foreign exchange and the impact of measurement period adjustments related to our acquisition of Hospira (see Note 2A), partially offset by amortization, impairments and the reclassification of $1.3 billion to Assets held for sale during the third quarter of 2016 (see Note 2B). For information about impairments, see Note 4.
[2]	Amounts may not add due to rounding.

Identifiable Intangible Asset65

Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)	Oct. 02, 2016
Operating Segments [Member] | Developed Technology Rights [Member] | IH [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	64.00%
Operating Segments [Member] | Developed Technology Rights [Member] | EH [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	35.00%
Operating Segments [Member] | Brands [Member] | IH [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	74.00%
Operating Segments [Member] | Brands [Member] | EH [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	26.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%

Identifiable Intangible Asset66

Identifiable Intangible Assets and Goodwill - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)	Oct. 02, 2016
IH [Member] | Operating Segments [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	71.00%
IH [Member] | Operating Segments [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	92.00%
EH [Member] | Operating Segments [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	29.00%
EH [Member] | Operating Segments [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	5.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	3.00%

Identifiable Intangible Asset67

Identifiable Intangible Assets and Goodwill - Narrative (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense for finite-lived intangible assets	$ 988	$ 950	$ 3,000	$ 2,800

Identifiable Intangible Asset68

Identifiable Intangible Assets and Goodwill - Goodwill (Detail) - USD ($) $ in Millions		9 Months Ended
		Oct. 02, 2016	Dec. 31, 2015
Goodwill [Roll Forward]
Balance, December 31, 2015	[1]	$ 48,242
Additions	[2]	7,415
Other	[3]	624
Balance, October 2, 2016	[1]	56,281
IH [Member] | Operating Segments [Member]
Goodwill [Roll Forward]
Balance, December 31, 2015		23,809
Additions	[2]	7,403
Other	[3]	494
Balance, October 2, 2016		31,706
EH [Member] | Operating Segments [Member]
Goodwill [Roll Forward]
Balance, December 31, 2015		24,433
Additions	[2]	12
Other	[3]	130
Balance, October 2, 2016		24,575
Held-for-sale [Member] | HIS [Member]
Goodwill [Roll Forward]
Reclassification of goodwill to assets held for sale		$ 243	$ 0
[1]	Amounts may not add due to rounding.
[2]	IH additions primarily relate to our acquisitions of Medivation, Anacor and Bamboo and are subject to change until we complete the valuations of assets acquired and liabilities assumed from Medivation, Anacor and Bamboo (see Note 2A).
[3]	Primarily reflects the impact of foreign exchange and, with respect to EH, the impact of the reclassification of $243 million to Assets held for sale during the third quarter of 2016 (see Note 2B).

Pension and Postretirement Be69

Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail) - USD ($) $ in Millions		1 Months Ended	3 Months Ended		9 Months Ended			12 Months Ended
		Jan. 31, 2016	Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016		Sep. 27, 2015	Dec. 31, 2016	Dec. 31, 2015
U.S. Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	[1],[2]		$ 69	$ 71	$ 193		$ 216
Interest cost	[1],[2]		218	169	486		505
Expected return on plan assets	[2]		(239)	(272)	(721)		(813)
Amortization of:
Actuarial losses	[2]		99	89	297		253
Prior service costs (credits)	[2]		1	(2)	4		(5)
Curtailments	[2]		2	1	5		2
Settlements	[2]		21	32	52		76
Special termination benefits	[2]		0	0	0		0
Defined benefit plan, net periodic benefit cost	[2]		170	88	316		235
Plan settlements									$ 1,100
Voluntary contribution		$ 1,000			1,000	[3]
U.S. Qualified [Member] | Change in Accounting Estimate [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest cost			57
Amortization of:
Pension expense			112
U.S. Supplemental (Non-Qualified) [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	[1],[4]		5	5	14		17
Interest cost	[1],[4]		18	13	40		41
Expected return on plan assets	[4]		0	0	0		0
Amortization of:
Actuarial losses	[4]		9	11	27		34
Prior service costs (credits)	[4]		0	0	(1)		(1)
Curtailments	[4]		1	0	1		0
Settlements	[4]		7	4	23		21
Special termination benefits	[4]		0	0	0		0
Defined benefit plan, net periodic benefit cost	[4]		39	33	105		110
Voluntary contribution	[3]				123
U.S. Supplemental (Non-Qualified) [Member] | Change in Accounting Estimate [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest cost			4
International [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	[1],[5]		41	46	126		140
Interest cost	[1],[5]		58	77	178		232
Expected return on plan assets	[5]		(95)	(105)	(291)		(314)
Amortization of:
Actuarial losses	[5]		23	31	70		94
Prior service costs (credits)	[5]		(1)	(2)	(2)		(5)
Curtailments	[5]		0	0	(1)		0
Settlements	[5]		1	1	2		1
Special termination benefits	[5]		0	1	0		1
Defined benefit plan, net periodic benefit cost	[5]		27	49	81		150
Voluntary contribution	[3]				145
International [Member] | Change in Accounting Estimate [Member] | Forecast [Member]
Amortization of:
Reduction of net periodic benefit cost								$ 42
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	[1],[6]		11	14	31		41
Interest cost	[1],[6]		33	26	77		91
Expected return on plan assets	[6]		(8)	(13)	(25)		(39)
Amortization of:
Actuarial losses	[6]		9	9	23		28
Prior service costs (credits)	[6]		(45)	(43)	(127)		(104)
Curtailments	[6]		(8)	(4)	(14)		(20)
Settlements	[6]		0	0	0		0
Special termination benefits	[6]		0	0	0		0
Defined benefit plan, net periodic benefit cost	[6]		(9)	$ (11)	(36)		$ (5)
Voluntary contribution	[3]				$ (28)
Postretirement Plans [Member] | Change in Accounting Estimate [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest cost			$ 8
[1]	Effective January 1, 2016, the Company changed the approach used to measure service and interest costs for certain international pension and other postretirement benefit plans. For fiscal 2015, the Company measured service and interest costs utilizing a single weighted-average discount rate derived from the yield curve used to measure the respective plan obligations. For fiscal 2016, we elected to measure service and interest costs by applying the spot rates along the yield curve for certain international plans to the plans' liability cash flows. The Company believes the new approach provides a more precise measurement of service and interest costs by aligning the timing of the plans’ liability cash flows to the corresponding spot rates on the yield curve. This change does not affect the measurement of our plan obligations. We have accounted for this change as a change in accounting estimate and, accordingly, have accounted for it on a prospective basis. The expected reduction in expense for 2016 associated with this change in estimate is $42 million, which is recognized evenly over each quarter of the year. Effective January 1, 2016, the Company made a similar change for its U.S. pension and other postretirement benefit plans, but in the third quarter of 2016, we determined that our use of the bond model required the measurement of such costs to be conceptually aligned with the measurement of the pension benefit obligation. As such, 2016 service and interest costs for the U.S. plans were measured utilizing a single weighted-average discount rate derived from the bond model consistent with the approach used in 2015, resulting in an adjustment to increase net periodic pension cost by $112 million in the third quarter of 2016.
[2]	The increase in net periodic benefit costs for the three months ended October 2, 2016, compared to the three months ended September 27, 2015, for our U.S. qualified pension plans was primarily due to (i) higher interest costs resulting from a change in our approach in the third quarter of 2016 for measuring service and interest costs (the adjustment increased interest costs by $57 million related to prior periods in 2016 (see (e) below)), (ii) a lower expected return on plan assets resulting from a lower expected rate of return, as well as a net decrease of approximately $1.1 billion in the asset base, due in part to lump-sum payments made in 2015 to certain terminated vested colleagues to settle Pfizer’s pension obligation, partially offset by a voluntary contribution of $1.0 billion made at the beginning of January 2016, and (iii) an increase in the amounts amortized for actuarial losses, primarily as a result of the addition of Hospira qualified plans. The aforementioned increases were partially offset by lower settlement activity in 2016. The increase in net periodic benefit costs for the nine months ended October 2, 2016, compared to the nine months ended September 27, 2015, for our U.S. qualified pension plans was primarily driven by (i) a lower expected return on plan assets resulting from a lower expected rate of return, as well as a net decrease of approximately $1.1 billion in the asset base, due in part to lump-sum payments made in 2015 to certain terminated vested colleagues to settle Pfizer’s pension obligation, partially offset by a voluntary contribution of $1.0 billion made at the beginning of January 2016, and (ii) an increase in the amounts amortized for actuarial losses, primarily as a result of the addition of Hospira qualified plans. The aforementioned increases were partially offset by (i) lower service costs resulting from a higher discount rate, (ii) lower settlement activity, and (iii) lower interest costs resulting from a lower beginning benefit obligation.
[3]	Contributions to the postretirement plans reflect IRC 401(h) reimbursements totaling $198 million received for eligible 2014 and 2015 prescription drug expenses for certain retirees.
[4]	The increase in net periodic benefit costs for the three months ended October 2, 2016, compared to the three months ended September 27, 2015, for our U.S. non-qualified pension plans was primarily due to (i) higher interest costs resulting from a change in our approach in the third quarter for measuring service and interest costs (the adjustment increased interest costs by $4 million related to prior periods in 2016 (see (e) below)), and (ii) higher settlement activity. The aforementioned increases were partially offset by a decrease in the amounts amortized for actuarial losses resulting from the increase in 2015 in the discount rate used to determine the benefit obligation. The decrease in net periodic benefit costs for the nine months ended October 2, 2016, compared to the nine months ended September 27, 2015, for our U.S. non-qualified pension plans was primarily driven by (i) a decrease in the amounts amortized for actuarial losses resulting from the increase in 2015 in the discount rate used to determine the benefit obligation, and (ii) lower service costs resulting from a higher discount rate. The aforementioned decreases were partially offset by an increase in settlement activity.
[5]	The decrease in net periodic benefit costs for the three and nine months ended October 2, 2016, compared to the three and nine months ended September 27, 2015, for our international pension plans was primarily driven by (i) lower service and interest costs, resulting from a change in our approach for measuring service and interest costs (see (e) below), and (ii) a decrease in the amounts amortized for actuarial losses resulting from large gains in 2015, which decreased the plan net loss position. The aforementioned decreases to our net periodic benefit costs were partially offset by a decrease in the expected return on plan assets due to a lower expected rate of return on plan assets.
[6]	The decrease in net periodic benefit credit for the three months ended October 2, 2016, compared to the three months ended September 27, 2015, for our postretirement plans was primarily driven by (i) higher interest costs resulting from a change in our approach in the third quarter of 2016 for measuring service and interest costs (the adjustment increased interest costs by $8 million related to prior periods in 2016 (see (e) below)), and (ii) a decrease in expected return on plan assets, resulting from a decrease in plan assets, reflecting payments by the plan for IRC 401(h) reimbursements to Pfizer for eligible 2014 and 2015 prescription drug expenses for certain retirees. The aforementioned changes were partially offset by (i) higher curtailment gains and (ii) lower service costs resulting from a higher discount rate. The increase in net periodic benefit credit for the nine months ended October 2, 2016, compared to the nine months ended September 27, 2015, for our postretirement plans was primarily driven by (i) an increase in prior service credits due to the postretirement medical plan cap changes during 2016 and 2015, (ii) lower interest costs resulting from a lower benefit obligation, and (iii) lower service costs resulting from a higher discount rate. The aforementioned changes were partially offset by (i) a decrease in expected return on plan assets, primarily resulting from a decrease in plan assets, reflecting payments by the plan for IRC 401(h) reimbursements to Pfizer for eligible 2014 and 2015 prescription drug expenses for certain retirees, (ii) lower curtailment gains, and (iii) a decrease in the amounts amortized for actuarial losses resulting from the increase in 2015 in the discount rate used to determine the benefit obligation.

Pension and Postretirement Be70

Pension and Postretirement Benefit Plans (Detail) - USD ($) $ in Millions		1 Months Ended	9 Months Ended
		Jan. 31, 2016	Oct. 02, 2016
Defined Benefit Plan Disclosure [Line Items]
Prescription expense reimbursements received			$ 198
U.S. Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the three months ended July 3, 2016		$ 1,000	1,000	[1]
Expected contributions from our general assets during 2016	[2]		1,000
U.S. Supplemental (Non-Qualified) [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the three months ended July 3, 2016	[1]		123
Expected contributions from our general assets during 2016	[2]		146
International [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the three months ended July 3, 2016	[1]		145
Expected contributions from our general assets during 2016	[2]		194
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the three months ended July 3, 2016	[1]		(28)
Expected contributions from our general assets during 2016	[2]		$ 20
[1]	Contributions to the postretirement plans reflect IRC 401(h) reimbursements totaling $198 million received for eligible 2014 and 2015 prescription drug expenses for certain retirees.
[2]	Contributions expected to be made for 2016 are inclusive of amounts contributed during the nine months ended October 2, 2016, including the $1.0 billion voluntary contribution that was made in January 2016 for the U.S. qualified plans, which was considered pre-funding for future anticipated mandatory contributions and is also expected to reduce Pension Benefit Guaranty Corporation variable rate premiums. The U.S. supplemental (non-qualified) pension plan, international pension plan and the postretirement plan contributions from our general assets include direct employer benefit payments.

Earnings Per Common Share Att71

Earnings Per Common Share Attributable to Common Shareholders (Details) - USD ($) shares in Millions, $ in Millions		3 Months Ended		9 Months Ended
		Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
EPS Numerator––Basic
Income from continuing operations	[1]	$ 1,320	$ 2,130	$ 6,380	$ 7,141
Less: Net income attributable to noncontrolling interests		0	9	25	23
Income from continuing operations attributable to Pfizer Inc.		1,320	2,122	6,355	7,118
Less: Preferred stock dividends––net of tax		0	0	1	1
Income from continuing operations attributable to Pfizer Inc. common shareholders		1,320	2,121	6,354	7,117
Discontinued operations––net of tax	[1]	0	8	0	14
Less: Discontinued operations––net of tax, attributable to noncontrolling interests		0	0	0	0
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders		0	8	0	14
Net income attributable to Pfizer Inc. common shareholders		1,319	2,130	6,355	7,131
EPS Numerator––Diluted
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions		1,320	2,121	6,355	7,117
Net income attributable to Pfizer Inc. common shareholders and assumed conversions		$ 1,320	$ 2,130	$ 6,355	$ 7,131
EPS Denominator
Weighted-average number of common shares outstanding––Basic	[1]	6,066	6,168	6,095	6,176
Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase (shares)		72	75	68	83
Weighted-average number of common shares outstanding––Diluted	[1]	6,138	6,243	6,164	6,259
Equity Option [Member]
EPS Denominator
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (shares)	[2]	36	55	56	48
[1]	Amounts may not add due to rounding.
[2]	These common stock equivalents were outstanding for the nine months ended October 2, 2016 and September 27, 2015, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ / shares in Units, shares in Millions	Jun. 20, 2016	Mar. 10, 2016	Mar. 08, 2016	Oct. 02, 2016
Commitments and Contingencies Disclosure [Abstract]
Share repurchase agreement, amount			$ 5,000,000,000
Accelerated share repurchases, cash paid		$ 5,000,000,000
Shares repurchased	18	136
Shares repurchased, price per share (in dollars per share)		$ 29.36
Shares received in initial delivery, percentage of agreement amount			80.00%
Average price for shares delivered under the accelerate share repurchase agreement (in dollars per share)	$ 32.38
Remaining authorized repurchase amount				$ 11,400,000,000

Commitments and Contingencies73

Commitments and Contingencies (Actions In Which We Are The Plaintiff) (Details)	1 Months Ended								2 Months Ended	4 Months Ended
	Aug. 31, 2016Patents	Jul. 31, 2016Patents	Jan. 31, 2016Patents	Dec. 31, 2015Patents	Jul. 31, 2015Defendant	Jun. 30, 2015Patents	Jan. 31, 2015Patents	Jun. 30, 2013Patents	Jul. 31, 2015Defendant	Dec. 31, 2015Patents
Tygacil [Member] | Pfizer Versus Mylan Laboratories Limited [Member] | Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents										2
Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents not infringed upon						4
Precedex Premix [Member] | Hospira Versus Fresenius [Member] | Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents not infringed upon				4
Precedex Premix [Member] | Hospira Versus Par [Member] | Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents not infringed upon	4
Patent Infringement [Member] | Toviaz [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents		5	5				5	5
Number of defendants | Defendant					4
Patent Infringement [Member] | Toviaz [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Settled Litigation [Member]
Gain Contingencies [Line Items]
Number of defendants | Defendant									4
Patent Infringement [Member] | Toviaz Composition-of-matter Patents [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents infringed upon			3				3

Commitments and Contingencies74

Commitments and Contingencies (Actions In Which We Are The Defendant) (Detail) Claim in Thousands, $ in Thousands	1 Months Ended					9 Months Ended
	Aug. 31, 2016USD ($)	Jul. 31, 2016USD ($)	Mar. 31, 2015Patents	Apr. 30, 2014	Mar. 31, 2013lagoon	Oct. 02, 2016USD ($)Claim
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]
Loss Contingencies [Line Items]
Number of patents			6
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of patents			2
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Claims dismissed			4
Xtandi [Member] | Regents Versus Medivation [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Percentage of payments Medivation received sought by Regents				10.00%
Damages from Product Defects [Member] | Class Action Versus American Optical Corporation And Various Other Defendants [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, pending claims, number | Claim						56
Product Safety Misrepresentation [Member] | Celebrex and Bextra [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Litigation settlement | $		$ 486,000				$ 486,000
Average Wholesale Price [Member] | State of Illinois Versus Pfizer [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, pending claims, number | Claim						0
Environmental Remediation Litigation [Member]
Loss Contingencies [Line Items]
Number of lagoons | lagoon					2
Environmental Remediation Litigation [Member] | PPLLC Versus EPA [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Litigation settlement | $	$ 190

Commitments and Contingencies75

Commitments and Contingencies (Matters Resolved During Current Year) (Detail) CAD in Millions, $ in Millions	Feb. 12, 2016USD ($)	Jun. 30, 2014CAD	Oct. 31, 2014Patents	Jun. 30, 2010Patents	May 31, 2010Patents	Dec. 31, 2006Patents	Dec. 31, 2012CAD	Dec. 31, 2009Actions
Sutent [Member] | Patent Infringement [Member] | Pfizer Versus Mylan Pharmaceuticals Inc. [Member]
Loss Contingencies [Line Items]
Number of patents				3	2
Number of patents infringed upon			2
Protonix / Pantoprazole [Member] | U.S. Department of Justice Versus Pfizer [Member] | Product Pricing [Member]
Loss Contingencies [Line Items]
Number of actions | Actions								2
Loss from contract settlement | $	$ 784.6
Pending Litigation [Member] | Effexor [Member] | Teva Canada Limited Versus Pfizer Canada Inc. [Member] | Patent Infringement [Member]
Loss Contingencies [Line Items]
Loss from contract settlement | CAD							CAD 52.5
Number of patents						1
Loss contingency, damages awarded, value | CAD		CAD 125

Segment, Geographic and Other76

Segment, Geographic and Other Revenue Information - Narrative (Detail) $ in Millions		3 Months Ended			9 Months Ended
		Oct. 02, 2016USD ($)	Apr. 03, 2016USD ($)	Sep. 27, 2015USD ($)	Oct. 02, 2016USD ($)Operating_Segment	Sep. 27, 2015USD ($)	Dec. 31, 2015USD ($)
Segment Reporting Information [Line Items]
Number of business segments | Operating_Segment					2
Revenues	[1],[2],[3]	$ 13,045		$ 12,087	$ 39,196	$ 34,804
Net income (loss)	[1]	1,320		2,130	6,355	7,132
Total assets	[4]	178,430			178,430		$ 167,381
Essential Health Business [Member] | EH [Member]
Segment Reporting Information [Line Items]
Revenues	[5]	5,712		5,335	17,725	15,683
Innovative Health Business [Member] | IH [Member]
Segment Reporting Information [Line Items]
Revenues	[6]	7,332		6,752	21,471	19,120
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		13,045		12,087	39,196	34,804
Operating Segments [Member] | EH [Member]
Segment Reporting Information [Line Items]
Revenues	[7]	5,712		5,335	17,725	15,683
Operating Segments [Member] | IH [Member]
Segment Reporting Information [Line Items]
Revenues	[8]	7,332		6,752	21,471	19,120
Operating Segments [Member] | Adjustment [Member] | Essential Health Business [Member] | EH [Member]
Segment Reporting Information [Line Items]
Revenues				116		360
Net income (loss)				15		66
Costs and expenses				68		202
Operating Segments [Member] | Adjustment [Member] | Innovative Health Business [Member] | IH [Member]
Segment Reporting Information [Line Items]
Costs and expenses			$ (76)	(77)		(223)
CentreOne [Member] | Essential Health Business [Member] | EH [Member]
Segment Reporting Information [Line Items]
Revenues	[9]	$ 156		136	$ 540	380
CentreOne [Member] | Segment Reconciling Items [Member] | Adjustment [Member]
Segment Reporting Information [Line Items]
Revenues				(116)		(360)
Net income (loss)				(15)		(52)
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Adjustment [Member]
Segment Reporting Information [Line Items]
Costs and expenses				(68)		(202)
Pfizer's Worldwide Research and Development [Member] | Costs Transferred in Reclassification [Member] | Segment Reconciling Items [Member] | Adjustment [Member]
Segment Reporting Information [Line Items]
Costs and expenses			(78)	(86)		(244)
Pfizer's Global Product Development [Member] | Segment Reconciling Items [Member] | Adjustment [Member]
Segment Reporting Information [Line Items]
Costs and expenses			76	77		223
Pfizer's Global Product Development [Member] | Costs Transferred in Reclassification [Member] | Segment Reconciling Items [Member] | Adjustment [Member]
Segment Reporting Information [Line Items]
Costs and expenses			$ 78	$ 86		$ 244
[1]	Amounts may not add due to rounding.
[2]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
[3]	On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Hospira. As a result, legacy Hospira operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. On June 24, 2016, we acquired Anacor. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Anacor. As a result, legacy Anacor operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic reporting period, our results of operations and IH's operating results for the third quarter and first nine months of 2016 include approximately three months of legacy Anacor operations. Additionally, on September 28, 2016, we acquired Medivation. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Medivation. As a result, legacy Medivation operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and IH's operating results for the third quarter and first nine months of 2016 reflect three business days of legacy Medivation operations, which were immaterial. See Note 2A for additional information.
[4]	Amounts may not add due to rounding.
[5]	The EH business, previously known as the Established Products business, encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Infusion Systems, Biosimilars and Pfizer CentreOne and includes all legacy Hospira commercial operations. Hospira's commercial operations, including the legacy Hospira One-2-One sterile injectables contract manufacturing business, are included in EH’s operating results in our condensed consolidated statements of income, commencing from the acquisition date of September 3, 2015. Therefore, in accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. Also, effective as of the beginning of 2016, our entire contract manufacturing business, Pfizer CentreOne (previously known as Pfizer CentreSource or PCS), is part of EH. Pfizer CentreOne consists of (i) legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including our manufacturing and supply agreements with Zoetis; and (ii) legacy Hospira's One-2-One sterile injectables contract manufacturing operation. Prior to 2016, PCS was managed outside our operating segments and its revenues were reported as other business activities. We have reclassified prior period PCS revenues ($116 million in the third quarter of 2015 and $360 million in the first nine months of 2015) to conform to the current period presentation as part of EH.
[6]	The IH business, previously known as the Innovative Products business, encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare and includes all legacy Medivation and Anacor commercial operations. Medivation’s and Anacor’s commercial operations are included in IH’s operating results in our condensed consolidated statements of income, commencing from the acquisition date of September 28, 2016 for Medivation and from the acquisition date of June 24, 2016 for Anacor. As a result, IH’s revenues for the third quarter and first nine months of 2016 include three business days of legacy Medivation operations and approximately three months of legacy Anacor operations, which were immaterial.
[7]	On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Hospira. As a result, legacy Hospira commercial operations, including the legacy Hospira One-2-One contract manufacturing business, are included in EH’s operating results in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. See Note 2A for additional information. Effective as of the beginning of 2016, our entire contract manufacturing business, Pfizer CentreOne (previously known as Pfizer CentreSource or PCS), is part of EH. Pfizer CentreOne consists of (i) the revenues and expenses of legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including the revenues and expenses related to our manufacturing and supply agreements with Zoetis; and (ii) the revenues and expenses of legacy Hospira's One-2-One sterile injectables contract manufacturing operation, which has been included in EH since we acquired Hospira on September 3, 2015. Prior to 2016, PCS was managed outside our operating segments as part of PGS and reported as "Other Business Activities". We have reclassified prior period PCS operating results ($116 million of PCS revenues and $15 million of PCS earnings in the third quarter of 2015, and $360 million of PCS revenues and $66 million of PCS earnings in the first nine months of 2015) to conform to the current period presentation as part of EH. As noted above, also effective as of the beginning of 2016, in connection with the formation of a new EH R&D organization, certain functions transferred from Pfizer’s WRD organization to the new EH R&D organization. We have reclassified approximately $68 million of costs in the third quarter of 2015 and $202 million of costs in the first nine months of 2015 from WRD to EH to conform to the current period presentation as part of EH.
[8]	Effective as of the beginning of the second quarter of 2016, in connection with the formation of the GPD organization, certain development-related functions transferred from IH to GPD. We have reclassified approximately $76 million of costs in the first quarter of 2016, approximately $77 million of costs in the third quarter of 2015 and approximately $223 million of costs in the first nine months of 2015 from IH to GPD to conform to the current period presentation as part of GPD. Additionally, Anacor's and Medivations’s commercial operations are included in IH's operating results in our condensed consolidated statements of income. As a result, commencing from the acquisition date of June 24, 2016, IH's operating results for the third quarter and first nine months of 2016 include approximately three months of legacy Anacor operations, which were immaterial, and commencing from the acquisition date of September, 28, 2016, IH's operating results for the third quarter and first nine months of 2016 reflect three business days of legacy Medivation operations, which were immaterial.
[9]	Pfizer CentreOne (previously known as Pfizer CentreSource or PCS) includes (i) revenues from legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including revenues related to our manufacturing and supply agreements with Zoetis; and (ii) revenues from legacy Hospira’s One-2-One sterile injectables contract manufacturing operation.

Segment, Geographic and Other77

Segment, Geographic and Other Revenue Information (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
Segment Reporting Information [Line Items]
Revenues	[1],[2],[3]	$ 13,045	$ 12,087	$ 39,196	$ 34,804
Earnings	[1],[4]	1,604	2,697	7,575	9,319
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		13,045	12,087	39,196	34,804
Earnings	[4]	7,315	7,199	22,454	20,371
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Earnings	[4],[5]	(786)	(715)	(2,190)	(2,127)
Segment Reconciling Items [Member] | Purchase Accounting Adjustments [Member]
Segment Reporting Information [Line Items]
Earnings	[4],[6]	(966)	(960)	(3,103)	(2,698)
Segment Reconciling Items [Member] | Acquisition-Related Costs [Member]
Segment Reporting Information [Line Items]
Earnings	[4],[6]	(280)	(541)	(598)	(631)
Segment Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Earnings	[4],[7]	(1,969)	(837)	(4,112)	(1,369)
Segment Reconciling Items [Member] | Other Unallocated [Member]
Segment Reporting Information [Line Items]
Earnings	[4]	(206)	(73)	(753)	(278)
Corporate [Member]
Segment Reporting Information [Line Items]
Earnings	[4],[6]	(1,504)	(1,376)	(4,123)	(3,949)
IH [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	[8]	7,332	6,752	21,471	19,120
Earnings	[4],[8]	4,187	4,018	12,470	10,831
EH [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	[9]	5,712	5,335	17,725	15,683
Earnings	[4],[9]	$ 3,128	$ 3,181	$ 9,985	$ 9,540
[1]	Amounts may not add due to rounding.
[2]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
[3]	On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Hospira. As a result, legacy Hospira operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. On June 24, 2016, we acquired Anacor. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Anacor. As a result, legacy Anacor operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic reporting period, our results of operations and IH's operating results for the third quarter and first nine months of 2016 include approximately three months of legacy Anacor operations. Additionally, on September 28, 2016, we acquired Medivation. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Medivation. As a result, legacy Medivation operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and IH's operating results for the third quarter and first nine months of 2016 reflect three business days of legacy Medivation operations, which were immaterial. See Note 2A for additional information.
[4]	Income from continuing operations before provision for taxes on income.
[5]	Other business activities includes the costs managed by our WRD, GPD and Pfizer Medical organizations.
[6]	For a description, see the “Other Costs and Business Activities” section above.
[7]	Certain significant items are substantive and in some cases recurring (such as restructuring or legal charges), or unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.For Earnings in the third quarter of 2016, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $375 million, (ii) income for certain legal matters of $40 million, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion, (iv) certain asset impairment charges of $126 million, (v) charges for business and legal entity alignment of $69 million and (vi) other charges of $17 million. For additional information, see Note 2B, Note 3 and Note 4.For Earnings in the third quarter of 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $107 million, (ii) certain asset impairment charges of $633 million, (iii) charges for business and legal entity alignment of $60 million and (iv) other charges of $36 million. For additional information, see Note 3 and Note 4.For Earnings in the first nine months of 2016, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $743 million, (ii) charges for certain legal matters of $506 million, (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion, (iv) certain asset impairment charges of $1.1 billion, (v) charges for business and legal entity alignment of $180 million and (vi) other charges of $189 million. For additional information, see Note 2B, Note 3 and Note 4.For Earnings in the first nine months of 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $302 million, (ii) certain asset impairment charges of $633 million, (iii) charges for business and legal entity alignment of $224 million, (iv) charges for certain legal matters of $92 million, and (v) other charges of $117 million. For additional information, see Note 3 and Note 4.
[8]	Effective as of the beginning of the second quarter of 2016, in connection with the formation of the GPD organization, certain development-related functions transferred from IH to GPD. We have reclassified approximately $76 million of costs in the first quarter of 2016, approximately $77 million of costs in the third quarter of 2015 and approximately $223 million of costs in the first nine months of 2015 from IH to GPD to conform to the current period presentation as part of GPD. Additionally, Anacor's and Medivations’s commercial operations are included in IH's operating results in our condensed consolidated statements of income. As a result, commencing from the acquisition date of June 24, 2016, IH's operating results for the third quarter and first nine months of 2016 include approximately three months of legacy Anacor operations, which were immaterial, and commencing from the acquisition date of September, 28, 2016, IH's operating results for the third quarter and first nine months of 2016 reflect three business days of legacy Medivation operations, which were immaterial.
[9]	On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Hospira. As a result, legacy Hospira commercial operations, including the legacy Hospira One-2-One contract manufacturing business, are included in EH’s operating results in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. See Note 2A for additional information. Effective as of the beginning of 2016, our entire contract manufacturing business, Pfizer CentreOne (previously known as Pfizer CentreSource or PCS), is part of EH. Pfizer CentreOne consists of (i) the revenues and expenses of legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including the revenues and expenses related to our manufacturing and supply agreements with Zoetis; and (ii) the revenues and expenses of legacy Hospira's One-2-One sterile injectables contract manufacturing operation, which has been included in EH since we acquired Hospira on September 3, 2015. Prior to 2016, PCS was managed outside our operating segments as part of PGS and reported as "Other Business Activities". We have reclassified prior period PCS operating results ($116 million of PCS revenues and $15 million of PCS earnings in the third quarter of 2015, and $360 million of PCS revenues and $66 million of PCS earnings in the first nine months of 2015) to conform to the current period presentation as part of EH. As noted above, also effective as of the beginning of 2016, in connection with the formation of a new EH R&D organization, certain functions transferred from Pfizer’s WRD organization to the new EH R&D organization. We have reclassified approximately $68 million of costs in the third quarter of 2015 and $202 million of costs in the first nine months of 2015 from WRD to EH to conform to the current period presentation as part of EH.

Segment, Geographic and Other78

Segment, Geographic and Other Revenue Information - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended			9 Months Ended
		Oct. 02, 2016	Apr. 03, 2016	Sep. 27, 2015	Oct. 02, 2016		Sep. 27, 2015
Segment Reporting Information [Line Items]
Revenues	[1],[2],[3]	$ 13,045		$ 12,087	$ 39,196		$ 34,804
Net income (loss)	[1]	1,320		2,130	6,355		7,132
Impairment on remeasurement of HIS net assets	[4]	1,422		0	1,422	[5]	0	[5]
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		13,045		12,087	39,196		34,804
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Cost reduction and productivity initiatives excluding acquisition related costs		375		107	743		302
Other legal matters, net		(40)			506		92
Asset impairment and other charges		126		633	1,100		633
Alignment costs		69		60	180		224
Other nonoperating charges		17		36	189		117
EH [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	[6]	5,712		5,335	17,725		15,683
IH [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues	[7]	7,332		6,752	21,471		19,120
Adjustment [Member] | CentreOne [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Revenues				(116)			(360)
Net income (loss)				(15)			(52)
HIS [Member]
Segment Reporting Information [Line Items]
Impairment on remeasurement of HIS net assets		1,422			1,400
Pfizer's Global Product Development [Member] | Adjustment [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Costs and expenses			$ 76	77			223
Essential Health Business [Member] | EH [Member]
Segment Reporting Information [Line Items]
Revenues	[8]	5,712		5,335	17,725		15,683
Essential Health Business [Member] | CentreOne [Member] | EH [Member]
Segment Reporting Information [Line Items]
Revenues	[9]	$ 156		136	$ 540		380
Essential Health Business [Member] | Adjustment [Member] | EH [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Costs and expenses				68			202
Revenues				116			360
Net income (loss)				$ 15			$ 66
[1]	Amounts may not add due to rounding.
[2]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
[3]	On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Hospira. As a result, legacy Hospira operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. On June 24, 2016, we acquired Anacor. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Anacor. As a result, legacy Anacor operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic reporting period, our results of operations and IH's operating results for the third quarter and first nine months of 2016 include approximately three months of legacy Anacor operations. Additionally, on September 28, 2016, we acquired Medivation. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Medivation. As a result, legacy Medivation operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and IH's operating results for the third quarter and first nine months of 2016 reflect three business days of legacy Medivation operations, which were immaterial. See Note 2A for additional information.
[4]	In the third quarter and first nine months of 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. In October 2016, ICU Medical and Pfizer announced that they entered into a definitive agreement under which ICU Medical will acquire all of Pfizer’s global infusion therapy net assets, HIS, for approximately $1 billion in cash and ICU Medical stock. HIS includes IV pumps, solutions and devices. See Note 2B for additional information.
[5]	Amounts may not add due to rounding.
[6]	On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Hospira. As a result, legacy Hospira commercial operations, including the legacy Hospira One-2-One contract manufacturing business, are included in EH’s operating results in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. See Note 2A for additional information. Effective as of the beginning of 2016, our entire contract manufacturing business, Pfizer CentreOne (previously known as Pfizer CentreSource or PCS), is part of EH. Pfizer CentreOne consists of (i) the revenues and expenses of legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including the revenues and expenses related to our manufacturing and supply agreements with Zoetis; and (ii) the revenues and expenses of legacy Hospira's One-2-One sterile injectables contract manufacturing operation, which has been included in EH since we acquired Hospira on September 3, 2015. Prior to 2016, PCS was managed outside our operating segments as part of PGS and reported as "Other Business Activities". We have reclassified prior period PCS operating results ($116 million of PCS revenues and $15 million of PCS earnings in the third quarter of 2015, and $360 million of PCS revenues and $66 million of PCS earnings in the first nine months of 2015) to conform to the current period presentation as part of EH. As noted above, also effective as of the beginning of 2016, in connection with the formation of a new EH R&D organization, certain functions transferred from Pfizer’s WRD organization to the new EH R&D organization. We have reclassified approximately $68 million of costs in the third quarter of 2015 and $202 million of costs in the first nine months of 2015 from WRD to EH to conform to the current period presentation as part of EH.
[7]	Effective as of the beginning of the second quarter of 2016, in connection with the formation of the GPD organization, certain development-related functions transferred from IH to GPD. We have reclassified approximately $76 million of costs in the first quarter of 2016, approximately $77 million of costs in the third quarter of 2015 and approximately $223 million of costs in the first nine months of 2015 from IH to GPD to conform to the current period presentation as part of GPD. Additionally, Anacor's and Medivations’s commercial operations are included in IH's operating results in our condensed consolidated statements of income. As a result, commencing from the acquisition date of June 24, 2016, IH's operating results for the third quarter and first nine months of 2016 include approximately three months of legacy Anacor operations, which were immaterial, and commencing from the acquisition date of September, 28, 2016, IH's operating results for the third quarter and first nine months of 2016 reflect three business days of legacy Medivation operations, which were immaterial.
[8]	The EH business, previously known as the Established Products business, encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Infusion Systems, Biosimilars and Pfizer CentreOne and includes all legacy Hospira commercial operations. Hospira's commercial operations, including the legacy Hospira One-2-One sterile injectables contract manufacturing business, are included in EH’s operating results in our condensed consolidated statements of income, commencing from the acquisition date of September 3, 2015. Therefore, in accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. Also, effective as of the beginning of 2016, our entire contract manufacturing business, Pfizer CentreOne (previously known as Pfizer CentreSource or PCS), is part of EH. Pfizer CentreOne consists of (i) legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including our manufacturing and supply agreements with Zoetis; and (ii) legacy Hospira's One-2-One sterile injectables contract manufacturing operation. Prior to 2016, PCS was managed outside our operating segments and its revenues were reported as other business activities. We have reclassified prior period PCS revenues ($116 million in the third quarter of 2015 and $360 million in the first nine months of 2015) to conform to the current period presentation as part of EH.
[9]	Pfizer CentreOne (previously known as Pfizer CentreSource or PCS) includes (i) revenues from legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including revenues related to our manufacturing and supply agreements with Zoetis; and (ii) revenues from legacy Hospira’s One-2-One sterile injectables contract manufacturing operation.

Segment, Geographic and Other79

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1],[2],[3]	$ 13,045	$ 12,087	$ 39,196	$ 34,804
Percentage Change In Revenue	[3]	8.00%		13.00%
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[3]	$ 6,530	5,565	$ 19,561	14,993
Percentage Change In Revenue	[3]	17.00%		30.00%
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[3],[4]	$ 2,218	2,315	$ 6,982	7,006
Percentage Change In Revenue	[3],[4]	(4.00%)		0.00%
Developed Rest Of World [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[3],[5]	$ 1,711	1,513	$ 4,940	4,562
Percentage Change In Revenue	[3],[5]	13.00%		8.00%
Emerging Markets [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[3],[6]	$ 2,586	$ 2,694	$ 7,714	$ 8,243
Percentage Change In Revenue	[3],[6]	(4.00%)		(6.00%)
[1]	Amounts may not add due to rounding.
[2]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
[3]	On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Hospira. As a result, legacy Hospira operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. On June 24, 2016, we acquired Anacor. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Anacor. As a result, legacy Anacor operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic reporting period, our results of operations and IH's operating results for the third quarter and first nine months of 2016 include approximately three months of legacy Anacor operations. Additionally, on September 28, 2016, we acquired Medivation. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Medivation. As a result, legacy Medivation operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and IH's operating results for the third quarter and first nine months of 2016 reflect three business days of legacy Medivation operations, which were immaterial. See Note 2A for additional information.
[4]	Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries. Revenues denominated in euros were $1.7 billion and $1.8 billion in the third quarter of 2016 and 2015, respectively, and $5.3 billion and $5.4 billion in the first nine months of 2016 and 2015, respectively.
[5]	Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea.
[6]	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.

Segment, Geographic and Other80

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1],[2],[3]	$ 13,045	$ 12,087	$ 39,196	$ 34,804
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[3],[4]	2,218	2,315	6,982	7,006
Euro Member Countries, Euro | Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 1,700	$ 1,800	$ 5,300	$ 5,400
[1]	Amounts may not add due to rounding.
[2]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
[3]	On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Hospira. As a result, legacy Hospira operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. On June 24, 2016, we acquired Anacor. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Anacor. As a result, legacy Anacor operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic reporting period, our results of operations and IH's operating results for the third quarter and first nine months of 2016 include approximately three months of legacy Anacor operations. Additionally, on September 28, 2016, we acquired Medivation. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Medivation. As a result, legacy Medivation operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and IH's operating results for the third quarter and first nine months of 2016 reflect three business days of legacy Medivation operations, which were immaterial. See Note 2A for additional information.
[4]	Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries. Revenues denominated in euros were $1.7 billion and $1.8 billion in the third quarter of 2016 and 2015, respectively, and $5.3 billion and $5.4 billion in the first nine months of 2016 and 2015, respectively.

Segment, Geographic and Other81

Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016	Sep. 27, 2015
Revenue from External Customer [Line Items]
Revenues	[1],[2],[3]	$ 13,045	$ 12,087	$ 39,196	$ 34,804
Innovative Health and Essential Health [Member]
Revenue from External Customer [Line Items]
Revenues		13,045	12,087	39,196	34,804
Innovative Health and Essential Health [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	1,240	1,220	3,730	3,626
Innovative Health and Essential Health [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	387	430	1,183	1,274
Innovative Health and Essential Health [Member] | Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		419	349	1,155	881
Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues	[6]	7,332	6,752	21,471	19,120
Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[7]	5,712	5,335	17,725	15,683
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[8]	2,708	2,919	8,373	8,701
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Lipitor [Member]
Revenue from External Customer [Line Items]
Revenues		422	454	1,294	1,404
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Premarin family [Member]
Revenue from External Customer [Line Items]
Revenues		244	263	751	753
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Norvasc [Member]
Revenue from External Customer [Line Items]
Revenues		238	241	714	744
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Epi Pen [Member]
Revenue from External Customer [Line Items]
Revenues		110	107	300	268
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Xalatan Xalacom [Member]
Revenue from External Customer [Line Items]
Revenues		91	98	273	299
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Relpax [Member]
Revenue from External Customer [Line Items]
Revenues		83	91	248	254
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Zoloft [Member]
Revenue from External Customer [Line Items]
Revenues		72	95	228	274
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Effexor [Member]
Revenue from External Customer [Line Items]
Revenues		70	66	207	213
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Zithromax / Zmax [Member]
Revenue from External Customer [Line Items]
Revenues	[9]	56	63	203	203
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Xanax/Xanax XR [Member]
Revenue from External Customer [Line Items]
Revenues		55	55	163	164
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Cardura [Member]
Revenue from External Customer [Line Items]
Revenues		49	52	143	158
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Neurontin [Member]
Revenue from External Customer [Line Items]
Revenues		45	45	136	148
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Tikosyn [Member]
Revenue from External Customer [Line Items]
Revenues		20	44	136	123
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Depo-Provera [Member]
Revenue from External Customer [Line Items]
Revenues		36	45	103	133
Legacy Established Products [Member] | Essential Health Business [Member] | EH [Member] | Other Legacy Established Products [Member]
Revenue from External Customer [Line Items]
Revenues		1,119	1,199	3,473	3,563
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[10]	1,461	957	4,481	2,436
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Medrol [Member]
Revenue from External Customer [Line Items]
Revenues		102	98	330	284
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Sulperazon [Member]
Revenue from External Customer [Line Items]
Revenues		102	72	304	251
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Fragmin [Member]
Revenue from External Customer [Line Items]
Revenues		80	84	240	246
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Tygacil [Member]
Revenue from External Customer [Line Items]
Revenues		69	81	203	231
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | All Other Sterile Injectable Pharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues		1,108	621	3,405	1,424
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[11]	1,023	1,229	3,224	4,073
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	191	273	623	925
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	89	97	286	318
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Celebrex [Member]
Revenue from External Customer [Line Items]
Revenues		194	212	550	640
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Pristiq [Member]
Revenue from External Customer [Line Items]
Revenues		174	185	546	523
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Vfend [Member]
Revenue from External Customer [Line Items]
Revenues		140	165	459	510
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Zyvox [Member]
Revenue from External Customer [Line Items]
Revenues		94	165	334	696
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Revatio [Member]
Revenue from External Customer [Line Items]
Revenues		73	53	213	181
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | All Other Peri-LOE Products [Member]
Revenue from External Customer [Line Items]
Revenues		68	79	214	280
Infusion Systems [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[12]	281	94	879	94
Biosimilars [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[13]	83	0	228	0
CentreOne [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[14]	156	136	540	380
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		2,243	1,954	6,557	5,500
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	1,049	947	3,107	2,701
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	297	333	897	955
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Chantix / Champix [Member]
Revenue from External Customer [Line Items]
Revenues		198	159	631	491
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Toviaz [Member]
Revenue from External Customer [Line Items]
Revenues		60	59	191	193
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | B M P 2 [Member]
Revenue from External Customer [Line Items]
Revenues		63	57	175	169
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues	[15]	417	343	1,139	841
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | All Other Internal Medicine [Member]
Revenue from External Customer [Line Items]
Revenues	[16]	159	56	416	149
Vaccines [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		1,641	1,629	4,576	4,536
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | Prevenar family [Member]
Revenue from External Customer [Line Items]
Revenues		1,536	1,576	4,302	4,384
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | FSME-IMMUN/TicoVac [Member]
Revenue from External Customer [Line Items]
Revenues		33	28	102	93
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | Other Vaccines Products [Member]
Revenue from External Customer [Line Items]
Revenues		72	26	172	60
Oncology [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		1,104	786	3,206	2,026
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Ibrance [Member]
Revenue from External Customer [Line Items]
Revenues		550	230	1,492	408
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Sutent [Member]
Revenue from External Customer [Line Items]
Revenues		260	279	823	815
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Xalkori [Member]
Revenue from External Customer [Line Items]
Revenues		140	122	415	353
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Inlyta [Member]
Revenue from External Customer [Line Items]
Revenues		95	105	304	311
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Other Oncology Products [Member]
Revenue from External Customer [Line Items]
Revenues		60	50	172	139
Inflammation and Immunology [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		960	987	2,907	2,816
Inflammation and Immunology [Member] | Innovative Health Business [Member] | IH [Member] | Enbrel (Outside the U.S. and Canada) [Member]
Revenue from External Customer [Line Items]
Revenues		701	844	2,201	2,426
Inflammation and Immunology [Member] | Innovative Health Business [Member] | IH [Member] | Xeljanz [Member]
Revenue from External Customer [Line Items]
Revenues		235	127	649	351
Inflammation and Immunology [Member] | Innovative Health Business [Member] | IH [Member] | All Other Inflammation and Immunology Products [Member]
Revenue from External Customer [Line Items]
Revenues		24	16	57	40
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		585	579	1,768	1,776
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | BeneFIX [Member]
Revenue from External Customer [Line Items]
Revenues		176	194	543	561
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Genotropin [Member]
Revenue from External Customer [Line Items]
Revenues		147	142	425	447
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | ReFacto AF/ Xyntha [Member]
Revenue from External Customer [Line Items]
Revenues		140	130	408	392
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Somavert [Member]
Revenue from External Customer [Line Items]
Revenues		59	54	173	158
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Rapamune [Member]
Revenue from External Customer [Line Items]
Revenues		38	32	131	138
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | All Other Rare Disease Products [Member]
Revenue from External Customer [Line Items]
Revenues		25	27	88	80
Consumer Healthcare [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		$ 798	$ 817	$ 2,457	$ 2,465
[1]	Amounts may not add due to rounding.
[2]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
[3]	On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Hospira. As a result, legacy Hospira operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. On June 24, 2016, we acquired Anacor. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Anacor. As a result, legacy Anacor operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic reporting period, our results of operations and IH's operating results for the third quarter and first nine months of 2016 include approximately three months of legacy Anacor operations. Additionally, on September 28, 2016, we acquired Medivation. Commencing from the acquisition date, our condensed consolidated statement of income includes the operating results of Medivation. As a result, legacy Medivation operations are included in our condensed consolidated statements of income for the third quarter and first nine months of 2016. In accordance with our domestic and international reporting periods, our results of operations and IH's operating results for the third quarter and first nine months of 2016 reflect three business days of legacy Medivation operations, which were immaterial. See Note 2A for additional information.
[4]	Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH.
[5]	Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH.
[6]	The IH business, previously known as the Innovative Products business, encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare and includes all legacy Medivation and Anacor commercial operations. Medivation’s and Anacor’s commercial operations are included in IH’s operating results in our condensed consolidated statements of income, commencing from the acquisition date of September 28, 2016 for Medivation and from the acquisition date of June 24, 2016 for Anacor. As a result, IH’s revenues for the third quarter and first nine months of 2016 include three business days of legacy Medivation operations and approximately three months of legacy Anacor operations, which were immaterial.
[7]	The EH business, previously known as the Established Products business, encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Infusion Systems, Biosimilars and Pfizer CentreOne and includes all legacy Hospira commercial operations. Hospira's commercial operations, including the legacy Hospira One-2-One sterile injectables contract manufacturing business, are included in EH’s operating results in our condensed consolidated statements of income, commencing from the acquisition date of September 3, 2015. Therefore, in accordance with our domestic and international reporting periods, our results of operations and EH's operating results for the third quarter and first nine months of 2015 reflect only one month of legacy Hospira U.S. operations but no financial results from legacy Hospira international operations. Also, effective as of the beginning of 2016, our entire contract manufacturing business, Pfizer CentreOne (previously known as Pfizer CentreSource or PCS), is part of EH. Pfizer CentreOne consists of (i) legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including our manufacturing and supply agreements with Zoetis; and (ii) legacy Hospira's One-2-One sterile injectables contract manufacturing operation. Prior to 2016, PCS was managed outside our operating segments and its revenues were reported as other business activities. We have reclassified prior period PCS revenues ($116 million in the third quarter of 2015 and $360 million in the first nine months of 2015) to conform to the current period presentation as part of EH.
[8]	Legacy Established Products include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products).
[9]	Prior period revenues for Medrol and Zithromax/Zmax may not agree to previously-disclosed revenues because revenues for those products are now split between the Legacy Established Products and the Sterile Injectable Pharmaceuticals categories.
[10]	Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products).
[11]	Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products primarily include Lyrica in certain developed Europe markets, Pristiq globally, Celebrex, Zyvox and Revatio in most developed markets, Vfend and Viagra in certain developed Europe markets and Japan, and Inspra in the EU.
[12]	Infusion Systems include Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.
[13]	Biosimilars include Inflectra (biosimilar infliximab) in certain European markets, Nivestim (biosimilar filgrastim) in certain Asian markets and Retacrit (biosimilar epoetin zeta) in certain international markets.
[14]	Pfizer CentreOne (previously known as Pfizer CentreSource or PCS) includes (i) revenues from legacy Pfizer's contract manufacturing and active pharmaceutical ingredient sales operation, including revenues related to our manufacturing and supply agreements with Zoetis; and (ii) revenues from legacy Hospira’s One-2-One sterile injectables contract manufacturing operation.
[15]	Includes Eliquis (2016 and 2015) and Rebif (2015 only).
[16]	Includes Eliquis direct sales markets.

Subsequent Event Regarding Eq82

Subsequent Event Regarding Equity (Details) - Subsequent Event [Member] - TSRU [Member]	Oct. 26, 2016USD ($)Employeetrading_day
Subsequent Event [Line Items]
Age of eligible unit holder which can elect to exercise and convert TSRUs when vested into PTUs	55 years
Award requisite service period	10 years
Trading day average used to calculate the conversion | trading_day	20
Number of employees affected by plan modification | Employee	2,900
Incremental compensation cost resulting from plan modification | $	$ 0